,ticker,content
0,HSIC,becton dickinson bdx have relative strength rs rating upgrade tuesday welcome improvement still shy better score prefer see try find best stock buy watch keep close eye relative price strength proprietary rating measure market leadership show stock price movement last week compare other stock database history show market biggest winner often have higher rs rating early stage move see becton dickinson continue rebound hit benchmark look best stock buy watch start herebecton dickinson be work consolidation buy point see break volume least higher normal earning grow last quarter prior report revenue also increase company earn rank peer medical supply industry group halyard health hyh henry schein hsic be also group highest rate stock get newsletter deliver inbox more info product service privacy policy term also stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
1,HSIC,major index strengthen premarket trading monday mixed early earning news europe market trim loss merck mrk caterpillar cat receive bullish upgrade future dow jone industrial average firm fair value merck caterpillar pull higher premarket trading nasdaq future claw gain toymaker hasbro have mattel mat post heaviest early loss nasdaq fall hasbro report broad first quarter earning miss earning season accelerate week get fairly slow start monday morning top roster alaska air group alk edge halliburton hal hasbro fall follow quarterly result thing pick close google parent alphabet googl lead report docket include barrick gold abx chicago bridge iron cbi whirlpool whr td ameritrade amtd get newsletter deliver inbox more info product service privacy policy term market young uptrend face challenge prepare enter third week dow have book straight loss nasdaq have book index open day move average nasdaq picked distribution day thursday friday decline overseas asian stock market book uneven loss monday hong kong hang seng index drop nikkei tokyo slough european market narrow early loss turn mixed afternoon trade frankfurt dax cac paris inched higher london ftse wrestle fractional decline crude oil be tight focus week price attempt hold year high benchmark crude slip early monday drop back barrel mark march exist home sale due et national association realtor be top item monday economic calendar researcher markit release preliminary april composite purchasing manager index estimate et merck caterpillar be early riser dow respectively nike carry largest early loss caterpillar receive upgrade buy neutral citigroup citigroup cite rebound construction activity china project rebound china metal price caterpillar share be attempt start right side month consolidation earning due tuesday merck receive goldman sachs upgrade buy neutral earn place brokerage americas conviction list note say merck keytruda drug be possible asset drive company specialty biopharma status away large primary care merck share be struggle retake support week move average climb right side possible bottom base apple aapl rise fang stock tech leader gain ground premarket trading facebook fb report wednesday close amazon com amzn report late thursday netflix nflx share rise company announce deal tap high yield bond market medical supply distributor henry schein hsic run ahead nasdaq more medical product distributor say spin animal health unit merge vet first choice new company trade name vet first corp have combine sale schein say receive tax free basis netapp ntap climb more premarket trading datum storage leader have be hammer new high big november have not pause shape valid base end friday november buy point hasbro dive nearly bottom report first quarter sale earning far analyst target company say remain track generate free cash flow year term challenge associate major customer liquidation mattel have earning due thursday fall nearly amazon swung head ibd leaderboardlist premarket trading commerce giant be buy point ahead first quarter report due thursday close ibd stock casa system casa power forward ahead open december ipo form week consolidation pattern be deep too deep qualify flat base pattern mean require week mature valid cup base stock end friday pattern left side high stock december ipo price be interested stock market answer big question weeknot just apple other big reason friday market sell big picture come week turn market aroundstock chart internet giant buy point earning duestock watch td ameritrade green dot stock add ibd listfacebook amazon alphabet lead tech earning bonanza investing action plan
2,HSIC,abc soar tuesday morning overnight report drugstore chain walgreen boot alliance wba seek acquire drug distributor also roil broader health care supply sector be word amazon com amzn be look turn medical supply business major supplier hospital outpatient clinic rival mckesson mck cardinal health cah fall tuesday morning medical supplier owen minor omi tumble stock market today share vault hit earlier walgreen boot alliance already own dip walgreen deal follow big venture health care sector late drug store pharmacy benefit manager cvs health cvs strike deal acquire health insurance giant aetna aet move be see pre emptive strike amazon january amazon team jpmorgan chase jpm berkshire hathaway brkb work lower health care cost employee ibd take stock market flux more important ever investor stay step market latest market analysis be sure read big picture regard medical supply amazon have meet hospital executive several time recently explore become bigger player field wall street journal report tuesday cite unnamed executive attend meeting mckesson lose cardinal health tumble be unclear mckesson cardinal health be react walgreen amerisoure buzz amazon report amazon report clearly seem impact medical supply firm owen minor give make new low henry schein hsic tumble patterson pdco drop amazon rise be interested amazon health care disruption fear clash realitycvs re go deliver amazon jpmorgan berkshire seek doamazon berkshire hathaway jpmorgan chase team health care cvs unitedhealth dive
3,HSIC,stock slip tuesday start bell threaten put damper market day bounce strong early move abc handful china base stock dow jone industrial average nasdaq composite open global stock china market picked rally retook lose ground ahead lunar new year holiday begin friday hong kong hang seng index pop shanghai composite rally shanghai exchange close thursday wednesday hong kong exchange be close friday monday japan tokyo stock exchange reopen monday holiday nikkei stumbling europe market remain mixed afternoon trade frankfurt dax cac paris be respectively london ftse hold gain dow microsoft msft drop head early downside share have be find support week line just clear flat base december apple aapl edge stock retook day line powerful rally monday have be struggle regain hold psychologically important level support feb mega cap mmm take early lead dow jone stock rise stock be look add third day rebound support day move average medical system supply name post deepest loss stock amazon com amzn announce plan expand medical supply business hospital supply chain henry schein hsic dive patterson pdco drop more open trade
4,HSIC,vertex pharmaceutical snap top nasdaq food drug administration approve company symdeko treat cystic fibrosis vertex say begin shipping drug week vertex share have pull back more buy point trigger automatic sell rule share have be testing support week move average drug wholesaler spiked premarket action news report say company be talk walgreen boot alliance wba regard possible takeover walgreen own company hold market capitalization more market sell have pull back buy point trigger automatic sell rule stock open back entry tuesday market correction mean move be not valid walgreen share rise early trade share be trading deep yearlong consolidation competitor cardinal health cah mckesson mck drop respectively early trade armour uaa grab gain mixed fourth quarter report revenue come stronger expect share end monday november low september peak china base name be early leader ibd name weibo wb board fourth quarter beat weibo share be testing support week move average fall more buy point trigger automatic sell rule sina sina rolled ahead generally strong fourth quarter report sina hold control stake weibo also fall more cup base buy point make also subject automatic sell rule vipshop hold vip swung higher online retailer turn fourth quarter report late monday top analyst earning revenue target raise first quarter revenue guidance expectation crude oil trade lower post gain monday just enough snap day downtrend benchmark crude be early action trading barrel other commodity natural gas pop look rebound fall hard recent session copper rise more nearly post gain monday dollar pull back euro slip month low vs yen bond gain ground trimming year yield basis point bitcoin slip monday high bitcoin blockchain related stock be generally quiet also be interested big picture stock jump again hurdle remainwhy stock market sell do nowthese defense stock stand market correctionnike microsoft lead dow stock hold market correction
5,HSIC,relative strength rs rating henry schein hsic moved higher percentile tuesday get lift ibd unique rs rating identify technical performance show stock price movement last week compare other stock database year market history show best stock tend have rs rating north early stage move see henry schein continue rebound hit benchmark henry schein be try complete flat base entry see clear price heavy trade revenue growth fall last quarter ep grow prior report look next report aug company earn rank peer medical supply industry group becton dickinson bdx be top rank stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
6,HSIC,stock open higher tuesday start short week packed big earning report miner shale oil producer dow jone industrial average nasdaq climb latter boost mondelez mdlz henry schein hsic russell be miner bhp billiton bhp edge less report month result top analyst estimate big retail name be early center attention stock market today wal mart wmt rumble almost report fourth quarter result analyst target first quarter full year earning guidance be line expectation management raise quarterly dividend stock be climb right side flat base fellow dow member home depot hd climb more atlanta base do chain report solid fourth quarter beat comparable store sale rise nearly company more revenue guidance fiscal be analyst expectation stock be extend buy point unilever ul swoon kraft heinz khc shed open kraft sunday withdraw takeover offer unilever say interest combination be reveal extremely early stage compete food giant mondelez gain tuesday premarket trade kraft share spiked last week new high news possible deal go public
7,HSIC,lumber liquidator ll pop clear analyst fourth quarter revenue earning target healthy margin share remain far peak have be consolidate high marked september base bank hsbc holding hsbc tumble report fourth quarter result monday night stock be buy range buy point cup base pattern larger consolidation oil price jump nearly send west texas intermediate barrel highest mark jan gold gain half percent ounce dollar gain bond fall lift year yield basis point comment federal reserve official have impact trade tuesday minneapoli federal reserve bank president neel kashkari speak et patrick harker president cleveland federal reserve bank be next speaking et follow san francisco federal reserve bank president john william et london base researcher markit report preliminary manufacturing purchasing manager index february et europe london ftse dip tuesday frankfurt dax rise paris cac be afternoon trade europe market have post mixed session monday tokyo nikkei japan climb add fractional gain monday index continue test support day move average china shanghai composite add follow advance monday hong kong hang seng index slip monday rise related wal mart earning top comp online sale jumptesla mobileye home depot acacia lead investing action plan
8,HSIC,vca massive west los angele animal hospital pet get chemotherapy mri scan receive acupuncture chinese herbal treatment rehab underwater treadmill be enter behavioral counsele well join weight management regimen dog cat rabbit bird prey potbelly pig welcome hospital offer high profile proof thrive pet health
9,HSIC,dental veterinary supplier patterson co pdco jump month high fiscal earning guidance late thursday beat low expectation further fuel stronger group medical stock dental supplier be few medical group hold well recent downturn thank business model depend more consumer spending government reimbursement patterson however be relative laggard compare such high rate stock align technology algn now ibd henry schein hsic patterson most direct competitor dentsply sirona xray give investor relatively low expectation stock relatively weaker year date quarter date performance vs henry schein stock react somewhat positively today write evercore isi analyst ross muken note market open patterson stock be close stock market today be more earlier even news be mixed adjust earning rise year earlier quarter cent share beating analyst consensus cent accord thomson reuter revenue period end april be slightly estimate patterson guide fiscal share midpoint previous year line consensus mark fourth quarter row double digit profit revenue growth patterson stretch decline ibd ep rank be strong relative strength rating be weak thursday move henry schein stock be close thursday
10,HSIC,month double dip market correction hardest hit industry have be medicine presidential election debate high drug price health care policy general have give investor jitter soft guidance most recent round earning report didn help matter notable exception have be stock involved dentistry not many
11,HSIC,mfs mid cap growth fund otcix keep steely eye fix prize fund seek stock company best poise growth several year future market retreat do december early february investor favor defensive name rather growthier one hurt fund mfs portfolio month trail performance go tuesday be mired middle midcap growth peer group mutual fund track morningstar inc lag pace more accustomed past year average annual gain top direct rival averaged yearly return gallop ahead yearly pace nvidia nvda be mid cap growth type stock fund increase stake weighting most recent monthly disclosure november january feb stock be near entry cup shape base earning share rise past quarters company design graphic process unit be used computer mobile device game console stock have composite rating ibd composite rating combine ibd stock performance rating include ep rs rating be highest stock also have dividend yield run chain target discount store sell variety good range apparel consumer electronic game candy stock sport comp rating be low dec uptrend begin post second quarter earning show ep growth reverse prior quarter decline company open first store miami march stock be ibd list lead growth stock payment processor vantiv vntv ibd name be low jan accelerate ep rise past quarters trading cup shape base stock show buy point vantiv have comp rating company benefit merchant financial firm switch chip card terminal vantiv other cybersecurity product also help stock climb henry schein hsic comp rating be feb stock climb begin day company announce record fourth quarter full year result company also affirm ep guidance ep global provider health care product medical equipment grow past quarters reilly automotive orly have cup shape base entry alternative earlier entry be early entry crop stock cross area price resistance base unmistakably strong volume volume be sign fund be stock move stock be benefit low gasoline price encourage more drive lead more maintenance analyst recently raise price target buy sell hold recommendation last month company report better expect result add share buyback plan
12,HSIC,manager best perform mutual fund past month have be nibble recently top rate stock have re-cover january steep loss major index rally sharply second half valentine month investor bottom fed lead stock lower price trim loss just february nasdaq be lead stock mutual fund have show interest defensive sector food processor financial stock utility firm recent month slow economy investor often flock food company such hormel hrl cal maine calm tyson tsn hormel tyson have perform well past year hit new high way click here see list new buy top mutual fund financial issue top fund be seek steady gain reit such agree realty adc equity lifestyle property el kimco realty kim federal realty trust frt sun community sui credit card payment processor leaderboard stock paypal pypl be also add lead fund latest report period area worth gander be utility include itc holding itc cms energy cms pinnacle west capital pnw telecom giant verizon communication vz find way top perform fund buy list lead fund add verizon investing estimate latest report period new york base firm get big marketing boost power rank verizon wireless highest network quality region wireless provider ibd spot best perform fund tap paypal investing estimate rowe price growth stock fund prfgx add share latest report period mobile online payment processor be spun long time parent ebay ebay july last year also own popular mobile payment app venmo now paypal be standing own foot san jose calif base firm stand grow mobile payment segment particularly store mobile wallet compete alphabet google android pay apple pay samsung pay mobile world congress paypal announce partnership vodafone vod america movil amx subsidiary telco claro latin america mean europe mexico brazil phone have paypal power mobile wallet already install partnership paypal offer merchant consumer more flexibility choice want pay get paid paypal doesn own operate platform be not connect device have broad scope growth paypal doesn have long trading history stock have be set good look shallow base july ipo creep buy point paypal earning grow cent share ex item revenue growth rise country top rate fund have be unload medical stock such johnson johnson jnj henry schein hsic quest diagnostic dgx latest report period large cap illinois tool work itw mmm have also be sell lead fund be top fund selling computer graphic chip maker nvidia nvda only fund buy leave net selling fund nvidia stock have be etching right side cup shape base near buy point click here top mutual fund latest sellsimage provide shutterstock
13,HSIC,supplier medical device be climb ibd industry rank quickly thank part acquisition improve earning stock industry have jump place past week wednesday ibd group have rise year outperform
14,HSIC,becton dickinson bdx big cap supplier catheter other equipment lead group composite rating
15,HSIC,becton have post straight quarters strong double digit sale growth follow march acquisition carefusion device help reduce medication error prevent infection prior acquisition big cap firm have post long string mostly low mid single digit sale gain
16,HSIC,profit growth have also rebound jump share latest quarter just cent same period year earlier
17,HSIC,addition carefusion becton be transform company be able comfortably hit double digit ep growth next year jp morgan say nov rate stock outperform
18,HSIC,becton initially clear buy point dec volume be unimpressive stock have waver
19,HSIC,dentsply international xray sell wide range dental product be slightly extend clear flat base entry late october stock be year
20,HSIC,dentsply announce buy sirona dental siro create world biggest provider dental supply product range anesthetic other consumable dental chair deal be expect be approve first quarter next year
21,HSIC,combine company be likely achieve significant cost revenue synergy back expand product portfolio bigger customer base better infrastructure zack equity research say dec zack have buy rating stock
22,HSIC,profit rise cent share decline sale efficiency improvement higher margin outweighed currency headwind
23,HSIC,henry schein hsic provider dental supply be third major stock group composite rating
24,HSIC,stock be year be buy range clear buy point october henry schein earning share rating be tie becton best industry henry schein accumulation distribution rating also lead group indicate strong demand
25,HSIC,melville ny base company announce nov profit rise share biggest increase quarters ahead wall street estimate
26,HSIC,sale rise
27,HSIC,fidelity contrafund rate ibd be institution increase holding latest quarter supplier medical device be climb ibd industry rank quickly thank part acquisition improve earning stock industry have jump place past week wednesday ibd group have rise year outperform becton dickinson bdx big cap supplier catheter other equipment lead group composite rating becton have post straight quarters strong double digit sale growth follow march acquisition carefusion device help reduce medication error prevent infection prior acquisition big cap firm have post long string mostly low mid single digit sale gain profit growth have also rebound jump share latest quarter just cent same period year earlier addition carefusion becton be transform company be able comfortably hit double digit ep growth next year jp morgan say nov rate stock outperform becton initially clear buy point dec volume be unimpressive stock have waver dentsply international xray sell wide range dental product be slightly extend clear flat base entry late october stock be year dentsply announce buy sirona dental siro create world biggest provider dental supply product range anesthetic other consumable dental chair deal be expect be approve first quarter next year combine company be likely achieve significant cost revenue synergy back expand product portfolio bigger customer base better infrastructure zack equity research say dec zack have buy rating stock profit rise cent share decline sale efficiency improvement higher margin outweighed currency headwind henry schein hsic provider dental supply be third major stock group composite rating stock be year be buy range clear buy point october henry schein earning share rating be tie becton best industry henry schein accumulation distribution rating also lead group indicate strong demand melville ny base company announce nov profit rise share biggest increase quarters ahead wall street estimate sale rise fidelity contrafund rate ibd be institution increase holding latest quarter
28,HSIC,fresh breakout new high provide investor new opportunity thursday market rally hain celestial hain gain new high breaking past flat base buy point average volume hain close lynch earlier week add natural organic food product maker list
29,HSIC,align technology algn stock vault time high morning trading friday day dental supplier handily beat estimate give upbeat guidance align stock be stock market friday far ahead former high touch oct align stock earlier session rise high
30,HSIC,update negotiation financial tourniquet automaker be delay late thursday add stock market deepen rout
31,HSIC,nyse composite plummet energy index collapse financial sector index shed
32,HSIC,slide undercut october low notch lowest close april nasdaq composite dow lop
33,HSIC,midcaps take direct hit
34,HSIC,volume ease elevated level earlier session finished well wednesday moderate level preliminary datum show trading higher nyse nasdaq
35,HSIC,capella education cpla post gain have add hour trading education stock have start lead market be mostly lower
36,HSIC,devry dv tumble close day move average new oriental education edu be rattle loss sink lowest level march
37,HSIC,computer maker dell dell fall regular session gain more hour trading report earning consensus view
38,HSIC,revenue fall estimate september company have warn soft demand statement thursday say expect environment remain challenge
39,HSIC,retailer cost cpwm gap gps be also slate report earning close
40,HSIC,axsys technology axys be day few winner fishing
41,HSIC,health care management service provider hms holding hmsy logged advance
42,HSIC,major economic report be due friday retailer ann taylor ann solar power component maker canadian solar csiq plan report prior open bell
43,HSIC,update benchmark close milestone low
44,HSIC,juan carlos arancibia
45,HSIC,undercut low bear market market free fall continue abate thursday
46,HSIC,benchmark index plunge accord preliminary reading
47,HSIC,nyse composite plummet energy stock track crude slide barrel dow lose nasdaq
48,HSIC,volume rise be average industry group fall
49,HSIC,index have rebound midday word compromise aid deal automaker retreat detail emerge
50,HSIC,financial also be batter spdr financial etf plunge more
51,HSIC,update stock drop floor democrat delay auto aid vote
52,HSIC,alan elliott
53,HSIC,index stage pell mell retreat democratic leader opted delay vote automaker aid december energy financial issue head slide
54,HSIC,nyse composite swoon energy index topple financial index crumble cave nasdaq composite dow carved respectively
55,HSIC,citigroup jpmorgan jpm bank america bac lead dow lower flextronic flex foster wheeler fwlt top nasdaq downside list clothing manufacturer jone apparel group liz claiborne liz show sharpest loss
56,HSIC,crude oil close just barrel natural gas stock be hammer unexpected rise weekly inventory drive gas future price lower
57,HSIC,trading volume backed bit remain well wednesday moderate trading level
58,HSIC,medical dental good supplier henry schein hsic gap slip dive continue third week loss drive share better year low
59,HSIC,update auto deal reach index gain reversed
60,HSIC,patrick
61,HSIC,stock erased gain nyse composite sank dow nasdaq clinge gain
62,HSIC,auto giant bounce news have reach deal senator fall back detail be release
63,HSIC,bipartisan agreement small group legislator still need be approve capitol hill approve speed release already approve relief package
64,HSIC,gm gm rise much be ford rocket much be
65,HSIC,governor wgov manufacturer energy control system energy industry turbine engine gap be research firm kevin dann downgrade company neutral buy
66,HSIC,mantech mant provider information technology service intelligence community be late wednesday standard poor announce mantech be moved small cap midcap
67,HSIC,mantech southern union be add midcap index replace avis budget group car medium general meg
68,HSIC,amedisys am gap start day be claw way back once home nursing provider be now just
69,HSIC,suntech power stp also open day gapping however have extend loss more
70,HSIC,update stock slate clean press higher solid volume
71,HSIC,alan elliott
72,HSIC,index break firmly positive territory lead tech telecom broad array advance issue tow
73,HSIC,dow erased early loss push ahead nasdaq composite jump nyse composite manage rise
74,HSIC,boee ba walmart wmt verizon communication vz show dow best gain petsmart petm lam research lrcx top nasdaq
75,HSIC,volume hold very high level vs wednesday
76,HSIC,crude future also hold steady just barrel natural gas metal remain generally lower dollar slip vs yen gain bit euro reflect investor turn yet more risk averse
77,HSIC,major discount retailer book solid move walmart jump target tgt rocket higher
78,HSIC,defense technology contractor axsys technology axys scream higher pull week line support just week line
79,HSIC,private college operator apollo group apol jump put share just stock have find resistance september
80,HSIC,update rebound wane nasdaq hang tough
81,HSIC,vincent mao
82,HSIC,rebound effort leveled leave stock mixed halfway point session
83,HSIC,nyse composite fall drop dow nasdaq show relative strength rise
84,HSIC,turnover be again tracking sharply higher board
85,HSIC,crude oil pare loss fall year low december contract lose barrel
86,HSIC,amedisys am gap tumble downgrade deutsche bank cut home nursing care firm hold buy worry increase number patient pay bill stock have be more
87,HSIC,group mate almost family afam gap drop slice stock day move average nursing care service provider clear buy point oct today rout trigger sell rule
88,HSIC,upside hms holding hmsy reversed earlier loss charge provider cost containment service clear buy point handle handle wedge upward be flaw
89,HSIC,update stock turn hard techs telecom
90,HSIC,alan elliott
91,HSIC,index be move fast telecom tech issue lead sharp turnaround have be furious unwinding global market
92,HSIC,nasdaq composite pull gain petsmart pet kla tencor klac show top gain nasdaq dow step lift largely verizon communication vz general motor gm citigroup jpmorgan jpm still pull lower nyse composite pull lows loss hover break even line
93,HSIC,volume power ahead huge level nyse nasdaq
94,HSIC,crude oil future slip further nearly barrel price level not see natural gas drop silver copper tumble gold edge higher dollar slip vs euro yen
95,HSIC,education stock see mixed result online educator capella education cpla perked first day list component standard poor small cap index
96,HSIC,strayer education stra go opposite route heavy trading
97,HSIC,canadian bank take solid hit toronto dominion td withdraw detail guidance cent share company say expect net loss wholesale banking division due trading loss approximately company report result dec
98,HSIC,royal bank canada ry plunge nearly time average volume
99,HSIC,investor europe take cue wall street weak start cac paris dig frankfurt dax ftse london sank lead energy mining issue be drag lower slumping oil commodity price
100,HSIC,update stock dive open dow undercut
101,HSIC,vincent mao
102,HSIC,stock open lower head further south thursday continue left prior session
103,HSIC,new york composite be nasdaq dow lose undercut nov oct lows blue chip index tank lowest april
104,HSIC,volume be tracking vastly higher board
105,HSIC,economic front conference board index lead economic indicator fall october view decline
106,HSIC,philly fed factory index worsen november october economist expect improvement
107,HSIC,ipos have be rare late grand canyon education lope debut today school operator price share cut offer price twice stock have yet trade
108,HSIC,akamai akam drop announce layoff provider internet content service slash staff job fourth quarter
109,HSIC,brady brc gap tumble year low id label maker slash profit outlook cut work force nearly person
110,HSIC,upside couple retailer buck trend gymboree gymb gap rally report earning view late wednesday morning jpmorgan raise child retailer overweight neutral
111,HSIC,petsmart pet gap rise solid third quarter result be release wednesday pet supply retailer bounce back lowest level year
112,HSIC,meanwhile ambac financial group abk gap surge cut exposure collateralize debt obligation goldman sachs trim bond insurer loss estimate
113,HSIC,update update economic wo fate auto industry weigh stock future
114,HSIC,vincent mao
115,HSIC,stock be head weaker open thursday worry economy uncertainty auto industry continue linger
116,HSIC,nasdaq future drop point vs fair value future lose point dow future give point
117,HSIC,economic news initial jobless claim climb week end nov revise prior week highest number claim year well forecast
118,HSIC,future drop follow news
119,HSIC,philly fed factory index index economic indicator be
120,HSIC,global market tumble follow wednesday performance
121,HSIC,japan nikkei dive news export tumble nearly october hong kong hang seng shed european index fared better london ftse lose germany dax fall
122,HSIC,fate big automaker appear be stick neutral senate majority leader harry reid nev wednesday cancel plan give auto industry loan wall street bailout plan
123,HSIC,ford share crumble pre market
124,HSIC,general motor gm rise majority own financing arm gmac financial service file become bank hold company gain entry government trouble asset relief program tarp
125,HSIC,citigroup rise pre open report saudi investor prince alwaleed bin talal bin abdulaziz al saud increase stake firm citigroup share be year
126,HSIC,suntech power holding stp plunge pre market deliver earning shy view lower sale outlook exclude item solar cell maker report earning cent share cent view cite currency fluctuation tighten credit market now expect full year sale prior guidance
127,HSIC,crude oil continue slide demand fear december contract dump barrel lowest january update negotiation financial tourniquet automaker be delay late thursday add stock market deepen rout nyse composite plummet energy index collapse financial sector index shed slide undercut october low notch lowest close april nasdaq composite dow lop midcaps take direct hit volume ease elevated level earlier session finished well wednesday moderate level preliminary datum show trading higher nyse nasdaq capella education cpla post gain have add hour trading education stock have start lead market be mostly lower devry dv tumble close day move average new oriental education edu be rattle loss sink lowest level march computer maker dell dell fall regular session gain more hour trading report earning consensus view revenue fall estimate september company have warn soft demand statement thursday say expect environment remain challenge retailer cost cpwm gap gps be also slate report earning close axsys technology axys be day few winner fishing health care management service provider hms holding hmsy logged advance major economic report be due friday retailer ann taylor ann solar power component maker canadian solar csiq plan report prior open bell update benchmark close milestone low juan carlos undercut low bear market market free fall continue abate thursday benchmark index plunge accord preliminary reading nyse composite plummet energy stock track crude slide barrel dow lose nasdaq volume rise be average industry group fall index have rebound midday word compromise aid deal automaker retreat detail emerge financial also be batter spdr financial etf plunge more update stock drop floor democrat delay auto aid vote alan elliottindex stage pell mell retreat democratic leader opted delay vote automaker aid december energy financial issue head slide nyse composite swoon energy index topple financial index crumble cave nasdaq composite dow carved respectively citigroup jpmorgan jpm bank america bac lead dow lower flextronic flex foster wheeler fwlt top nasdaq downside list clothing manufacturer jone apparel group liz claiborne liz show sharpest loss crude oil close just barrel natural gas stock be hammer unexpected rise weekly inventory drive gas future price lower trading volume backed bit remain well wednesday moderate trading level medical dental good supplier henry schein hsic gap slip dive continue third week loss drive share better year low update auto deal reach index gain reversed patrick cainstock erased gain nyse composite sank dow nasdaq clinge gain auto giant bounce news have reach deal senator fall back detail be release bipartisan agreement small group legislator still need be approve capitol hill approve speed release already approve relief package gm gm rise much be ford rocket much be governor wgov manufacturer energy control system energy industry turbine engine gap be research firm kevin dann downgrade company neutral buy mantech mant provider information technology service intelligence community be late wednesday standard poor announce mantech be moved small cap midcap mantech southern union be add midcap index replace avis budget group car medium general meg amedisys am gap start day be claw way back once home nursing provider be now just suntech power stp also open day gapping however have extend loss more update stock slate clean press higher solid volumeby alan elliottindex break firmly positive territory lead tech telecom broad array advance issue tow dow erased early loss push ahead nasdaq composite jump nyse composite manage rise boee ba walmart wmt verizon communication vz show dow best gain petsmart petm lam research lrcx top nasdaq volume hold very high level vs wednesday crude future also hold steady just barrel natural gas metal remain generally lower dollar slip vs yen gain bit euro reflect investor turn yet more risk averse major discount retailer book solid move walmart jump target tgt rocket higher defense technology contractor axsys technology axys scream higher pull week line support just week line private college operator apollo group apol jump put share just stock have find resistance september update rebound wane nasdaq hang toughby vincent maorebound effort leveled leave stock mixed halfway point session nyse composite fall drop dow nasdaq show relative strength rise turnover be again tracking sharply higher board crude oil pare loss fall year low december contract lose barrel amedisys am gap tumble downgrade deutsche bank cut home nursing care firm hold buy worry increase number patient pay bill stock have be more group mate almost family afam gap drop slice stock day move average nursing care service provider clear buy point oct today rout trigger sell rule upside hms holding hmsy reversed earlier loss charge provider cost containment service clear buy point handle handle wedge upward be flaw update stock turn hard techs telecom alan elliottindex be move fast telecom tech issue lead sharp turnaround have be furious unwinding global market nasdaq composite pull gain petsmart pet kla tencor klac show top gain nasdaq dow step lift largely verizon communication vz general motor gm citigroup jpmorgan jpm still pull lower nyse composite pull lows loss hover break even line volume power ahead huge level nyse nasdaq crude oil future slip further nearly barrel price level not see natural gas drop silver copper tumble gold edge higher dollar slip vs euro yen education stock see mixed result online educator capella education cpla perked first day list component standard poor small cap index strayer education stra go opposite route heavy trading canadian bank take solid hit toronto dominion td withdraw detail guidance cent share company say expect net loss wholesale banking division due trading loss approximately company report result dec royal bank canada ry plunge nearly time average volume investor europe take cue wall street weak start cac paris dig frankfurt dax ftse london sank lead energy mining issue be drag lower slumping oil commodity price update stock dive open dow undercutsby vincent maostock open lower head further south thursday continue left prior session new york composite be nasdaq dow lose undercut nov oct lows blue chip index tank lowest april volume be tracking vastly higher board economic front conference board index lead economic indicator fall october view decline philly fed factory index worsen november october economist expect improvement ipos have be rare late grand canyon education lope debut today school operator price share cut offer price twice stock have yet trade akamai akam drop announce layoff provider internet content service slash staff job fourth quarter brady brc gap tumble year low id label maker slash profit outlook cut work force nearly person upside couple retailer buck trend gymboree gymb gap rally report earning view late wednesday morning jpmorgan raise child retailer overweight neutral petsmart pet gap rise solid third quarter result be release wednesday pet supply retailer bounce back lowest level year meanwhile ambac financial group abk gap surge cut exposure collateralize debt obligation goldman sachs trim bond insurer loss estimate update update economic wo fate auto industry weigh stock futuresby vincent maostock be head weaker open thursday worry economy uncertainty auto industry continue linger nasdaq future drop point vs fair value future lose point dow future give point economic news initial jobless claim climb week end nov revise prior week highest number claim year well forecast future drop follow news philly fed factory index index economic indicator be global market tumble follow wednesday performance japan nikkei dive news export tumble nearly october hong kong hang seng shed european index fared better london ftse lose germany dax fall fate big automaker appear be stick neutral senate majority leader harry reid nev wednesday cancel plan give auto industry loan wall street bailout plan ford share crumble pre market general motor gm rise majority own financing arm gmac financial service file become bank hold company gain entry government trouble asset relief program tarp citigroup rise pre open report saudi investor prince alwaleed bin talal bin abdulaziz al saud increase stake firm citigroup share be year suntech power holding stp plunge pre market deliver earning shy view lower sale outlook exclude item solar cell maker report earning cent share cent view cite currency fluctuation tighten credit market now expect full year sale prior guidance crude oil continue slide demand fear december contract dump barrel lowest january
128,HSIC,update stock close mixed wednesday follow headline filled session
129,HSIC,early major index rally forecast economic datum later add gain fed stand pat interest rate round late selling cut gain most index send nasdaq negative territory
130,HSIC,dow nyse composite rise be apiece session peak
131,HSIC,meanwhile pare gain just index again finished day move average retake line intraday
132,HSIC,nasdaq slip be
133,HSIC,nyse volume edge lower nasdaq trade rise
134,HSIC,blackboard bbbb gap vault nearly time average trade software maker hit week high follow latest quarterly result late tuesday blackboard accumulation distribution rating improve just session
135,HSIC,schweitzer mauduit swm jump regain day move average almost triple average trade late tuesday tobacco paper product maker smash view pop earning sale fall view firm also raise full year profit outlook analyst estimate
136,HSIC,medifast med gap rally time high maker weight loss product recently report bulge earning third straight period accelerate growth sale have also picked recent quarters
137,HSIC,downside stec stec gap day move average plunge nearly month low firm say key customer emc emc carry inventory
138,HSIC,earning thursday include abovenet abvt brink home security cfl fuel system solution fsys orion marine group orn royal gold rgld starbucks sbux sxc health solution sxci
139,HSIC,datum productivity jobless claim also be thursday
140,HSIC,update late selling dent rally
141,HSIC,vincent mao
142,HSIC,stock lose steam last hour finishing event filled session mixed result wednesday
143,HSIC,dow nyse composite rise tick meanwhile nasdaq slip index be more session high
144,HSIC,accord preliminary datum nasdaq volume edge higher nyse turnover dip
145,HSIC,hmo rally possibility congress miss deadline health care reform foreign bank steel producer also climb tire maker apparel manufacturer fall
146,HSIC,stock high late trade
147,HSIC,vincent mao
148,HSIC,update stock find direction be best level wednesday session experience volatility fed decision
149,HSIC,dow nyse composite rally climb nasdaq
150,HSIC,turnover be again tracking lower board
151,HSIC,cisco system csco rise regain day move average networking giant report fiscal result close analyst be expect earning cent share cent year sale be expect company outlook provide key insight tech spending
152,HSIC,tech heavyweight qualcomm qcom also report close
153,HSIC,downside ebix ebix erased earlier gain fall heavy trading open software firm beat view rise earning sale rise view stock be near day move average
154,HSIC,update fed reaffirm extend low rate
155,HSIC,ed carson
156,HSIC,federal reserve slightly upgrade view economy wednesday reaffirm pledge keep interest rate very low extend period
157,HSIC,expect fomc vote keep fed fund target rate record low range
158,HSIC,policymaker say post meeting statement economic activity have continue pick household spending improve have intention even hint take away monetary punch bowl foreseeable future unemployment high inflation low fed keep rate low extend period
159,HSIC,however central bank say buy worth agency mortgage debt news year treasury yield briefly jump recent high
160,HSIC,major average modestly fed announcement begin fade volatile trade dow rise nasdaq
161,HSIC,update index pull back fed decision loom
162,HSIC,vincent mao
163,HSIC,stock pare gain ahead fed interest rate decision due
164,HSIC,dow rise session high nyse composite climb
165,HSIC,meanwhile nasdaq lag gain
166,HSIC,volume continue track lower nyse slightly higher nasdaq
167,HSIC,netlogic microsystem netl jump report higher earning sale first time quarters late tuesday integrate circuit maker beat view rise profit sale grow analyst see income rise current period
168,HSIC,sxc health solution sxci climb fast trade open provider pharmacy benefit management service health care service say win contract sxc report earning thursday analyst see profit rise cent share
169,HSIC,downside garmin grmn reversed morning gain tumble month low gps device maker have big change heart deliver result well view last week google goog enter navigation market google map navigation android device
170,HSIC,dolby laboratory dlb trim earlier loss late tuesday developer entertainment technology report lower fiscal earning beat view sale miss estimate dolby board approve share buyback earlier wednesday jpmorgan maxim group downgrade share
171,HSIC,update stock higher midday
172,HSIC,jonah keri
173,HSIC,major index retain gain mixed volume midday wednesday
174,HSIC,nasdaq rise dow picked nyse composite advanced
175,HSIC,volume be mixed trading fall nyse compare same period tuesday nasdaq volume climb
176,HSIC,rock tenn rkt rise twice normal trade maker packaging merchandising display beat fiscal fourth quarter earning view stock have be consolidate hit new high late august
177,HSIC,atwood oceanic atw advanced rapid turnover offshore drill firm stock find support day move average tuesday
178,HSIC,downside true religion apparel trlg plunge gigantic volume upscale jean maker miss profit view issue weak forecast send stock tumble day line
179,HSIC,update market surge late morning action
180,HSIC,jonah keri
181,HSIC,major index gain accelerate wednesday number lead stock fare well nasdaq rise dow picked nyse composite advanced
182,HSIC,volume be mixed trading fall nyse compare same period tuesday nasdaq volume climb
183,HSIC,schweitzer mauduit swm surge massive volume cigarette paper tobacco product maker top earning view raise full year forecast push stock new high ground
184,HSIC,china green agriculture cga gain nearly twice usual turnover company launch new fertilizer product china green stock vault day move average
185,HSIC,medifast med gain rapid trade maker weight control disease management product climb week high
186,HSIC,update stock open higher mixed trade
187,HSIC,update stock close mixed wednesday follow headline filled session
188,HSIC,early major index rally forecast economic datum later add gain fed stand pat interest rate round late selling cut gain most index send nasdaq negative territory
189,HSIC,dow nyse composite rise be apiece session peak
190,HSIC,meanwhile pare gain just index again finished day move average retake line intraday
191,HSIC,nasdaq slip be
192,HSIC,nyse volume edge lower nasdaq trade rise
193,HSIC,blackboard bbbb gap vault nearly time average trade software maker hit week high follow latest quarterly result late tuesday blackboard accumulation distribution rating improve just session
194,HSIC,schweitzer mauduit swm jump regain day move average almost triple average trade late tuesday tobacco paper product maker smash view pop earning sale fall view firm also raise full year profit outlook analyst estimate
195,HSIC,medifast med gap rally time high maker weight loss product recently report bulge earning third straight period accelerate growth sale have also picked recent quarters
196,HSIC,downside stec stec gap day move average plunge nearly month low firm say key customer emc emc carry inventory
197,HSIC,earning thursday include abovenet abvt brink home security cfl fuel system solution fsys orion marine group orn royal gold rgld starbucks sbux sxc health solution sxci
198,HSIC,datum productivity jobless claim also be thursday
199,HSIC,update late selling dent rally
200,HSIC,vincent mao
201,HSIC,stock lose steam last hour finishing event filled session mixed result wednesday
202,HSIC,dow nyse composite rise tick meanwhile nasdaq slip index be more session high
203,HSIC,accord preliminary datum nasdaq volume edge higher nyse turnover dip
204,HSIC,hmo rally possibility congress miss deadline health care reform foreign bank steel producer also climb tire maker apparel manufacturer fall
205,HSIC,stock high late trade
206,HSIC,vincent mao
207,HSIC,update stock find direction be best level wednesday session experience volatility fed decision
208,HSIC,dow nyse composite rally climb nasdaq
209,HSIC,turnover be again tracking lower board
210,HSIC,cisco system csco rise regain day move average networking giant report fiscal result close analyst be expect earning cent share cent year sale be expect company outlook provide key insight tech spending
211,HSIC,tech heavyweight qualcomm qcom also report close
212,HSIC,downside ebix ebix erased earlier gain fall heavy trading open software firm beat view rise earning sale rise view stock be near day move average
213,HSIC,update fed reaffirm extend low rate
214,HSIC,ed carson
215,HSIC,federal reserve slightly upgrade view economy wednesday reaffirm pledge keep interest rate very low extend period
216,HSIC,expect fomc vote keep fed fund target rate record low range
217,HSIC,policymaker say post meeting statement economic activity have continue pick household spending improve have intention even hint take away monetary punch bowl foreseeable future unemployment high inflation low fed keep rate low extend period
218,HSIC,however central bank say buy worth agency mortgage debt news year treasury yield briefly jump recent high
219,HSIC,major average modestly fed announcement begin fade volatile trade dow rise nasdaq
220,HSIC,update index pull back fed decision loom
221,HSIC,vincent mao
222,HSIC,stock pare gain ahead fed interest rate decision due
223,HSIC,dow rise session high nyse composite climb
224,HSIC,meanwhile nasdaq lag gain
225,HSIC,volume continue track lower nyse slightly higher nasdaq
226,HSIC,netlogic microsystem netl jump report higher earning sale first time quarters late tuesday integrate circuit maker beat view rise profit sale grow analyst see income rise current period
227,HSIC,sxc health solution sxci climb fast trade open provider pharmacy benefit management service health care service say win contract sxc report earning thursday analyst see profit rise cent share
228,HSIC,downside garmin grmn reversed morning gain tumble month low gps device maker have big change heart deliver result well view last week google goog enter navigation market google map navigation android device
229,HSIC,dolby laboratory dlb trim earlier loss late tuesday developer entertainment technology report lower fiscal earning beat view sale miss estimate dolby board approve share buyback earlier wednesday jpmorgan maxim group downgrade share
230,HSIC,update stock higher midday
231,HSIC,jonah keri
232,HSIC,major index retain gain mixed volume midday wednesday
233,HSIC,nasdaq rise dow picked nyse composite advanced
234,HSIC,volume be mixed trading fall nyse compare same period tuesday nasdaq volume climb
235,HSIC,rock tenn rkt rise twice normal trade maker packaging merchandising display beat fiscal fourth quarter earning view stock have be consolidate hit new high late august
236,HSIC,atwood oceanic atw advanced rapid turnover offshore drill firm stock find support day move average tuesday
237,HSIC,downside true religion apparel trlg plunge gigantic volume upscale jean maker miss profit view issue weak forecast send stock tumble day line
238,HSIC,update market surge late morning action
239,HSIC,jonah keri
240,HSIC,major index gain accelerate wednesday number lead stock fare well nasdaq rise dow picked nyse composite advanced
241,HSIC,volume be mixed trading fall nyse compare same period tuesday nasdaq volume climb
242,HSIC,schweitzer mauduit swm surge massive volume cigarette paper tobacco product maker top earning view raise full year forecast push stock new high ground
243,HSIC,china green agriculture cga gain nearly twice usual turnover company launch new fertilizer product china green stock vault day move average
244,HSIC,medifast med gain rapid trade maker weight control disease management product climb week high
245,HSIC,update stock open higher mixed trade
246,HSIC,early major index rally forecast economic datum later add gain fed stand pat interest rate round late selling cut gain most index send nasdaq negative territory dow nyse composite rise be apiece session peak meanwhile pare gain just index again finished day move average retake line intraday nasdaq slip be nyse volume edge lower nasdaq trade rise blackboard bbbb gap vault nearly time average trade software maker hit week high follow latest quarterly result late tuesday blackboard accumulation distribution rating improve just session schweitzer mauduit swm jump regain day move average almost triple average trade late tuesday tobacco paper product maker smash view pop earning sale fall view firm also raise full year profit outlook analyst estimate medifast med gap rally time high maker weight loss product recently report bulge earning third straight period accelerate growth sale have also picked recent quarters downside stec stec gap day move average plunge nearly month low firm say key customer emc emc carry inventory earning thursday include abovenet abvt brink home security cfl fuel system solution fsys orion marine group orn royal gold rgld starbucks sbux sxc health solution sxci datum productivity jobless claim also be thursday update late selling dent rallyby vincent maostock lose steam last hour finishing event filled session mixed result wednesday dow nyse composite rise tick meanwhile nasdaq slip index be more session high accord preliminary datum nasdaq volume edge higher nyse turnover dip hmo rally possibility congress miss deadline health care reform foreign bank steel producer also climb tire maker apparel manufacturer fall stock high late tradeby vincent mao update stock find direction be best level wednesday session experience volatility fed decision dow nyse composite rally climb nasdaq turnover be again tracking lower board cisco system csco rise regain day move average networking giant report fiscal result close analyst be expect earning cent share cent year sale be expect company outlook provide key insight tech spending tech heavyweight qualcomm qcom also report close downside ebix ebix erased earlier gain fall heavy trading open software firm beat view rise earning sale rise view stock be near day move average update fed reaffirm extend low ratesby ed federal reserve slightly upgrade view economy wednesday reaffirm pledge keep interest rate very low extend period expect fomc vote keep fed fund target rate record low range policymaker say post meeting statement economic activity have continue pick household spending improve have intention even hint take away monetary punch bowl foreseeable future unemployment high inflation low fed keep rate low extend period however central bank say buy worth agency mortgage debt news year treasury yield briefly jump recent high major average modestly fed announcement begin fade volatile trade dow rise nasdaq update index pull back fed decision loomsby vincent maostock pare gain ahead fed interest rate decision due dow rise session high nyse composite climb meanwhile nasdaq lag gain volume continue track lower nyse slightly higher nasdaq netlogic microsystem netl jump report higher earning sale first time quarters late tuesday integrate circuit maker beat view rise profit sale grow analyst see income rise current period sxc health solution sxci climb fast trade open provider pharmacy benefit management service health care service say win contract sxc report earning thursday analyst see profit rise cent share downside garmin grmn reversed morning gain tumble month low gps device maker have big change heart deliver result well view last week google goog enter navigation market google map navigation android device dolby laboratory dlb trim earlier loss late tuesday developer entertainment technology report lower fiscal earning beat view sale miss estimate dolby board approve share buyback earlier wednesday jpmorgan maxim group downgrade share update stock higher middayby jonah major index retain gain mixed volume midday wednesday nasdaq rise dow picked nyse composite advanced volume be mixed trading fall nyse compare same period tuesday nasdaq volume climb rock tenn rkt rise twice normal trade maker packaging merchandising display beat fiscal fourth quarter earning view stock have be consolidate hit new high late august atwood oceanic atw advanced rapid turnover offshore drill firm stock find support day move average tuesday downside true religion apparel trlg plunge gigantic volume upscale jean maker miss profit view issue weak forecast send stock tumble day line update market surge late morning actionby jonah major index gain accelerate wednesday number lead stock fare well nasdaq rise dow picked nyse composite advanced volume be mixed trading fall nyse compare same period tuesday nasdaq volume climb schweitzer mauduit swm surge massive volume cigarette paper tobacco product maker top earning view raise full year forecast push stock new high ground china green agriculture cga gain nearly twice usual turnover company launch new fertilizer product china green stock vault day move average medifast med gain rapid trade maker weight control disease management product climb week high update stock open higher mixed trade
247,HSIC,few year stan bergman joined henry schein chief financial officer boss give key assignment buy stake pharmaceutical maker foreign country accountant training bergman soon become embroil mess employee acquire firm grow suspicious american interloper bergman delve
248,HSIC,orthodontic specialist align technology algn be expect report growth profit sale wednesday slower pace last few quarters
249,HSIC,analyst poll thomson reuter expect profit cent share average third quarter year quarter revenue be forecast rise previous quarters growth rate range drive company ep rank top publicly trade company
250,HSIC,firm have history lumpy quarters sensitivity economic cycle due discretionary nature premium price invisible dental brace ibd profile company
251,HSIC,report dental stock whole issue early tuesday william blair analyst write survey dental practitioner suggest soft third quarter channel check indicated stability compare other player such henry schein hsic patterson co pdco sirona dental siro analyst say align have best ability beat expectation quarter soft environment due market share gain new product offering
252,HSIC,company have be regular member ibd ranking top stock april usually top rank monday list stock early trading tuesday have rise more year have more double past month orthodontic specialist align technology algn be expect report growth profit sale wednesday slower pace last few quarters analyst poll thomson reuter expect profit cent share average third quarter year quarter revenue be forecast rise previous quarters growth rate range drive company ep rank top publicly trade company firm have history lumpy quarters sensitivity economic cycle due discretionary nature premium price invisible dental brace ibd profile company report dental stock whole issue early tuesday william blair analyst write survey dental practitioner suggest soft third quarter channel check indicated stability compare other player such henry schein hsic patterson co pdco sirona dental siro analyst say align have best ability beat expectation quarter soft environment due market share gain new product offering company have be regular member ibd ranking top stock april usually top rank monday list stock early trading tuesday have rise more year have more double past month
253,HSIC,orthodontic specialist align technology algn late wednesday report result miss analyst estimate send share plummet nearly hour
254,HSIC,align main product be invisalign invisible brace say profit special item be cent share penny year quarter cent shy analyst consensus sale rise analyst expect guidance current quarter fall well short wall street view
255,HSIC,align also announce smarttrack call highly elastic new aligner material deliver gentle more constant force improve control tooth movement invisalign clear aligner treatment company say be standard invisalign material start
256,HSIC,company also say end agreement straumann distribute itero scanner europe north america year end align acquire scanner relationship straumann buy cadent last year
257,HSIC,goodwill impairment uncertain
258,HSIC,move seem slow release earning report come minute later expect align say be still try figure end deal decline sale former unit generate goodwill impairment charge so call result preliminary
259,HSIC,align say test hasn conclude goodwill say have carry value be impair
260,HSIC,company face other problem statement ceo thomas prescott say usual summer downturn be sharper average have fail recover so far fall lead cut fourth quarter guidance align now expect revenue single digit last year well short analyst consensus forecast profit cent share vs analyst cent
261,HSIC,prescott say bright spot be invisalign rise sequentially year year align have be push hard market roth capital analyst matt dolan call extremely important
262,HSIC,think market have lot implication strategically begin chip away competitive market share traditional wire bracket dolan tell ibd earning release
263,HSIC,acquisition rumor
264,HSIC,note issue jmp security analyst haresco write market be key competitive advantage dhr have launch own invisible brace product call clearguide
265,HSIC,clearguide remain nonissue orthodontist seem have relegate class adult case have speak have be incline use product teenager write
266,HSIC,own align share have long be rumore possible acquirer dolan say large dental industry company such henry schein hsic even mmm also be interested align continue succeed market say remain ideal suitor
267,HSIC,company earning release didn blame europe haresco tell ibd other medtech firm shortfall europe have drive decline align share wednesday regular trading session problem be here general practitioner channel tell ibd email orthodontic specialist align technology algn late wednesday report result miss analyst estimate send share plummet nearly hour align main product be invisalign invisible brace say profit special item be cent share penny year quarter cent shy analyst consensus sale rise analyst expect guidance current quarter fall well short wall street view align also announce smarttrack call highly elastic new aligner material deliver gentle more constant force improve control tooth movement invisalign clear aligner treatment company say be standard invisalign material start company also say end agreement straumann distribute itero scanner europe north america year end align acquire scanner relationship straumann buy cadent last year goodwill impairment uncertainthat move seem slow release earning report come minute later expect align say be still try figure end deal decline sale former unit generate goodwill impairment charge so call result preliminary align say test hasn conclude goodwill say have carry value be impair company face other problem statement ceo thomas prescott say usual summer downturn be sharper average have fail recover so far fall lead cut fourth quarter guidance align now expect revenue single digit last year well short analyst consensus forecast profit cent share vs analyst cent prescott say bright spot be invisalign rise sequentially year year align have be push hard market roth capital analyst matt dolan call extremely important think market have lot implication strategically begin chip away competitive market share traditional wire bracket dolan tell ibd earning release acquisition rumorsin note issue jmp security analyst haresco write market be key competitive advantage dhr have launch own invisible brace product call clearguide clearguide remain nonissue orthodontist seem have relegate class adult case have speak have be incline use product teenager write own align share have long be rumore possible acquirer dolan say large dental industry company such henry schein hsic even mmm also be interested align continue succeed market say remain ideal suitor company earning release didn blame europe haresco tell ibd other medtech firm shortfall europe have drive decline align share wednesday regular trading session problem be here general practitioner channel tell ibd email
268,HSIC,sirona dental system siro top analyst fiscal estimate announce new ceo friday morning send share early trading sale quarter end rise year quarter well wall street consensus profit exclude item be cent share cent
269,HSIC,medical supplier patterson co pdco gap hard thursday morning fiscal profit miss expectation
270,HSIC,company sell equipment dental veterinary rehabilitation market report earning cent share year quarter cent short analyst consensus revenue beat estimate however climb shortfall company affirm previous fiscal ep guidance last year
271,HSIC,patterson press release ceo scott anderson say sale dental consumable have be lower expect equipment sale be strong especially dental restoration system cerec add new camera introduce sirona dental siro boost sale make cerec easier use
272,HSIC,share tumble nearly first hour trading have re-cover few point late morning earning season have not be kind dental supplier dentsply xray align technology algn guide low side industry heavweight henry schein hsic beat estimate didn translate much action stock have stick day move average medical supplier patterson co pdco gap hard thursday morning fiscal profit miss expectation company sell equipment dental veterinary rehabilitation market report earning cent share year quarter cent short analyst consensus revenue beat estimate however climb shortfall company affirm previous fiscal ep guidance last year patterson press release ceo scott anderson say sale dental consumable have be lower expect equipment sale be strong especially dental restoration system cerec add new camera introduce sirona dental siro boost sale make cerec easier use share tumble nearly first hour trading have re-cover few point late morning earning season have not be kind dental supplier dentsply xray align technology algn guide low side industry heavweight henry schein hsic beat estimate didn translate much action stock have stick day move average
273,HSIC,think big re efficient large operation accomplish more spending less leader analyze apply grand scale resource take outside advanced technology service begin internal group caterpillar cat task make firm factory run generate increase efficiency heavy equipment manufacturer at spun
274,HSIC,share dental supplier align technology algn be early trading thursday continue free fall company earning report late wednesday disappoint
275,HSIC,ibd report maker invisalign invisible brace badly miss wall street estimate cut outlook create uncertainty say wasn sure be go take goodwill impairment charge acquisition last year conference call analyst ceo thomas prescott say company research market show conflict datum
276,HSIC,hand datum such surprisingly strong recent consumer sentiment rating well uptick visitor invisalign com find doctor search point continue strong consumer interest say other hand additional insight customer regard invisalign practice indicate more adult patient be delay push acceptance clincheck treatment plan summer early fall possibly due concern economy
277,HSIC,most other medical firm quarter align report weak sale europe prescott say be exacerbate execution miss italy lead replacement department leadership
278,HSIC,align rival shareholder possible buyer dhr be nearly miss expectation result report early thursday ominous sign industry put other dental stock pressure sirona dental system siro be nearly patterson co pdco henry schein hsic be dentsply xray be
279,HSIC,align share have more double past month wednesday have be regular member ibd ranking top stock share be trading month lows early thursday share dental supplier align technology algn be early trading thursday continue free fall company earning report late wednesday disappoint ibd report maker invisalign invisible brace badly miss wall street estimate cut outlook create uncertainty say wasn sure be go take goodwill impairment charge acquisition last year conference call analyst ceo thomas prescott say company research market show conflict datum hand datum such surprisingly strong recent consumer sentiment rating well uptick visitor invisalign com find doctor search point continue strong consumer interest say other hand additional insight customer regard invisalign practice indicate more adult patient be delay push acceptance clincheck treatment plan summer early fall possibly due concern economy most other medical firm quarter align report weak sale europe prescott say be exacerbate execution miss italy lead replacement department leadership align rival shareholder possible buyer dhr be nearly miss expectation result report early thursday ominous sign industry put other dental stock pressure sirona dental system siro be nearly patterson co pdco henry schein hsic be dentsply xray be align share have more double past month wednesday have be regular member ibd ranking top stock share be trading month lows early thursday
280,HSIC,be last leg first quarter earning season latest earning preview already member have report financial result overall performance reflect many positive sign buoy optimism investor latest earning scorecard highlight increase total earning higher revenue beat ratio have be impressive well company surpass bottom line expectation beating top line mark medical sector zack sector have put stellar show so far be project rise revenue growth earning season await medical product stock broadly speaking latest tax cut job act have have also raise hope stakeholder have slash corporate tax rate earlier many other change medical product space be part broader medical sector have be hog lot limelight back certain favorable development sector have be go strong courtesy encourage demographic change market dynamic artificial intelligence ai big datum application upbeat consumer sentiment increase business investment further senate decision defer implementation industry wide excise tax medical device tax couple year have instilled confidence investor tax be effective jan bill also delay so call cadillac tax tax employer insurance backdrop let take sneak peek major medical product stock schedule release earning report quantitative zack model stock perfect combination solid zack rank strong buy buy hold positive earning esp have higher chance beating estimate uncover best stock buy sell re report earning esp filter henry schein inc hsic free report henry schein strategy globally expand digital dentistry be impressive management also look forward sustainable dental equipment business growth europe other region company bank digital dentistry be line strategic plan furthermore management believe company be well position gain ongoing trend digitalization global dental market be also content well diversify animal health product portfolio feature software diagnostic equipment surgical instrument good news be array solid product offering have be drive growth domestically well globally notably company earning outpaced zack consensus estimate average beat trail quarters moreover consensus mark first quarter earning cent share have remain unchanged last day same company revenue be peg improvement year figure henry schein have earning esp zack rank read more overall growth drive henry schein hsic free report earning henry schein inc price ep surprise henry schein inc price ep surprise henry schein inc quotepenumbra inc pen free report first quarter result be expect gain traction strong product uptake last report quarter company witness better sequential growth higher procedural volume additionally company be actively pursue marketing strategy also management seem cheer internal effort generate awareness domestic region also appear positive heighten cooperation hospital handle stroke case zack consensus estimate be peg loss cent share indicate year year improvement however be difficult conclusively predict earning beat stock last complete quarter penumbra have zack rank earning esp read more store penumbra earning season see complete list today zack rank stock here penumbra inc price ep surprise penumbra inc price ep surprise penumbra inc quotebio rad laboratory inc bio free report be global provider broad range innovative product solution life science research clinical diagnostic market company have net sale exceed consensus estimate earning cent translate surge year quarter however metric outperformed zack consensus estimate average beat last quarters bio rad have earning esp be zack rank player bio rad laboratory inc price ep surprise bio rad laboratory inc price ep surprise bio rad laboratory inc quotehaemonetic corporation hae free report haemonetic have be benefit continue momentum new business generation geographical expansion be happy haemonetic consistent growth plasma franchise strong end market demand plasma derive continue enhance growth company be now focuse development launch nexsys pcs plasmapheresis system additionally strong cash position lift investor trust notably company earning outshined zack consensus estimate average positive surprise precede quarters haemonetic have earning esp carry zack rank sell zack consensus estimate fourth quarter fiscal earning stand cent share depict significant rise prior year tally estimate revision company revenue see decline year year value haemonetic corporation price ep surprise haemonetic corporation price ep surprise haemonetic corporation quotemore stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
281,HSIC,cvs health cvs free report be schedule report first quarter result open bell last report quarter company deliver positive earning surprise trail quarter average positive earning surprise be let take look thing be shape prior announcement factor playcvs health have so far progressed well pbm selling season last report number gross new business win totale net new business win gross impressive client retention rate momentum be expect continue be report quarter tough pricing competition cvs health be currently gain high level service execution competitive pricing unique integrate model company be also upbeat sustain solid year year earning trend first quarter gain be realize pharmacy service segment performance be be drive higher specialty pharmacy pharmacy network claim volume well brand inflation management state cvs health specialty business be top priority help company expand customer base cvs health be poise capitalize opportunity back wide differentiate offering include specialty connect cvs health corporation price ep surprise cvs health corporation price ep surprise cvs health corporation quotefurther company expect drug price inflation product launch higher utilization fuel growth expect pharmacy service segment be stable growth platform cvs health also project better expect performance be report quarter primarily back ofscript utilization retail company have project rise consolidated net revenue first quarter further strong flu season have lead improve outlook overall first quarter company expect register adjust operate profit growth range zack consensus estimate total revenue reflect increase year year cvs health retail ltc business register revenue growth several quarters slump last report quarter be multiple factor raise concern firstly year year growth be just marginal further continue reimbursement pressure increase generic dispense rate andrecent generic drug introduction have be affect business apart marketplace change keep cvs pharmacy participate certain network have basis point negative impact same store prescription volume previously report quarter however cvs health have be strive return growth retail ltc business management claim company be focuse work payer drive volume capture market share cvs health be also poise gain program such health tag extracare health card company also expect witness revenue growth operate profit growth low mid single digit range retail ltc business here be quantitative model predict proven model do not conclusively show cvs health beat estimate earning season be stock need have positive earning esp solid zack rank strong buy buy hold happen be not case here see zack esp cvs health have earning esp uncover best stock buy sell re report earning esp filter zack rank cvs health carry zack rank sell please note stock zack rank strong sell never be consider go earning announcement especially company be see negative estimate revision meanwhile zack consensus estimate first quarter adjust ep reflect increase year year stock considerhere be few medical stock worth consider right combination element beat estimate time laboratory corporation america holding lh free report have earning esp zack rank henry schein inc hsic free report have earning esp zack rank align technology inc algn free report have earning esp be zack rank player today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
282,HSIC,boston scientific corporation bsx free report be schedule report first quarter result open bell apr last quarter company deliver earning line zack consensus estimate however average trail quarter earning surprise be peg let see thing be shape prior announcement key catalystswithin structural heart be look forward boston scientific watchman acurate iris product line expect strongly contribute company top line yet be report quarter earlier company state expect revenue watchman acurate tavr franchise gross approximately be optimistic gradually improve performance interventional cardiology ic lead innovative portfolio robust commercial team globally more specifically company have late successfully gain business strong sale watchman left atrial appendage closure device portfolio complex pci intervention product watchman platform be anticipate experience excellent quarter consistent global momentum boston scientific multiple market development effort continue push growth apart new launch ic business wolverine cut balloon company next generation rotational atherectomy platform call rotapro be likely strongly contribute top line upcoming quarter be also upbeat company acurate tavr transcatheter aortic valve replacement program have recently complete training european sale clinical team boston scientific corporation price ep surprise boston scientific corporation price ep surprise boston scientific corporation quote however ahead company earning release first quarter believe ic business be once again deeply impact product recall issue europe notably company have recently announce further delay earlier report timeline commercial return lotus edge aortic valve system europe well unite state follow product voluntary recall last february other factor playamong segment medsurg be estimate demonstrate steady performance lead endoscopy urology woman health be also project grow market level drive investment strategy key international geography however company be expect face business too yet be report quarter headwind come form year year difficult pacer comparison more competition drug eluting stent space new entrant overall zack consensus estimate first quarter endoscopy revenue be peg prior year quarter report count urology woman health consensus mark remain ahead year earlier quarter report tally flip side severe currency headwind boston scientific have be face late remain concern fact company record sale international market get highly expose currency fluctuation apart immaterial be report quarter ongoing tension unite state well china regard imposition tariff import have raise concern major medtech player adverse move affect top line number future here quantitative model predictsper proven zack model company favorable zack rank strong buy buy hold have good chance beating estimate also have positive earning esp boston scientific have zack rank increase predictive power esp earning esp make surprise prediction difficult together combination do not suggest company be likely beat earning quarter caution sell rate stock go earning announcement especially company be see negative estimate revision uncover best stock buy sell re report earning esp filter stock worth lookhere be few medical stock worth consider right combination element beat estimate time myriad genetic inc mygn free report have earning esp zack rank see complete list today zack rank stock here henry schein inc hsic free report have earning esp zack rank quest diagnostic incorporate dgx free report have earning esp be zack rank player today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
283,HSIC,abbott free report establish pharmaceutical division epd business have be record operational sale growth last few quarters expect strength get reflect first quarter result well be schedule release apr click here know company overall performance be expect be key business majorly focus emerge market notably key emerge market include india russia china numerous other latin america well brazil other country sale key emerge market increase comparable operational basis drive double digit growth india china latin america last report quarter moreover management believe emerge market continue offer immense opportunity favorable demographic accordingly zack consensus estimate epd revenue key emerge market indicate rise year quarter immaterial be report quarter ongoing tension unite state china regard imposition tariff import have raise concern major medtech player adverse move affect sale performance china term abbott laboratory price ep surprise abbott laboratory price ep surprise abbott laboratory quote encouragingly note management expect high single digit growth epd sale first quarter furthermore zack consensus estimate epd revenue show rise year quarter favorable currency translation also have positive impact epd revenue last report quarter encouragingly note management expect foreign exchange continue act tailwind be report quarter epd abbott consistent focus enhance local capability expand product portfolio core therapeutic area be target specifically address local market need effort company also continue strengthen leadership position epd market abbott sale develop market business acquisition cfr pharmaceutical latin america veropharm russia have contribute epd business zack rank stock considerabbott carry zack rank hold few better rank stock broader medical sector be bio rad laboratory bio free report myriad genetic inc mygn free report abiom inc abmd free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here have long term expect earning growth rate myriad genetic have long term expect earning growth rate stock carry zack rank buy abiom have long term expect earning growth rate stock carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
284,HSIC,value investing be easily most popular way find great stock market environment wouldn want find stock be fly radar be compelling buy offer tantalize discount compare fair value way find company be look several key metric financial ratio many be crucial value stock selection process let put henry schein inc hsic free report stock equation find be good choice value oriented investor right now investor subscribe methodology look elsewhere top pick pe ratioa key metric value investor always look be price earning ratio pe short show much investor be willing pay dollar earning give stock be easily most popular financial ratio world best use pe ratio be compare stock current pe ratio ratio have be past compare average industry sector compare market whole front henry schein have trail month pe ratio see chart level actually compare pretty favorably market large pe stand focus long term pe trend henry schein current pe level put midpoint past year fact current level stand close lows stock suggest be superb entry point further stock pe compare favorably zack medical sector trail month pe ratio stand very least indicate stock be relatively undervalue right now compare peer also point henry schein have forward pe ratio price relative year earning just so be fair say slightly more value oriented path be ahead henry schein stock term too ratioanother key metric note be price sale ratio approach compare give stock price total sale lower read be generally consider better person metric more other value focuse one look sale something be far harder manipulate accounting trick earning right now henry schein have ratio be much lower average come right now also see chart be well high stock particular past few year broad value outlookin aggregate henry schein currently have value score putt top stock cover look make henry schein solid choice value investor stock overall henry schein be good choice value investor be plenty other factor consider investing name particular be worth note company have growth score momentum score give hsic zack vgm score overarch fundamental grade read more zack style score here meanwhile company recent earning estimate have be quite mixed current quarter have see estimate go higher past day compare lower full year estimate have see upward downward revision same time period have have slightly positive impact consensus estimate full year estimate consensus estimate have rise past month current quarter have remain unchanged see consensus estimate trend recent price action stock chart henry schein inc price consensus henry schein inc price consensus henry schein inc quotegiven trend stock have just zack rank hold be be look line performance company term bottom linehenry schein be inspire choice value investor be hard beat incredible lineup statistic front however sluggish zack industry rank bottom more industry zack rank be hard get too excited company overall fact past year industry have clearly underperform broader market see so value investor want broader industry factor turn name first once happen stock be compelling pick look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
285,HSIC,medical device tax suspension jan be very few amendment have garner maximum number bipartisan vote house enactment tax have be quite menace medical device industry statement advanced medical technology association lobbying group tax have significant negative impact medical innovation employment consider house place suspension tax january december only bring back jan recently house come bill tax cut include abatement infamous medical device tax medtech fraternity have be cheer latest repeal share price net margin performance medical device manufacturer be show different story let delve deeper glitzy be repeal medtech innumerable report claim repeal ramp domestic production increase hire skilled professional lower nation overdependence offshore production further medtech bigwig be expect enhance improve margin launch product reduce capital depreciation invest early stage medtech company execute clinical trial turn fuel next generation medical device industry reinvest profit tax saving notably johnson johnson jnj free report shell lump sum medical device sale tax meanwhile medical device giant stryker corporation syk free report report net earning paid approximately medical device excise tax nearly earning datum med device online report tax didn exist analyst believe company have used cash expand improve pipeline draw heavy criticism compelling democrat republican lift tax history say different storysince tax be abolish end company be expect rake profit also put impressive show bourse start however price performance margin trend contradict expectation fact tax repeal news create quite stir analyst back deal blow share medical device manufacturer datum show broader medical product industry have underperform market last year industry cut sorry figure comparison here take sneak peek net margin trend company last tax repeal single metric determine profitability business accurately investor count net margin get fair idea amount profit company be make decline net margin post tax repeal amendment throw light enormous risk cost associate compliance requirement medtech manufacturer also raise question tax repeal provide impetus medtech space do nothing significant year back stock grapple decline price net marginhere have medtech stock have witness significant margin contraction tax repeal draw attention share price net margin performance company follow tax abolition past year medtronic plc mdt free report have be observed underperform broader market latest share price movement stock lose compare unfavorably gain company have be face escalate cost expense be weigh margin also company reiteration guidance projection favorable foreign currency translation fail lift investor spirit past year henry schein inc hsic free report have underperform index stock have lose be disappoint continue deterioration company gross operate net margin thank higher cost sale expense also tough competitive landscape pricing pressure weigh stock healthcare product service distribution industry be highly competitive consist principally national regional local distributor north american dental product market company face stiff competition patterson dental business patterson company inc benco dental supply dentsply sirona inc xray free report share price movement have be disheartening past year company have lose period lackluster margin trend same time frame indicate company failure garner profit post tax repeal day comedentsply expect gross operate margin remain flat decline slightly level underlie margin rate improvement be expect be offset adverse foreign exchange target inventory equipment reduction allscript healthcare solution inc mdrx free report have underperform broader market term price past month notably stock have return compare rally further company margin have contract significantly past year allscript also expect modest increase operate expense company face sluggishness international market competition larger player bruker corporation brkr free report have underperform broader market term price past year stock have return just much lower market further company margin have decline steeply past year bruker conduct business international market result currency fluctuation continue result foreign currency transaction loss latest medtech tax overhaul paint different picture stock history repeat analysis clearly show broader industry hasn react positively tax repeal amendment be legislate consider repeal effect medtech space trend be expect continue time well however medtech industry have be favore massive change consumer behavior lately couple change market dynamic lead dramatic transformation healthcare system last couple year be evident rise minimally invasive surgery higher demand liquid biopsy test use quick improve patient care shift payment system value base model further strategic application artificial intelligence sphere healthcare provide boost productivity medtech space company have adopt ai technology witness reduction healthcare cost be expect record strong margin expansion well never know current favorable trend turn table medtech industry more stock news company verge apple rundid miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
286,HSIC,henry schein inc hsic free report latest deal grifol grfs free report add stimulus distribution business company have sign distribution agreement enable former market distribute latter ml normal saline solution sodium chloride injection usp market notably grifol be lead producer plasma derive medicine forerunner research development therapeutic alternative company manufacture ml normal saline solution industrial complex murcia spain receive fda approval market product unite state only last year grow demand saline product market believe partnership be strategically beneficial henry schein company solution grifol have capacity quickly meet customer need shortage iv solution company gain impetus global supply infrastructure well henry schein widespread network regard note henry schein distribution business boast broad global footprint distribution center locate apart north america europe company have presence australia new well emerge market china brazil israel czech republic poland be latest target hub grifol apart company significant distribution partner be terason dentsply sirona henry schein exclusively distribute terason usmart nexgen canadian dental subsidiary distribute entire dentsply sirona product line share price movement past month share henry schein have underperform industry belong stock have lose contrast industry gain expect latest development help boost investor confidence stock zack rank key pickshenry schein carry zack rank hold better rank stock broader medical sector be bio rad laboratory bio free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank buy wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
287,HSIC,henry schein inc hsic free report report adjust earning share ep cent fourth quarter year year adjust ep remain line zack consensus estimate year year upside earning be drive strong revenue growth business segment adjust ep year be improvement year period also remain line zack consensus estimate revenue detailhenry schein report net sale fourth quarter year year marginally zack consensus estimate year year improvement come back internal sale growth local currency increase owing foreign currency exchange acquisition growth be quarter net sale full year be improvement year number top line also exceed zack consensus estimate henry schein inc price consensus ep surprise henry schein inc price consensus ep surprise henry schein inc quotein fourth quarter company record sale north american market year year sale totale international market year year segment analysis henry schein derive revenue operate segment dental medical animal health technology value add service fourth quarter company derive revenue global dental sale year year include growth local currency contribution foreign currency exchange local currency internally generate sale increase acquisition growth be quarterly result also have negative impact additional week year period internal growth local currency include growth north america rise internationally company global animal health segment witness rise revenue include growth local currency increase foreign currency exchange local currency internally generate sale increase acquisition growth be extra week have negative impact quarterly sale performance internal growth local currency include rise north america improvement internationally worldwide medical revenue rise year year growth local currency be increase owing favorable foreign exchange revenue global technology value add service grow include growth local currency rise related foreign currency exchange acquisition contribute quarter review margin trend gross profit increase report quarter however gross margin contract basis point bps year quarter due rise cost sale higher revenue growth rate rise selling general administrative expense adjust operate income improve year year however adjust operate margin decline bps year year report quarter financial positionhenry schein exit year cash cash equivalent compare end full year net cash provide operate activity be compare year period quarter review company buy back approximately share almost close fourth quarter company have authorize repurchase common stock guidancehenry schein raise ep guidance reflect impact tax reform legislation include estimate cent impact associate certain time cash bonus company currently expect ep range reflect growth report ep figure previous ep guidance range be zack consensus estimate adjust ep be guide range takehenry schein exit fourth quarter mixed note company operate segment record strong year year growth henry schein strong share gain north american overseas market solid revenue raise optimism better expect revenue performance be disappoint year year deterioration henry schein gross operate margin due higher cost sale expense increase ep guidance buoy optimism zack rank key pickshenry schein have zack rank hold better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank see complete list today zack rank stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
288,HSIC,headquarter melville ny henry schein inc hsic free report be global lead provider healthcare product service company serve office base dental medical animal health practitioner dental laboratory government well institutional health care clinic other alternate care site presently henry schein serve more customer have operation country company enter prestigious standard poor index mar currently henry schein have zack rank hold change follow fourth quarter earning report have just release see complete list today zack rank strong buy stock here have highlighted key detail just release announcement henry schein inc price ep surprise henry schein inc price ep surprise henry schein inc quoteearning zack consensus estimate be peg cent share henry schein adjust earning share remain line estimate revenue henry schein post net sale ahead zack consensus estimate revenue key stat revenue fourth quarter derive henry schein dental segment grow year year animal health segment record sale compare prior year quarter revenue medical segment increase year year sale technology value add service segment grow major factor management global segment gain solid market share quarter deliver solid earning growth back strategy grow business organically acquisition company have raise ep guidance new range compare earlier provide band stock price follow earning release share price do not show significant movement pre market trading session check back later full henry schein earning report later hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
289,HSIC,henry schein inc hsic free report be expect report fourth quarter result feb last quarter company miss earning estimate however henry schein earning surpass zack consensus estimate past quarters average let see thing be shape prior announcement factor playhenry schein third quarter result be quite impressive record growth segment dental animal health medical technology value add service geographically company gain traction north america overseas expect similar trend fourth quarter favorable dental business trend company strategy expand digital dentistry globally be encourage be also upbeat management expectation least low single digit growth north america dental consumable merchandise market second half zack consensus estimate fourth quarter total revenue reflect increase year quarter company bank digital dentistry be part strategic plan henry schein be busy promote digital workflow general dentistry well dental specialty start sep company start selling full range dentsply sirona dental equipment north america include lead cerec cad cam restoration system be expect boost top line considerable extent henry schien also continue represent product planmeca dec midmark shape well dental equipment consumer product line longstanding partner kavo kerr brand henry schein inc price ep surprise henry schein inc price ep surprise henry schein inc quote solid animal health portfolio be optimistic well diversify animal health product portfolio feature software diagnostic equipment surgical instrument solid product offering have be drive growth domestically well globally notably fourth quarter henry schein acquire merritt veterinary supply integrate animal health business merritt have veterinary clinic eastern unite state strong presence southeastern part nation company offer comprehensive line product include pharmaceutical diagnostic equipment however accord henry schein acquisition drive earning post grow medical business henry schein be consistently work boost medical segment notably worldwide medical revenue rise year year last report third quarter october company inked agreement cerebral assessment system distribute cognivue be first computerize cognitive assessment screening device clear fda detection early sign dementia believe development bolster growth company field mental cognitive disease same month company announce exclusive distribution agreement terason distribute latter usmart nexgen development remain part henry schein medical emergency medical service business broad distribution network be also upbeat company widespread distribution network apart north america europe company have presence australia new well emerge nation china brazil israel czech republic poland flip side henry schein disappointing gross operate margin performance past few quarters due higher cost sale expense be matter concern apart currency fluctuation tough competitive landscape add wo also entry group purchasing organization gpos unite state have intensified competition overall henry schein expect ep range reflect growth adjust ep figure earning whispersour proven model do not conclusively show henry schein be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp henry schein have earning esp be most accurate estimate be peg cent zack consensus estimate stand cent zack rank henry schein carry zack rank increase predictive power esp however esp make surprise prediction difficult nonetheless zack consensus estimate fourth quarter adjust earning cent reflect rise year year stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter amphastar pharmaceutical amph free report have earning esp zack rank see complete list today zack rank stock here audro biotech inc adro free report have earning esp zack rank cooper company inc coo free report have earning esp zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
290,HSIC,laboratory corporation america holding lh free report also know labcorp be slate report fourth quarter result market open feb last quarter company deliver positive earning surprise have average earning beat trail quarters let see thing be shape announcement factor playsimilar last quarter labcorp be expect gain strength labcorp diagnostic segment fourth quarter notably third quarter revenue segment grow primarily banking favorable price mix tuck acquisition organic volume several quarters weak show covance drug development have start report revenue growth third quarter back chiltern acquisition strong organic growth favorable foreign currency translation chiltern have add highly complementary capability labcorp offering include scale expansion asia pacific broader reach fast grow emerge mid tier biopharma customer segment expertise oncology drug development factor continue benefit labcorp covance drug development topline yet be report quarter well laboratory corporation america holding price ep surprise laboratory corporation america holding price ep surprise laboratory corporation america holding quotewe be also look forward company latest deal agilent make latter cancer diagnostic test available expand use development start contribute labcorp top line fourth quarter also company comprehensive laboratory partnership capital health be positive labcorp earlier provide guidance net revenue be now expect band year year include bps impact unfavorable foreign exchange zack consensus estimate revenue be peg adjust ep be expect remain range zack consensus estimate be guide range however last year labcorp have face several reimbursement issue have hurt revenue company be concern cms center medicare medicaid service proposal related protect access medicare act pama believe reimbursement pressure affect company performance soon be report quarter well labcorp have be constantly try check rise operate expense affected operate margin last report quarter chance turnaround scenario time soon be slim here be quantitative model predict labcorp do not have right combination main ingredient positive earning esp zack rank hold higher increase odd earning beat zack esp earning esp labcorp be uncover best stock buy sell re report earning esp filter zack rank labcorp carry zack rank increase predictive power esp however negative esp make surprise prediction difficult stock considerhere be few medical stock worth consider have right combination element post earning beat quarter bio rad laboratory bio free report have earning esp zack rank buy see complete list today zack rank strong buy stock here myriad genetic mygn free report have earning esp zack rank henry schein hsic free report have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
291,HSIC,myriad genetic inc mygn free report be schedule report second quarter fiscal result feb close bell last quarter company post positive earning surprise moreover myriad genetic beat zack consensus estimate trail quarters average be let take look thing be shape prior announcement factor influence resultssimilar last quarter myriadgenetic be expect gain strong molecular diagnostic performance lead solid contribution genesight endopredict test company genesight test represent significant opportunity genesight be place highly penetrate preventive care market product have huge growth potential also last report quarter company announce favorable datum multus center double blind randomize controlled trial evaluate impact genesight psychotropic test psychiatric treatment response patient major depressive disorder be expect stimulate expand genesight adoption payer coverage management expect consistent growth genesight test revenue quarters ahead also encouragingly note last few month myriad genetic have be make encourage progress endopredict test fiscal company receive reimbursement approval endopredict france quebec increase number german site company also receive positive coverage decision test palmetto gba medicare administrative contractor mac anthem antm free report august month test launch unite state notably full implementation decision lend myriad genetic coverage approximately breast cancer patient moreover accord myriad genetic endopredict present global market opportunity more annually major demand country canada unite state myriad genetic inc price ep surprise myriad genetic inc price ep surprise myriad genetic inc quote be also upbeat management expectation double digit volume growth fiscal genesight vectra da prolaris revenue make chunk molecular diagnostic portfolio prolaris testing volume grow double digit last report quarter well be also encourage company receipt positive final local coverage determination expand medicare coverage prolaris test palmetto gba mac first half moreover management seem upbeat prospect prolaris test represent global market opportunity approximately annually myriad genetic witness continue year year growth hereditary cancer volume pricing match expectation last report quarter management company continue witness solid sample trend space last september company launch riskscore myrisk hereditary cancer testing portfolio notably riskscore help determine woman risk develop breast cancer combine genetic marker genome patient family clinical history management believe company be well position breast cancer testing market fiscal courtesy encourage hereditary cancer volume steady growth predictable long term pricing thus believe company be position cash huge potential breast cancer screening market zack consensus estimate fiscal second quarter revenue reflect decline year quarter report number flip side unfavorable foreign currency translation continue threat considerable portion revenue come outside unite state company face risk exchange rate fluctuation additionally macroeconomic uncertainty higher expense owing extensive pipeline testsmay impact margin earning whispersour proven model do not conclusively show myriad genetic be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp myriad genetic have earning esp be most accurate estimate be peg cent zack consensus estimate be cent zack rank myriad genetic carry zack rank increase predictive power esp however esp make surprise prediction difficult zack consensus estimate second quarter adjust earning cent reflect decline year quarter stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter bio rad laboratory bio free report have earning esp zack rank see complete list today zack rank stock here henry schein hsic free report have earning esp zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
292,HSIC,corp abc free report first quarter fiscal result schedule release feb be expect show steady growth pharmaceutical distribution segment significant contributor revenue last quarter company post positive earning surprise have outperformed zack consensus estimate precede quarters average beat be let take look thing be shape prior announcement earning precede quarter surpass zack consensus estimate courtesy strong growth consult service mwi animal health world courier business revenue rise almost year quarter corporation hold co price ep surprise corporation hold co price ep surprise corporation hold co quote zack consensus estimate pharmaceutical distribution segment stand quarter review reflect improvement almost year quarter other factor specialty group perform impressively recent past revenue rise year year last report quarter upside be attribute strong oncology product sale solid performance third party logistic business factor be expect play pivotal role boost segmental revenue first quarter well other segment segment include consult service world courier mwi veterinary supply also perform well last quarter revenue segment be year year basis drive record number shipment world courier strong volume revenue growth mwi segment be expect maintain performance quarter be report meanwhile zack consensus estimate first quarter earning stand share penny year year company expect ep growth second half fiscal be much better first half courtesy benefit gradual onboard walgreen rite aid store company also expect slight rise tax rate fiscal have see time benefit tax credit fiscal generic inflation have be nominal rate deflation be rise gradually factor combine anticipate shift product mix lower margin higher price specialty brand drug lack generic inflation affect company bottom line temporary slowdown pharmedium segment be expect mar bottom line first quarter notably company aim boost investment enhance pharmedium quality assurance qa quality control qc system term product quality patient safety lend company competitive edge affect bottom line first quarter fiscal here be quantitative model predict have right combination main ingredient positive earning esp zack rank hold higher increase odd earning beat zack esp earning esp be uncover best stock buy sell re report earning esp filter zack rank carry zack rank buy other stock considerhere be few other medical stock worth consider have right combination element post earning beat quarter bio rad laboratory bio free report have earning esp zack rank strong buy see complete list today zack rank stock here myriad genetic mygn free report have earning esp zack rank henry schein hsic free report have earning esp zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
293,HSIC,pacific bioscience california inc pacb free report be schedule report fourth quarter result feb last quarter company post positive earning surprise pacific bioscience have underperform zack consensus estimate precede quarters average negative surprise be let see thing be shape prior announcement key factorsin past quarters product revenue demonstrated consistent uptrend strength consumable revenue however zack consensus estimate fourth quarter product revenue stand reflect expect year year decline believe termination agreement hoffman la roche ltd effective february be likely affect revenue yet be report quarter agreement have be sign development supply diagnostic product base pacific bioscience single molecule real time smrt technology pacific bioscience california inc price ep surprise pacific bioscience california inc price ep surprise pacific bioscience california inc quote similar last quarters pacific bioscience fourth quarter service other revenue be expect decline prior year quarter decline be lead higher price rs service contract be replace lower price sequel contract zack consensus estimate service revenue stand fourth quarter reflect expect year year decline however company expect service revenue service related cost level improve lead improve gross margin yet be report quarter here be other factor influence pacific bioscience fourth quarter result company expect rise operate expense year year basis further management project loss report basis meanwhile operate expense third quarter totale compare year expect trend affect fourth quarter bottom line too company continue see significant strength china business sale china last quarter be more total sale china be fourth largest develop nation term nominal gdp believe progress country open channel pacific bioscience thereby drive top line zack consensus estimate fourth quarter revenue be reflect decline year quarter zack consensus estimate bottom line be peg loss cent narrower year loss cent here be quantitative model predict pacific bioscience do not have right combination main ingredient positive earning esp zack rank hold higher increase odd earning beat zack esp earning esp pacific bioscience be uncover best stock buy sell re report earning esp filter zack rank pacific bioscience carry zack rank sell stock considerhere be few medical stock worth consider have right combination element post earning beat quarter bio rad laboratory bio free report have earning esp zack rank strong buy see complete list today zack rank stock here myriad genetic mygn free report have earning esp zack rank henry schein hsic free report have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
294,HSIC,quest diagnostic inc dgx free report be schedule report fourth quarter fiscal earning result open bell feb last quarter company surpass zack consensus estimate cent deliver positive earning surprise also outperformed consensus mark trail quarters average beat let take look thing be shape prior announcement factor playafter phase sustain drag several quarters company revenue requisition performance last couple quarters see slight rebound however still remain be see upside be here stay not company professional lab service engagement wj barnabas health healthone system hca holding inc hca carry lower revenue requisition due nature work overall believe lack employment slow growth commercially insure life continuously affect company volume measure number requisition economy turn better quest diagnostic incorporate price ep surprise quest diagnostic incorporate price ep surprise quest diagnostic incorporate apart unit price headwind be less bps third quarter unit price challenge hover moderate range approximately last few year company continue expect same rest too also last couple year quest diagnostic face several reimbursement issue hurt revenue company be concern cms center medicare medicaid service proposal related protect access medicare act believe reimbursement pressure be reflect overhang company performance soon be report quarter too notably december company key member american clinical laboratory association acla have come forward support lawsuit file acla act secretary department health human service hhs lawsuit charge cms operate purview hhs have fail follow congressional directive implement market base laboratory payment system however come leave impact company yet be report quarter revenue number positive note quest diagnostic seem well align point growth agenda accelerate same drive operational excellence be also optimistic company successful execution strategy build esoteric testing business boost profitable growth additionally quest diagnostic have recently witness significant improvement infectious disease testing prescription drug monitoring industry lead wellness business therefore expect growth driver replicate company success story upcoming quarterly result have thus remain active drive same primary metric well precede quarter strongly believe recent development have significantly contribute company top line fourth quarter company expect revenue approximately annualize growth approximately zack consensus estimate full year revenue be peg higher guide range moreover company adjust ep range remain zack consensus estimate period also remain company project range earning whispersour proven model do not conclusively show quest diagnostic be likely beat earning quarter be stock need have positive earning esp favorable zack rank strong buy buy hold happen be not case here see zack esp quest diagnostic have earning esp be most accurate estimate be peg lower zack consensus estimate uncover best stock buy sell re report earning esp filter zack rank quest diagnostic have zack rank increase predictive power esp however need positive esp be confident earning surprise hence combination leave surprise prediction inconclusive caution sell rate stock go earning announcement especially company be see negative estimate revision stock worth lookhere be few medical stock worth consider right combination element surpass estimate time bio rad laboratory bio free report have earning esp zack rank see complete list today zack rank stock here myriad genetic mygn free report have earning esp zack rank henry schein hsic free report have earning esp be zack rank player wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
295,HSIC,weight management product service provider nutrisystem inc ntri free report be schedule release third quarter result oct nutrisystem have impressive track beating estimate trail quarters overall company record be favorable evident quarter average positive surprise let see thing be shape prior quarter factor playnutrisystem innovative product be expect expand customer base eventually drive reactivation revenue be generate exist customer first month purchase however sluggish dieting market intense competition be primary headwind term third quarter management expect revenue range zack consensus estimate third quarter revenue be currently peg meanwhile adjust ebitda be anticipate range earning share be expect band cent share positive note company portray impressive price performance past month share nutrisystem have return industry decline however overall activity nutrisystem third quarter be inadequate analyst confidence result zack consensus estimate be report quarter fall cent cent share last day earning whispersour proven model do not conclusively show nutrisystem be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp nutrisystem have earning esp most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank nutrisystem currently carry zack rank increase predictive power esp however company esp make surprise prediction difficult caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision nutrisystem inc price ep surprise nutrisystem inc price ep surprise nutrisystem inc quote stock warrant lookhere be company want consider model show have right combination element post earning beat quarter abbott free report have earning esp carry zack rank see complete list today zack rank stock here align technology inc algn free report have earning esp carry zack rank henry schein inc hsic free report have earning esp carry zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
296,HSIC,medical instrument manufacturer thermo fisher scientific inc tmo free report be slate release third quarter result oct market open last quarter company post earning share surpass zack consensus estimate fact thermo fisher earning outpaced zack consensus estimate past quarters average beat let see thing be shape prior announcement key acquisition fei have already start generate synergy largely contribute waltham base company analytical instrument portfolio last quarters acquisition have enabled thermo fisher access fei industry lead high performance electron microscopy platform used protein study facilitate life science research be also vital highlight quarter be report thermo fisher scientific inc price ep surprise thermo fisher scientific inc price ep surprise thermo fisher scientific inc quotethermo fisher anticipate realize total synergy approximately end year follow deal closure cost synergy roughly adjust operate income benefit revenue related synergy get reflect third quarter performance overall company be gear yet quarter strong analytical instrument segmental growth third quarter thermo fisher expect see positive impact electron microscopy business well strong volume leverage productivity zack consensus estimate analytical instrument operate income be peg line sequentially last quarter report number total revenue estimate segment also remain impressive level here be other factor influence thermo fisher third quarter result company focus boost growth implementation strategy strengthen product offering be encourage initiative be likely help post solid result third quarter company have spend research development same trend be continue last couple quarters major development field be novartis chimeric antigen receptor cell car therapy kymriah first fda approve cell therapy leukemia utilize thermo fisher ct dynabead technology expect innovation product launch significantly contribute company top line third quarter company aim expand capability fast grow asia pacific zone well emerge market also lead impressive result standout contributor recent time be china india south korea strategic investment support key customer application thermo fisher hope maintain bullish momentum rest growth be also likely be see apply market such environmental food safety apart life science addition company be currently bet key area focus enormous opportunity be advance precision medicine mass spectrometry target gene sequence structural biology however be apprehensive thermo fisher cite foreign exchange headwind revenue adjust ep also unfavorable macroeconomic condition continue weigh heavily stock stiff competition continue impose challenge stock value here quantitative model predict thermo fisher have right combination main ingredient positive earning esp favorable zack rank strong buy buy hold earning beat see complete list today zack rank stock here zack esp thermo fisher have earning esp uncover best stock buy sell re report earning esp filter zack rank thermo fisher carry zack rank buy increase predictive power esp other stock considerhere be few medical stock worth consider model indicate consist right combination element post earning beat quarter abbott free report have earning esp zack rank align technology inc algn free report have earning esp zack rank henry schein inc hsic free report have earning esp aslo carry zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
297,HSIC,henry schein medical subsidiary henry schein inc hsic free report announce exclusive distribution agreement terason distribute latter usmart nexgen development remain part henry schein medical emergency medical service em business terason division teratech corporation be manufacturer portable ultrasound machine usmart be portable ultrasound device allow emergency responder carry exam emergency medical transport vehicle aircraft reduce need speculate em professional usmart nexgen be portable light weight ultrasound tablet easy transport operate terason usmart feature many advanced feature include customize preset fast boot grab go portability wi fi capability responder recognize issue point care transportation also alert emergency room staff important vital usmart accord company access patient vital help emergency responder make more inform decision treatment also help emergency room staff prepare ahead patient arrival henry schein be consistently work boost medical segment notably worldwide medical revenue rise year year last report second quarter henry schein medical recently inked agreement cerebral assessment system cas distribute cognivue be first computerize cognitive assessment screening device clear fda detection early sign dementia moreover henry schein announce partnership simplifeye create mobile platform health care provider use practice management electronic health record software micromd accord report market market ultrasound market be expect reach value cagr consider substantial potential market believe latest development be strategic past year henry schein have underperform broader industry stock have gain compare gain broader industry estimate revision estimate revision trend have be favorable company current quarter estimate moved north compare movement opposite direction last month result zack consensus estimate current quarter earning share have increase cent cent zack rank key pickshenry schein have zack rank hold few better rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report abbott idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here abbott have long term expect earning growth rate stock rally roughly last year idexx laboratory have long term expect earning growth rate stock gain last year thermo fisher have long term expect earning growth rate stock gain last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
298,HSIC,express script hold company esrx free report be schedule report third quarter result oct market close result be expect show decline revenue pharmacy benefit manager pbm segment major revenue component majorly affect earning let take look thing be shape release zack consensus estimate pbm revenue stand reflect decline sequentially year quarter st loui mo base company be largest pbm north america pbm be highly competitive industry report market research project pbm market see cagr take account express script have be consistently try expand core pbm business company complete acquisition mymatrixx pharmacy benefit solution provider worker compensation industry recently furthermore company anticipate compound annual ebitda growth rate core pbm business zack consensus estimate net sale stand year year basis express script hold company price consensus express script hold company price consensus express script hold company quote factor playcome major component zack consensus estimate pbm product network stand year year zack consensus estimate pbm service revenue stand year year lackluster performance segment be likely mar express script revenue third quarter come guidance third quarter express script expect total adjust claim range notably zack consensus estimate total claim stand sequentially adjust earning diluted share third quarter be estimate range represent growth year year basis exclude contribution anthem other transition client regard express script announce biggest customer lead health insurer anthem inc antm free report be not likely extend pharmacy benefit management agreement be slate expiration end management express script lose almost revenue related anthem contract third quarter anthem sue express script overcharge drug operational failure meanwhile second quarter anthem generate revenue compare second quarter here be quantitative model predict express script have right combination main ingredient positive earning esp zack rank buy notably earning esp express script be uncover best stock buy sell re report earning esp filter fact zack consensus estimate earning reflect increase year year basis other stock considerhere be few other medical stock worth consider have right combination element post earning beat quarter abbott free report have earning esp zack rank see complete list today zack rank strong buy stock here henry schein inc hsic free report have earning esp zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
299,HSIC,intuitive surgical isrg free report third quarter result schedule release oct be expect show steady growth instrument accessory revenue major revenue component majorly drive third quarter earning expect improvement revenue other segment help company generate solid result season be important note intuitive surgical deliver positive earning surprise past quarters average be similar prior quarter strong procedure growth increase sale stapling vessel sealing product be expect be main factor drive surge instrument accessory revenue zack consensus estimate instrument accessory revenue stand third quarter reflect increase year quarter continue development european market solid access company product asia new platform imaging advanced instrument be likely drive revenue segment intuitive surgical inc price consensus intuitive surgical inc price consensus intuitive surgical inc quoteother factor playwe believe grow adoption intuitive surgical da vinci system physician general surgery oncology urology gynecology procedure be catalyst third quarter overall revenue be expect prior year quarter be other factor influence intuitive surgical quarterly result earning season solid procedure trend expectation outperformance mature growth procedure especially general thoracic surgery be likely boost company top line add solid growth prostatectomy procedure volume be likely lend intuitive surgical competitive edge broader prostate surgery market third quarter geographically procedure growth third quarter be expect be lead china germany japan germany procedure growth be likely be support solid install base expansion furthermore procedure trend be expect be solid globally growth lead general surgery global urology segment system service unit hold promise solid growth company product system segment be expect drive company third quarter earning fact zack consensus estimate revenue segment stand year year basis increase reflect higher system placement operate lease revenue however be partially offset lower average selling price lease buyout revenue segment come revenue service segment zack consensus estimate stand year year basis growth system install base buoy higher system placement operate lease revenue expect company total system install base be unit unit last quarter be important note intuitive surgical generate approximately revenue operate lease last quarter compare second quarter here be quantitative model predict intuitive surgical do not have right combination main ingredient positive earning esp zack rank hold higher increase odd earning beat zack esp earning esp intuitive surgical be most accurate estimate be zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank intuitive surgical carry zack rank increase predictive power esp however also need positive esp be confident earning beat fact zack consensus estimate earning reflect decline year year basis stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter abbott free report have earning esp zack rank buy see complete list today zack rank strong buy stock here align technology inc algn free report have earning esp zack rank henry schein inc hsic free report have earning esp zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
300,HSIC,cr bard inc be schedule report third quarter earning market close oct last quarter company report adjust earning exceed zack consensus estimate cent also company earning surpass zack consensus estimate last quarters average beat delve fundamental stock let see thing be shape prior release factor playwe believe grow adoption company flagship lutonix drug coat balloon dcb continue be key growth catalyst be report quarter regard lutonix dcb be used treat patient suffering peripheral arterial disease pad endovascular business peripheral pta line sale be solely drive accelerate demand lutonix dcb unite state expect product significantly contribute company top line quarter zack consensus estimate third quarter revenue be currently peg however management expect revenue growth report basis exclude impact foreign exchange company project revenue increase prior year furthermore company investment emerge market have strengthen position internationally be also upbeat solid contribution company vascular product line urology oncology segment be likely drive third quarter sale positive note company portray impressive price performance past month share cr bard have return compare industry decline flip side challenge med tech environment especially hernia fixation peripheral stent business raise concern company continue witness significant pricing pressure well also unfavorable foreign currency continue hurt top bottom line growth furthermore uncertainty associate possibility repeal affordable care act president trump add company concern earning whispersour quantitative model doesn point earning beat quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp cr bard be be most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank cr bard currently carry zack rank increase predictive power esp however company esp make surprise prediction difficult caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision bard inc price ep surprise bard inc price ep surprise bard inc quote stock considerhere be few company want consider proven model show have right combination element post earning beat quarter abbott free report have earning esp carry zack rank see complete list today zack rank strong buy stock here align technology inc algn free report have earning esp carry zack rank henry schein inc hsic free report have earning esp carry zack rank trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
301,HSIC,patterson company inc pdco free report have have dismal run bourse late year date company have lose underperform broader industry gain rapidly change healthcare environment unite state unfavorable price movement competitive dental product distribution industry integration risk significant challenge company political qualm ongoing political conundrum pertain repeal obamacare republican have give rise uncertainty dental space last week medtech space receive heavy blow trump latest executive order pull plug obamacare subsidy reduce net health care cost american low income again legislation regulation be expect affect expenditure reimbursement dental service private dental insurance plan believe mar patterson overall result quarters come dental segment lack luster patterson dental segment contribute significantly total revenue year net revenue fiscal however decrease sale cerec other digital technology equipment be likely mar revenue dental consumable dental equipment furthermore management patterson anticipate headwind technology equipment business persist fiscal company transition new go market strategy expand technology product portfolio decline estimate estimate revision trend patterson have be unfavorable full next year analyst moved south compare movement opposite direction last month result zack consensus estimate full year inched share next year earning estimate drop share stock have zack rank sell patterson company inc price consensus patterson company inc price consensus patterson company inc quotecutthroat competition dental product distribution industry be highly competitive consist principally national regional local full service mail order distributor patterson face competition national full service firm henry schein dental unit henry schein hsic free report addition be least full service distributor operate regional level hundred small local distributor patterson need continue introduce product market counter competition failure do so dent company market share key picksa few better rank stock broader medical sector be sonova hold sonvy free report luminex corp lmnx free report sonova luminex sport zack rank strong buy see complete list today zack rank stock here sonova represent solid return last year company have long term expect earning growth rate luminex come positive earning surprise last quarter stock have long term expect earning growth rate trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
302,HSIC,resm rmd free report be slate report first quarter fiscal result market close oct last quarter company deliver positive earning surprise average earning beat trail quarters let see thing be shape announcement key prior quarter resm be expect gain strong performance domestic international front company revenue domestic front be drive solid growth device well low double digit software sale growth previous quarter internationally company receipt french reimbursement approval telemonitoring buoy optimism company believe reimbursement grant drive uptake air solution ecosystem include airsense aircurve device platform well airview myair software platform be report quarter zack consensus estimate domestic revenue include contribution reflect increase year quarter also zack consensus estimate international revenue indicate rise year quarter overall fiscal first quarter total revenue be project prior year quarter resm inc price ep surprise resm inc price ep surprise resm inc quotehere be other factor influence resm first quarter result management be particularly upbeat top line contribution launch make last fiscal last report quarter introduce product include airfit airfit airtouch full face mask world smallest continuous positive airway pressure cpap resm airmini resm continue progress steadily back prong growth strategy regard company recently announce tuck acquisition product portfolio conduit technology llc allcall connect moreover last report quarter company progressed new offer outcome assessment information set oasis home health hospice market expect get reflect resm top line first quarter current zack consensus estimate revenue reflect increase year quarter flip side management expect sg expense margin band be report quarter be fourth quarter fiscal also expense margin be project first quarter fiscal compare precede quarter guidance reflect quarter gloomy operate margin scenario meanwhile company generate significant portion revenue international market expose company foreign currency fluctuation notably last report quarter foreign exchange movement hurt earning cent share reflect unfavorable impact weaker euro stronger australian dollar relative dollar be likely dent result first quarter moreover overall macroeconomic uncertainty be major obstacle company international operation also market sleep disordered breathe sdb product be highly competitive respect product price feature reliability other challenge competitive bidding reimbursement pressure continue hurt stock here be quantitative model predict resm do not have right combination main ingredient positive earning esp zack rank hold higher increase odd earning beat zack esp earning esp resm be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank resm carry zack rank buy increase predictive power esp however also need have positive esp be confident positive earning surprise nonetheless zack consensus estimate earning cent reflect improvement year year basis stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter abbott free report have earning esp zack rank see complete list today zack rank strong buy stock here align technology inc algn free report have earning esp zack rank henry schein inc hsic free report have earning esp zack rank trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
303,HSIC,oct issue update research report henry schein inc hsic free report lead distributor health care product service globe company carry zack rank hold term price return performance past month stock remain line broader industry expect trend improve balanced growth operate segment henry schein be also encourage company effort grow internationally apart north america europe have presence australia new well emerge nation china brazil israel czech republic poland also company continue ride high dental business majorly accretive strategic merger integration colossal merger field be poland base dental cremer henry schein animal health revenue growth have be consistently support niche acquisition begin company have make foray brazilian animal health market investment tecnew same time company announce decision acquire southern sas turn benefit dental business controlled controlled pharmaceutical well surgical supply also henry schein gain several trend end market customer demographic increase number life cover follow healthcare reform unite state be likely boost company additionally henry schein gain traction animal health business back tailwind north america well overseas market burgeon demand animal health product unite state further drive company growth flip side escalate cost expense continue be drag company margin bottom line tough competitive landscape pricing pressure also weigh henry schein stock key better rank stock medical sector be qiagen qgen free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report carry zack rank buy see complete list today zack rank strong buy stock here qiagen have long term expect earning growth rate stock have rally roughly last year idexx laboratory have long term expect earning growth rate stock have surge last year thermo fisher have long term expect earning growth rate stock have gain last year stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
304,HSIC,henry schein inc hsic free report recently complete earlier announce buyout merritt veterinary supply certain undisclosed financial term merritt be part veterinary business henry schein namely henry schein animal health merritt be independent family own supplier animal health product merritt have veterinary clinic eastern unite state strong presence southeastern part nation company offer comprehensive line product include pharmaceutical diagnostic equipment merritt generate revenue approximately accord henry schein acquisition drive earning share henry schein have be consistently try expand animal health business company global animal health segment witness improvement revenue last report second quarter recently henry schein animal health announce open new national distribution service center columbus brookhollow neighborhood expand presence central ohio begin henry schein have enter brazilian animal health market investment tecnew privately hold distributor animal health product prior company have acquire rxwork lead provider veterinary practice management software primarily customer australia new netherlands other country accord report grand view research global animal health market be expect reach value consider huge potential market believe latest development be strategic past year henry schein have underperform broader industry stock have gain compare broader industry rise estimate revision trend estimate revision trend have be favorable company current quarter estimate moved north compare movement opposite direction last month result zack consensus estimate current quarter have increase cent share cent zack rank key pickshenry schein currently carry zack rank hold few better rank stock medical sector be qiagen qgen free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report qiagen idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here qiagen have long term expect earning growth rate stock have rally roughly last year idexx laboratory have long term expect earning growth rate stock have gain last year thermo fisher have long term expect earning growth rate stock have gain last year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
305,HSIC,henry schein medical subsidiary henry schein inc hsic free report recently inked agreement cerebral assessment system cas distribute cognivue be first computerize cognitive assessment screening device clear fda detection early sign dementia believe development bolster growth company field mental cognitive disease cas be medical device company engage research commercialize automate solution routine measurement monitoring brain health accord company cognivue be fully automate solution display visual stimuli computer screen physician conduct quantitative analysis brain health get single score overall brain functional integrity result be store cloud enable doctor observe current brain health identify potential issue be address problem worsen henry schein be consistently work boost medical segment notably worldwide medical revenue rise year year last report second quarter recently henry schein announce partnership simplifeye create mobile platform health care provider use practice management electronic health record software micromd accord report research market global treatment syndrome dementia movement disorder market be anticipate reach value cagr consider huge potential market believe latest development be strategic past year henry schein have underperform broader industry stock have gain compare gain broader industry estimate revision trend estimate revision trend have be favorable company current quarter estimate moved north compare movement opposite direction last month result zack consensus estimate current quarter earning share have increase cent cent same period zack rank key pickshenry schein currently carry zack rank hold few better rank stock medical sector be orthofix international ofix free report luminex corporation lmnx free report idexx laboratory inc idxx free report orthofix international luminex sport zack rank strong buy idexx laboratory carry zack rank buy see complete list today zack rank stock here orthofix international have long term expect earning growth rate stock have rally roughly last month luminex have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last year stock watch massive equifax hack cybersecurity stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
306,HSIC,solidify footprint fast grow healthcare market henry schein inc hsic free report recently announce receipt office national coordinator health information technology onc health edition health module certification group llc practice management electronic health record software micromd certification deem micromd suitable end user itfully comply federal government guideline successful usage cms payment incentive program notably program include medicare quality payment program qpp medicaid ehr incentive program believe latest development boost company sale global technology value add service business interestingly segment witness increase revenue last report quarter also gross margin front segment happen be biggest contributor henry schein offer depth suite practice management software system cover dental animal health medical customer large customer base more practice inclusive micromd physician practice continue slew development company earlier announce partnership medical system simplifeye combine entity aim create mobile experience integration simplifeye henry schein micromd order allow physician provide more customize patient experience simplify practice workflow keep concern team member well connect away workplace report global healthcare market be project reach value cagr period give current market potential company development space believe henry schein be track gain traction believe agee population unhealthy lifestyle rise awareness expenditure healthcare continue drive growth healthcare market however market be dominate many well establish player nextgen division quality system inc qsii free report be prominent moreover henry schein have be gain investor confidence consistent positive result past month company share price have outperformed broader industry stock have gain higher broader industry gain company have also outperformed decline market same time frame zack rank key pickshenry schein carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report edward lifescience sport zack rank strong buy lantheus holding carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
307,HSIC,henry schein inc hsic free report have recently team integrate medical foundation imf lugpa association independent urology group practice raise awareness prostate cancer more specifically henry schein global corporate social responsibility program henry schein care work matter henry schein support imf lugpa series communication effort increase awareness practitioner public importance early detection prostate cancer accord have be widely accept early detection prostate cancer greatly enhance patient chance recover disease believe company move be well time take consideration frequency rate prostate cancer be grow national cancer institute estimate approximately man be diagnosed disease lifetime american cancer society more man be expect be diagnosed prostate cancer more man succumb disease henry schein be yet make foray world cancer research have already come several awareness drife late only last month company announce offer dental animal health medical customer opportunity join fight cancer proposal be open september december purchasing range pink product customer support company practice pink program initiative design increase awareness back cure breast cancer well other cancer therapy past month henry schein have underperform broader industry stock have lose compare broader industry decline zack rank key pickshenry schein carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have surge last month idexx laboratory have long term expect earning growth rate stock have gain last month be reissue article correct mistake original article issue september longer be rely zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
308,HSIC,lead veterinary product distributor henry schein inc hsic free report continue expand global footprint successfully several partnership acquisition latest list be company agreement buy merritt veterinary supply inc independent family own supplier animal health product financial term deal have be keep wrapped company declare expect transaction get complete third quarter headquarter columbia south carolina merritt have veterinary clinic eastern unite state strong presence southeastern part nation company offer comprehensive line product include pharmaceutical diagnostic equipment lead independent regional veterinary supplier have total sale approximately post close transaction merritt become part henry schein animal health company acquisition meaningfully strengthen exist animal health business also benefit animal health diagnostic equipment surgical instrument business include scil kruuse veterinary instrumentation henry schein henry schein inc price henry schein inc price henry schein inc quotenotably henry schein revenue growth animal health business have be consistently support niche acquisition robust buyout strategy help pursue target provide access additional product line begin henry schein enter brazilian animal health market investment tecnew privately hold distributor animal health product prior company acquire rxwork lead provider veterinary practice management software primarily customer australia new uk netherlands other world wide country business impending merritt buyout be set fortify global animal health operation go forward henry schein have outperformed broader industry year stock have gain compare broader industry rise zack rank key pickshenry schein currently carry zack rank hold few better rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report edward lifescience corporation ew free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here idexx laboratory have long term expect earning growth rate stock have gain last month lantheus holding have long term expect earning growth rate stock have surge last month edward lifescience have long term expect earning growth rate stock have rally roughly last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
309,HSIC,lead distributor health care product service henry schein inc hsic free report be constantly focuse expand dental business account nearly half total revenue keep line henry schein dental enter agreement distribute caek inc flagship product health insurance portability accountability act hipaa software layercompliance notably caek be software service saas company focuse compliance related software healthcare industry layercompliance be cloud base tool help doctor navigate requirement hipaa notably hipaa be federal law provide privacy security standard protect patient health information layercompliance help user manage datum security program online dashboard tool help streamline process oral health care expenditure dental industry be likely rise increase population believe boost demand henry schein product service well meanwhile management have enter year agreement dentsply sirona broaden henry schein digital dentistry product line moreover second quarter henry schein announce extension agreement dentsply sirona extend agreement be valid dec henry schein include cerec cad cam restoration system schick line imaging sensor henry schein also be entitle represent entire dentsply sirona product line start sep addition henry schein continue offer planmeca shape well dental equipment consumer product longstanding partner kavo kerr brand past year henry schein have outperformed broader industry stock have gain compare gain broader industry zack rank key pickshenry schein currently carry zack rank hold few better rank medical stock be edward lifescience corp ew free report lantheus holding inc lnth free report align technology inc algn free report edward lifescience align technology sport zack rank strong buy lantheus holding carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month align technology have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
310,HSIC,henry schein inc hsic free report report adjust earning share ep second quarter year year adjust ep also surpass zack consensus estimate year year upside earning be drive strong revenue growth henry schein report net income second quarter come share reflect year year growth respectively revenue detailhenry schein report revenue second quarter year year also zack consensus estimate year year improvement come back growth local currency partially offset decline owing foreign currency exchange local currency internally generate sale increase acquisition growth be henry schein inc price consensus ep surprise henry schein inc price consensus ep surprise henry schein inc company record sale north american market year year sale be international market year year segment analysis henry schein derive revenue operate segment dental medical animal health technology value add service second quarter company derive revenue global dental sale year year include growth local currency decline owing foreign currency exchange local currency internally generate sale increase acquisition growth be internal growth local currency include growth north america rise internationally company global animal health segment witness improvement revenue include growth local currency decline related foreign currency exchange local currency internally generate sale increase acquisition growth be internal growth local currency include growth north america growth internationally worldwide medical revenue scale year year growth local currency be decrease owing adverse foreign exchange revenue global technology value add service grow include growth local currency decline related foreign currency exchange be contribution acquisition quarter review margin trend gross profit increase report quarter however gross margin decline basis point bps year quarter due rise cost sale higher revenue growth rate rise selling general administrative expense adjust operate income improve year year moreover adjust operate margin remain flat year year report quarter financial positionhenry schein exit second quarter cash cash equivalent compare end first quarter year date net cash provide operate activity be compare year period quarter review company buy back approximately share almost close second quarter company have authorize future repurchase common stock ep guidance intacthenry schein reaffirm report ep guidance litigation settlement expense company still expect ep range reflect growth ep figure zack consensus estimate adjust ep be guide range takehenry schein exit second quarter solid note earning sale beating zack consensus estimate operate segment deliver strong year year growth company strong share gain north american overseas market strong revenue raise optimism however better expect earning performance be disappoint company unchanged ep guidance meanwhile year year deterioration henry schein gross operate margin be due higher cost sale expense also foreign currency fluctuation continue mar company financial zack rank key pickshenry schein have zack rank buy few other top rank medical stock be edward lifescience corporation ew free report insys therapeutic inc insy free report align technology inc algn free report notably edward lifescience insys therapeutic align technology sport zack rank strong buy see complete list today zack rank stock here insys therapeutic have long term expect earning growth rate stock post stellar quarter average earning surprise align technology have expect long term adjust earning growth almost stock have add roughly last month edward lifescience have long term expect earning growth rate stock have gain last month look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
311,HSIC,headquarter melville ny henry schein inc hsic free report be global lead provider healthcare product service company serve office base dental medical animal health practitioner dental laboratory government well institutional health care clinic other alternate care site presently henry schein serve more customer have operation country company enter prestigious standard poor index mar currently henry schein have zack rank buy change follow second quarter earning report have just release see complete list today zack rank strong buy stock here have highlighted key detail just release announcement earning zack consensus estimate remain steady share last day henry schein adjust earning share beat estimate couple cent revenue henry schein post revenue ahead zack consensus estimate revenue key stat revenue second quarter derive henry schein dental segment grow year year animal health segment record sale compare prior year quarter revenue medical segment increase year year sale technology value add service segment grow henry schein inc price ep surprise henry schein inc price ep surprise henry schein inc quotemajor factor management global segment gain solid market share quarter deliver solid earning growth back strategy grow business organically acquisition company reaffirm adjust ep guidance stock price follow earning release share price do not show significant movement pre market trading session check back later full henry schein earning report later look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
312,HSIC,be last lap earning season earning preview aug member index total market cap have report quarterly number putt together result see pace earning revenue growth be steadily accelerate relative pre season expectation latest scorecard show year year increase total earning member higher revenue earning beat ratio be revenue beat ratio be store medical space medical broader zack sector be absolutely exception improvement trend so far member sector have release quarterly earning result earning revenue beat register impressive level respectively more more company line earning announcement aggregate growth pace sector be expect pick further notably medical device industry boast powerful long term tailwind include merger acquisition emerge market expansion positive demographic trend new product innovation have be major drive force sector laudable performance past few quarters even severe socio economic political instability let find major medical product company broader medical space be place ahead earning release aug henry schein inc hsic free report renown healthcare product service distributor strategy expand digital dentistry globally be encourage notably management expect least mid single digit growth north america dental equipment market second quarter company be currently banking digital dentistry part strategic plan be thus busy promote digital workflow general dentistry well dental specialty henry schein be schedule report second quarter result market open however proven model do not conclusively show company be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here stock currently carry zack rank earning esp make surprise prediction difficult base zack methodology positive zack esp serve lead indicator likely earning surprise bullish zack rank increase predictive power esp uncover best stock buy sell re report earning esp filter read more henry schein spring surprise earning henry schein inc price consensus henry schein inc price consensus henry schein inc quote agio pharmaceutical inc agio free report development stage company agio have not approve product portfolio yet investor be thus expect keep eye pipeline update earning call be worth mention company have several interesting pipeline candidate cancer pipeline comprise idhifa enasidenib ag idh mutant inhibitor ag pan idh mutant inhibitor importantly agio be develop enasidenib ag collaboration celgene corporation celg research report bring collaboration revenue agio pharmaceutical be schedule report second quarter result aug previous article store agio pharma earning be not certain earning beat season however estimate change thereafter company currently carry zack rank earning esp make confident positive earning surprise hence expect beat estimate quarter caution sell rate stock go earning announcement agio pharmaceutical inc price consensus agio pharmaceutical inc price consensus agio pharmaceutical inc quote penumbra inc pen free report be content company focus product development innovation get reflect second quarter significantly research development expense surge first quarter line company introduce product indigo family cat also company recently receive fda clearance device neuro franchise segment company be schedule report second quarter earning market close currently carry zack rank increase predictive power esp however company earning esp make surprise prediction difficult hence be unable conclude penumbra be likely beat earning quarter read more be surprise store penumbra earning see complete list today zack rank stock here penumbra inc price consensus penumbra inc price consensus penumbra inc quote opko health inc opk free report be multinational diagnostic company diagnostic business include bio reference laboratory nation third largest clinical laboratory core genetic testing business pharmaceutical business feature rayaldee fda approve treatment shpt stage ckd patient vitamin deficiency varubi chemotherapy induced nausea vomit other company be also schedule report second quarter earning close bell currently carry zack rank earning esp opko health inc price consensus opko health inc price consensus opko health inc quote steris plc ste free report headquarter ohio steris develop manufacture market infection prevention decontamination microbial reduction surgical support product service company be schedule report first quarter fiscal earning open bell currently carry zack rank increase predictive power esp earning esp however leave earning surprise prediction inconclusive steris plc price consensus steris plc price consensus steris plc quote trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
313,HSIC,henry schein inc hsic free report be expect report second quarter result aug last quarter renown healthcare product service distributor deliver positive earning surprise encouragingly henry schein earning surpass zack consensus estimate past quarters average let see thing be shape prior announcement factor playhenry schein first quarter result be quite impressive record growth segment dental animal health medical technology value add service geographically company gain traction north america overseas market expect similar trend second quarter well henry schein inc price ep surprise henry schein inc price ep surprise henry schein inc quotenotably be report second quarter henry schein animal health open new national distribution service center ndsc columbus brookhollow neighbourhood have enabled company be complete solution provider veterinary practice country expect boost top line yet be report quarter company strategy expand digital dentistry globally be also encourage regard note management expect least mid single digit growth north america dental equipment market second quarter company be currently banking digital dentistry be part strategic plan henry schein be thus busy promote digital workflow general dentistry well dental specialty flip side henry schein year year deterioration gross operate margin past few quarters due higher cost sale expense be matter concern meanwhile management solid sale second quarter be likely be partially offset timing good friday year notably international holiday have fall second quarter year compare last year timing be first quarter apart currency fluctuation tough competitive landscape add wo also advent group purchasing organization gpos add competitiveness market overall company reaffirm ep guidance reflect growth year period second quarter have be change estimate revision last day same have be observed magnitude estimate revision earning estimate remain same time frame earning whispersour proven model do not conclusively show earning beat henry schein quarter be stock need have positive earning esp zack rank strong buy buy hold happen however be not case here see zack esp henry schein have earning esp be most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank henry schein zack rank increase predictive power esp however company esp make surprise prediction difficult meanwhile caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision stock considerhere be company consider model show have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank thermo fisher scientific inc tmo free report have earning esp zack rank see complete list today zack rank stock here stryker corporation syk free report have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
314,HSIC,boston scientific corporation bsx free report be schedule report second quarter result open bell jul last report quarter company earning share beat zack consensus estimate moreover company deliver positive earning surprise trail quarters average beat be let see thing be shape prior announcement key prior quarter be upbeat solid contribution boston scientific cardiovascular business comprise interventional cardiology ic peripheral intervention pi last report quarter company generate total revenue highest revenue generate segment be optimistic ic business help company maintain impressive global growth courtesy innovative portfolio robust commercial team division perform well last report quarter lotus recall europe worldwide ic growth come back strength structural heart complex pci intervention portfolio however upside be partially offset weak performance drug eluting stent boston scientific corporation price ep surprise boston scientific corporation price ep surprise boston scientific corporation quotewithin structural heart be look forward boston scientific watchman acurate iris product line be expect contribute top line yet be report quarter company expect revenue watchman acurate tavr franchise total approximately watchman program depict impressive performance first quarter product have be used more implant worldwide moreover company expect continue growth platform back increase utilization geographical expansion additionally recent launch ic business wolverine cut balloon company next generation rotational atherectomy platform rotapro be expect contribute significantly top line upcoming quarterly result zack consensus estimate ic revenue be peg indicate increase year year basis company be expect keep gain strength business last report quarter pi business perform impressively back higher sale drug eluting stent ranger balloon europe geographically company witness strength asia well boston scientific atherectomy jetstream platform also perform well first quarter trend be expect continue be report quarter accordingly zack consensus estimate second quarter pi revenue be peg reflect rise year year overall zack consensus estimate total revenue indicate increase prior year quarter tally also earning estimate cent reflect rise year year basis other factor playamong other segment medsurg be estimate demonstrate steady performance lead endoscopy urology woman health be also project surpass market level drive investment strategy key international geography be impressed boston scientific recent acquisition have add several product many be development immense potential nxthera nvision buyout urology pelvic health emcision buyout endoscopy deserve mention company be gradually strengthen presence emerge market brazil russia india china bric first quarter business emerge market register growth business china be once again remarkable year year company be currently look forward improve performance ahead china follow recent approval synergy region boston scientific be gain traction india well be currently target emerge market additional emphasis company be also optimistic core cardiology segment be gradually stabilize growth bric nation trend be expect continue yet be report quarter result however immaterial be report quarter ongoing tension unite state china regard imposition tariff import have raise concern major medtech player adverse move affect top line number upcoming quarters company also provide second quarter financial outlook adjust ep be expect range cent revenue here quantitative model predictsper proven zack model company zack rank strong buy buy hold have good chance beating estimate also have positive earning esp uncover best stock buy sell re report earning esp filter boston scientific have zack rank increase predictive power esp have earning esp make surprise prediction easier combination suggest company be likely beat earning quarter other stock worth lookhere be few other medical stock worth consider right combination element beat estimate resm rmd free report have earning esp carry zack rank see complete list today zack rank stock here stryker corporation syk free report have earning esp zack rank henry schein inc hsic free report zack rank company have earning esp medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
315,HSIC,investor interested stock medical dental supply sector have probably already hear henry schein hsic free report merit medical mmsi free report stock be more attractive value investor ll need take closer look find best way find great value stock be pair strong zack rank impressive grade value category style score system proven zack rank emphasize company positive estimate revision trend style score highlight stock specific trait henry schein merit medical have zack rank buy right now zack rank favor stock have recently see positive revision earning estimate so investor rest assured company have improve earning outlook be just piece puzzle value investor value investor also tend look number traditional try true figure help find stock believe be undervalue current share price level style score value grade factor variety key fundamental metric include popular ratio ratio earning yield cash flow share number other key stat be commonly used value investor hsic currently have forward ratio mmsi have forward also note hsic have peg ratio figure be similar commonly used ratio peg ratio also factor company expect earning growth rate mmsi currently have peg ratio notable valuation metric hsic be ratio be method compare stock market value book value be defined total asset total liability comparison mmsi have be just few metric contribute hsic value grade mmsi value grade hsic mmsi be impressive stock solid earning outlook base valuation figure feel hsic be superior value option right now
316,HSIC,becton dickinson company bdx free report also know bd recently complete acquisition texas base tva medical financial term deal have be keep wrapped post announcement share bd inched management transaction be not expect be accretive bd financial result fiscal past year company share have rally compare industry rise stock carry zack rank hold come back news tva medical develop minimally invasive vascular access solution patient chronic kidney disease require hemodialysis recent integration be likely boost bd core medical segment additionally buyout enable bd provide tva flagship everlinq endoavf system everlinq endoavf receive marketing clearance fda be used hemodialysis rely open surgery acquisition allow bd serve physician patient provide minimally invasive procedure patient chronic kidney disease market opine be more patient end stage renal disease esrd depend hemodialysis unite state moreover research market minimally invasive surgical device be project reach cagr benefit minimally invasive surgery compare traditional open surgeriesa well asreduction healthcare cost growth market hence bd latest move be timely strategic medtech minimally invasive invasive surgery involve fewer incision reduce trauma patient late medtech space have be witness increase usage surgical procedure bd be major global medtech player have be rake huge profit minimally invasive procedure company flagship mueller snowden pencer laparoscopic instrument be most advanced surgical instrument available market intuitive surgical isrg free report coveted da vinci platform deserve special mention here system be power robotic technology enable surgeonsto make smaller precise movement also stryker corporation syk free report robotic arm assist mako surgery platform facilitate advanced joint replacement surgery solution want more industry better rank stock medical dental supply space be henry schein inc hsic free report henry schein gain unite state well overseas raise optimism stock carry zack rank buy see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
317,HSIC,henry schein inc hsic free report recently announce have complete earlier announce joint venture jv internet brand kkr portfolio company bid fortify dental business company have name joint venture henry schein however financial term deal have be keep wrapped henry schein have integrate portfolio practice management system dental practice management software company henry schein practice solution internet brand web base software application new company be expect deliver integrate dental technology help improve practice management marketing well patient communication henry schein newly form jv combine henry schein practice solution product service dentrix dentrix ascend easy dental techcentral henry schein international dental practice management system include software excellence logiciel julie infome exan labnet dental business internet brand include web base solution such demandforce sesame communication officite dentalplan com combine entity register pro sale approximately approximately be draw internet brand dental business exclude impact time transfer taxe henry schein have earlier anticipate deal be immaterial rest earning share be accretive bottom line thereafter furthermore annual synergy be expect be realize end third year joint venture initiation dental business major growth driverhenry schein dental business account total revenue last report quarter accordingly have be leave stone unturned strengthen foothold business moreover henry schein sign distribution agreement dentsply sirona inc xray only last year distribute latter entire product line be also encourage henry schein reliance part strategic plan be digital dentistry company be busy promote digital workflow general dentistry well dental specialty management company solid performance be attribute continue focus offer diversify portfolio value add service favorable end market thus believe henry schein latest tie be strategic leap take company market potentialper company rise oral healthcare expenditure dental industry be predict tandem increase middle age population year moreover henry schein be upbeat expect growth dental insurance coverage lower insurance reimbursement rate lead frequent need new technology believe bullish sentiment boost demand henry schein product service moreover transparency market research report global dental practice management software market be likely witness cagr give huge market potential perceive latest development help henry schein cash bountiful opportunity market share price movementover past month henry schein have outperformed broader industry stock have gain compare industry increase zack rank key pickshenry schein currently carry zack rank hold better rank stock broader medical space be genomic health ghdx free report abiom abmd free report stryker corporation syk free report genomic health have skyrocket expect earning growth rate be report quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate zack rank stryker have estimate long term earning growth rate stock carry zack rank buy look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
318,HSIC,walgreen boot alliance inc wba free report be slate release third quarter fiscal result market open jun last quarter company deliver positive earning surprise walgreen boot have outperformed zack consensus estimate precede quarters average positive earning surprise be let take look thing be shape prior announcement key catalystsover recent past walgreen boot retail pharmacy usa division have witness comparable prescription growth benefit strength retail prescription market notably revenue division account total second quarter fiscal revenue several plan development early benefit new pharmacy contract well increase volume owing previously announce pharmacy partnership have be drive growth space same time company have be gain strategic partnership fedex respect exist store last report quarter walgreen boot witness strength pharmacy sale account increase prescription volume company have already start gain recently acquire rite aid store walgreen boot alliance inc price ep surprise walgreen boot alliance inc price ep surprise walgreen boot alliance inc quotemoreover retail pharmacy market have be see rise expenditure prescription drug grow demand specialty drug furthermore company effort boost digital capability have start pay regard company retail resale script be initiate digital channel walgreen mobile app record download launch zack consensus estimate total revenue retail pharmacy usa division reflect rise year meanwhile tough market condition particularly retail have be lead sluggishness retail pharmacy international division however company have be take action enter tie up control cost boost segment zack consensus estimate revenue retail pharmacy international division highlight improvement prior year quarter strong growth certain emerge market be expect continue drive company pharmaceutical wholesale division zack consensus estimate division revenue show rise prior year quarter zack consensus estimate total revenue reflect rise year year basis flip side walgreen boot gross margin figure have be decline recent past however company be work gain efficiency provide high quality cost effective pharmacy service order reduce pharmacy cost overall walgreen boot fiscal earning outlook look quite promising company expect register ep range zack consensus estimate earning share remain guidance range here be quantitative model predict walgreen boot have right combination main ingredient positive earning esp zack rank hold higher need increase odd earning beat zack esp earning esp walgreen boot be uncover best stock buy sell re report earning esp filter zack rank walgreen boot carry zack rank zack consensus estimate earning reflect rise year year basis other stock worth lookhere be few other medical stock worth consider have right combination element post earning beat quarter align technology inc algn free report have earning esp zack rank buy see complete list today zack rank strong buy stock here boston scientific corporation bsx free report have earning esp zack rank henry schein hsic free report have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
319,HSIC,suspension controversial medical device tax year medical device industry be currently ride high optimism advame medical device industry lobbying group strongly advocate relief note tax repeal provide huge impetus company channelize turnover strategic consolidation research development also help create new job opportunity accord article publish daily news tax go effect january save device company much year suspension medical device market be undergo substantial transformation age population longer expectancy life grow healthcare awareness emerge economy combine powerful long term tailwind include merger acquisition product innovation have be contribute growth sector boom continue be yet be see far benefit tax repeal have be redirect now meanwhile accord mark bonifacio president bonifacio consult service private equity strategic oem original equipment manufacturer buyer be compete asset sector medical contract manufacturing broaden portfolio investing new technology strongly state start be sluggish respect be due uncertainty change global healthcare market fate obamacare medical device tax now doubt be gradually get clear industry be once again head year significant activity year biggest deal seem be card wall street journal latest rumore news related mammoth medtech space boston scientific bsx stryker corporation syk free report report say rival consider bid consolidation analyst seem be optimistic rumore deal believe colossal merger medtronic mdt free report covidien abbott st jude medical last couple year boston scientific also need make mammoth move maintain foothold highly competitive medical technology space follow company consolidation st jude medical january abbott recently close acquisition alere successful wrap transaction combine company be anticipate emerge lead player point care diagnostic space mega consolidation recent time be medical device major becton dickinson co medical surgical diagnostic patient care device provider bard completion deal january becton dickinson be way expand new area vascular access segment piccs peripherally insert central catheter midline drug delivery port baxter international bax purchase thrombin topical preveleak surgical sealant specialty pharmaceutical company mallinckrodt plc mnk free report varian medical var free report also inked major deal company recently sign agreement acquire australia base global life science company sirtex medical limit total deal value investment strengthen company position interventional oncology therapy apart effort gain foothold emerge economy company recently acquire cooperative cl enterprise lead distributor radiotherapy equipment taiwan johnson johnson jnj free report subsidiary depuy synthe inked deal acquire medical enterprise distribution apart boston scientific announce several strategic acquisition include nxthera nvision urology pelvic health emcision endoscopy securus ep millipede structural heart inorganic expansion plan bode well stock operational growth divestment medical device major continue offload core business line asset be similar one acquire merger focus main segment divesture have be mandate federal trade commission ftc other international trust regulator restrict chance monopoly market earlier month johnson johnson get offer fortive corporation sell subsidiary ethicon inc advanced sterilization product business unit fortive jnj accept proposal be step streamline business strategic roadmap better resource utilization higher shareholder return apart accord massdevice report medtronic recently divest stake lifetech scientific china everbright ltd unnamed investor bd also divest soft tissue core needle biopsy line aspira product line merit medical divestment be related acquisition bard april henry schein hsic announce decision spin company major segment global animal health business believe initiative remain part henry schein strategic plan focus more dental medical business accord company transaction enable make most opportunity dental space order deliver quality clinical care advanced wellness prevention apprehend china drug distribution reform slow company growth region accord reuter report cardinal health sell china business shanghai pharmaceutical hold follow announcement major buyout abbott divest eye care business abbott medical optic amo johnson johnson streamline newly add business line marketer aesthetic treatment system cynosure sell hologic notably hologic acquire outstanding cynosure share approximately emerge market healthcare scenario bright survey report gallup analytic last july reveal adult cite healthcare second major problem face country new presidential administration follow new healthcare reform announcement december gallup poll reveal past decade marked biggest increase uninsured rate meanwhile explode population rise middle class increase governmental awareness health issue emerge geography be face huge demand modern cheaper healthcare option go report guardian international finance corp ifj datum show develop country account global death chronic disease indicate enormous market opportunity recent bcg report share emerge market be currently less quarter global medtech revenue be likely increase nearly third revenue medtech market china currently second largest world be project grow annually india fifth largest medtech market world currently record annual growth pace india emerge strong competitor japan germany give huge potential region long back johnson johnson have set manufacturing center brazil china india company emerge market medical device segment continue grow time faster develop market abbott continue lead emerge market investment trend sale region recent quarters sale key emerge market be double digit drive strength bric well strong growth several country latin america include colombia mexico peru argentina medtronic mdt free report fourth quarter fiscal business latin america middle east africa eastern europe china show sustain strength grow double digit overall medtronic long term outlook emerge market be encourage boston scientific emerge market business register growth first quarter reflect significant increase growth business china be once again remarkable year year key pick spacein medical instrument space be positive abiom inc abmd intuitive surgical inc isrg free report carry zack rank strong buy see complete list today zack rank stock here medical product stock baxter international surmodic inc srdx free report boston scientific orasure technology inc osur free report be also well poise zack rank buy weak linkswe advise investor stay away company offer little growth opportunity term include company estimate revision trend reflect bearish sentiment stock do not look inspiring moment be nephew plc snn tg therapeutic inc tgtx free report nxstage medical inc nxtm free report insys therapeutic inc insy free report carry zack rank sell orthofix international ofix free report eagle pharmaceutical inc egrx hold zack rank strong sell zack ipo watch listbefore look stock mentioned want get head start potential tech ipos be pop zack radar imagine be first wave investor jump company almost unlimited growth potential special report give current scoop go public time have drive valuation year other be little less obvious already show jaw drop growth download ipo watch list today free
320,HSIC,have be month last earning report henry schein inc hsic free report share have lose time frame recent negative trend continue lead next earning release be hsic due dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst recent earningshenry schein report adjust earning share ep cent first quarter year year adjust ep remain ahead zack consensus estimate year year upside earning be drive strong revenue growth business segment report basis ep come cent first quarter improvement year year revenue detailhenry schein report net sale first quarter year year ahead zack consensus estimate year year improvement come back internal sale growth local currency increase owing foreign currency exchange acquisition growth be quarter first quarter company record sale north american market year year sale totale international market year year segment analysis henry schein derive revenue operate segment dental medical animal health technology value add service first quarter company derive revenue global dental sale year year include growth local currency contribution foreign currency exchange local currency internally generate sale increase acquisition growth be internal growth local currency include growth north america rise internationally company global animal health segment witness rise revenue include growth local currency increase foreign currency exchange local currency internally generate sale increase acquisition growth be internal growth local currency include rise north america improvement internationally worldwide medical revenue rise year year growth local currency be increase owing favorable foreign exchange revenue global technology value add service grow include growth local currency rise related foreign currency exchange acquisition contribute quarter review margin trend gross profit increase report quarter however gross margin contract basis point bps year quarter due rise cost sale rise selling general administrative expense adjust operate income improve year year however adjust operate margin decline bps year year report quarter financial positionhenry schein exit first quarter cash cash equivalent compare end first month net operate cash outflow be compare cash outflow year period result blackout period related spin merger company animal health business quarter review company do not repurchase share common stock close first quarter company have authorize repurchase common stock guidanceexclude cost related restructure spin merger henry schein global animal health business company have reiterate ep guidance company still expect ep range reflect growth adjust ep figure zack consensus estimate adjust ep be remain guide range have estimate be move then past month investor have witness downward trend fresh estimate have be revision higher current quarter compare lower henry schein inc price consensus henry schein inc price consensus henry schein inc quotevgm scoresat time hsic have subpar growth score however momentum be do lot better stock be allocate grade value side putt second quintile investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested style score indicate stock be more suitable momentum investor value investor outlookestimate have be trend downward stock magnitude revision look promising interestingly hsic have zack rank hold expect line return stock next few month
321,HSIC,first trust nasdaq equal weight index fund qqew free report be launch be passively manage exchange trade fund design offer broad exposure large cap growth segment equity market fund be sponsored first trust advisor have amassed asset make average size etfs attempt match large cap growth segment equity market large cap growthcompany find large cap category typically have market capitalization consider more stable option large cap company boast more predictable cash flow be less volatile mid small cap counterpart quality growth stock include faster growth rate compare broader market well higher valuation higher average sale earning growth rate something keep mind be higher level volatility be affiliated growth stock be likely outperform value stock strong bull market longer term value stock have deliver better return growth stock almost market costswhen consider etf total return expense ratio be important factor cheaper fund significantly outperform more expensive counterpart long term other factor remain equal annual operate expense etf be putt par most peer product space have month trail dividend yield sector exposure top holdingswhile etfs offer diversify exposure minimize single stock risk deep look fund holding be valuable exercise most etfs be very transparent product disclose holding daily basis etf have heaviest allocation information technology sector portfolio consumer discretionary healthcare round top look individual holding shire plc adr shpg free report account total asset follow ulta beauty inc ulta free report henry schein inc hsic free report top holding account total asset management performance riskqqew seek match performance nasdaq equal weight index fee expense nasdaq equal weight index be equal weight version nasdaq index include largest financial security list nasdaq base market capitalization etf have add roughly so far year be last year past week period have trade etf have beta standard deviation trail year period make medium risk choice space holding effectively diversify company specific risk trust nasdaq equal weight index fund carry zack etf rank hold be base expect asset class return expense ratio momentum other factor thus qqew be good option seek exposure large cap etfs area market investor also want consider other etf option space ishare russell growth etf iwf free report powershare qqq qqq free report track similar index ishare russell growth etf have asset powershare qqq have iwf have expense ratio qqq charge bottom lineretail institutional investor increasingly turn passively manage etfs offer low cost transparency flexibility tax efficiency kind fund be also excellent vehicle long term investor learn more product other etfs screen product match investment objective read article latest development etf investing universe please visit zack etf center
322,HSIC,design provide broad exposure large cap etfs category equity market first trust nasdaq equal weight index fund qqew free report be smart beta exchange trade fund launch be smart beta etfs etf industry have traditionally be dominate product base market capitalization weight index be design represent market particular segment market investor believe market efficiency consider market cap index replicate market return low cost convenient transparent way be investor rather invest smart beta fund fund track cap weight strategy be strong option prefer choose great stock order beat market attempt pick stock have better chance risk return performance cap weight index be base certain fundamental characteristic combination such methodology equal weighting simplest option fundamental weighting volatility momentum base weighting be choice offer investor space not deliver superior return fund sponsor indexmanage first trust advisor qqew have amassed asset make average size etfs large cap etfs particular fund seek match performance nasdaq equal weight index fee expense nasdaq equal weight index be equal weight version nasdaq index include largest financial security list nasdaq base market capitalization cost other etf investor expense ratio be important factor consider fund return long term cheaper fund actually have ability outperform more expensive cousin other thing remain same annual operate expense etf be make par most peer product space fund have month trail dividend yield sector exposure top holdingseven etfs offer diversify exposure minimize single stock risk be still important look fund holding investing luckily most etfs be very transparent product disclose holding daily basis represent portfolio fund have heaviest allocation information technology sector consumer discretionary healthcare round top take account individual holding shire plc adr shpg free report account fund total asset follow ulta beauty inc ulta free report henry schein inc hsic free report qqew top holding account total asset management performance riskqqew have gain so far year be last year past week period fund have trade etf have beta standard deviation trail year period make medium choice space holding effectively diversify company specific risk trust nasdaq equal weight index fund be reasonable option investor seek outperform large cap etfs segment market however be other etfs space investor consider ishare russell growth etf iwf free report track russell growth index powershare qqq qqq free report track nasdaq index ishare russell growth etf have asset powershare qqq have iwf have expense ratio qqq charge investor look cheaper lower risk option consider traditional market cap weight etfs aim match return large cap etfs bottom lineto learn more product other etfs screen product match investment objective read article latest development etf investing universe please visit zack etf center
323,HSIC,henry schein inc hsic free report report adjust earning share ep cent first quarter year year adjust ep remain ahead zack consensus estimate year year upside earning be drive strong revenue growth business segment report basis ep come cent first quarter improvement year year revenue detailhenry schein report net sale first quarter year year ahead zack consensus estimate year year improvement come back internal sale growth local currency increase owing foreign currency exchange acquisition growth be quarter henry schein inc price consensus ep surprise henry schein inc price consensus ep surprise henry schein inc quotein first quarter company record sale north american market year year sale totale international market year year segment analysis henry schein derive revenue operate segment dental medical animal health technology value add service first quarter company derive revenue global dental sale year year include growth local currency contribution foreign currency exchange local currency internally generate sale increase acquisition growth be internal growth local currency include growth north america rise internationally company global animal health segment witness rise revenue include growth local currency increase foreign currency exchange local currency internally generate sale increase acquisition growth be internal growth local currency include rise north america improvement internationally worldwide medical revenue rise year year growth local currency be increase owing favorable foreign exchange revenue global technology value add service grow include growth local currency rise related foreign currency exchange acquisition contribute quarter review margin trend gross profit increase report quarter however gross margin contract basis point bps year quarter due rise cost sale rise selling general administrative expense adjust operate income improve year year however adjust operate margin decline bps year year report quarter financial positionhenry schein exit first quarter cash cash equivalent compare end first month net operate cash outflow be compare cash outflow year period result blackout period related spin merger company animal health business quarter review company do not repurchase share common stock close first quarter company have authorize repurchase common stock guidanceexclude cost related restructure spin merger henry schein global animal health business company have reiterate ep guidance company still expect ep range reflect growth adjust ep figure zack consensus estimate adjust ep be remain guide range takehenry schein exit first quarter strong note earning revenue steering past respective zack consensus estimate company operate segment record strong year year growth henry schein strong share gain north american overseas market solid revenue raise optimism better expect revenue performance be disappoint year year deterioration henry schein gross operate margin due higher cost sale expense currently await completion company global animal health business plan spin business contribute nearly company topline spin accordingly be expect bring major change henry schein overall operate result accord company follow spinoff animal health business merge privately hold vet first choice form new public company call vet first corp believe initiative remain part henry schein strategic plan focus more dental medical business zack rank key pickshenry schein have zack rank buy few other top rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corp che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent beat zack consensus estimate revenue also edge past zack consensus estimate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
324,HSIC,headquarter melville ny henry schein inc hsic free report be global lead provider healthcare product service company serve office base dental medical animal health practitioner dental laboratory government well institutional health care clinic other alternate care site presently henry schein serve more customer have operation country company enter prestigious standard poor index mar currently henry schein have zack rank buy change follow first quarter earning report have just release see complete list today zack rank strong buy stock here have highlighted key detail just release announcement earning zack consensus estimate be peg cent share henry schein adjust earning share cent exceed estimate revenue henry schein post net sale ahead zack consensus estimate revenue henry schein inc price ep surprise henry schein inc price ep surprise henry schein inc quotekey stat revenue first quarter derive henry schein dental segment grow year year animal health segment record sale compare prior year quarter revenue medical segment increase year year sale technology value add service segment grow major factor henry schein global segment gain solid market share quarter deliver solid earning growth back strategy grow business organically acquisition company have reiterate earlier provide ep guidance range stock price follow earning release share price do not show significant movement pre market trading session check back later full henry schein earning report later look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
325,HSIC,henry schein inc hsic free report be expect report first quarter result last quarter company earning meet estimate earning surpass zack consensus estimate last quarters average positive surprise be let see thing be shape prior announcement factor playover last few quarters henry schein demonstrated solid growth segment dental animal health medical technology value add service geographically company gain traction north america overseas expect trend continue first quarter favorable dental business trend company strategy expand digital dentistry globally be encourage regard management believe company be well position gain ongoing trend digitalization global dental market zack consensus estimate first quarter total revenue reflect increase year quarter furthermore be also upbeat management expectation sustain dental equipment business growth europe other region henry schein be busy promote digital workflow general dentistry well dental specialty start sep company start selling full range dentsply sirona xray free report dental equipment north america include lead cerec cad cam restoration system be expect boost top line considerable extent also management agreement be expect prove accretive earning share year onward thus be look forward deal contribution henry schein bottom line be report quarter henry schein inc price ep surprise henry schein inc price ep surprise henry schein inc quote addition henry schein continue distribute product planmeca shape well dental equipment consumer product line longstanding partner kavo kerr brand solid animal health portfolio be optimistic well diversify animal health product portfolio feature software diagnostic equipment surgical instrument product offering have be drive growth domestically well globally notably fourth quarter henry schein acquire merritt veterinary supply integrate animal health business merritt have veterinary clinic eastern unite state strong presence southeastern part nation company offer comprehensive line product include pharmaceutical diagnostic equipment however accord henry schein acquisition drive earning year onward thus be look forward deal contribution henry schein financial be report quarter grow medical business henry schein be consistently work boost medical segment notably worldwide medical revenue rise year year fourth quarter last october company inked agreement cerebral assessment system distribute cognivue be first computerize cognitive assessment screening device clear fda detection early sign dementia believe development bolster company presence field mental cognitive disease broad distribution network be also upbeat company widespread distribution network apart north america europe company have presence australia new well emerge nation china brazil israel czech republic poland believe henry schein continue ride strength broad distribution network be report quarter further begin march henry schein sign distribution agreement grifol enable former market distribute latter ml normal saline solution sodium chloride injection usp unite state grow demand saline product market believe partnership prove beneficial henry schein flip side henry schein disappointing gross operate margin performance past few quarters due higher cost sale expense be matter concern earning whispersour proven model do not conclusively show beat henry schein be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp henry schein have earning esp zack rank henry schein carry zack rank increase predictive power esp however negative esp make surprise prediction difficult nonetheless zack consensus estimate first quarter adjust earning cent reflect rise year year stock worth lookhere be few stock worth consider have right combination element post earning beat quarter brady corporation brc free report have earning esp zack rank see complete list today zack rank stock here michael kor holding limit kor free report have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
326,HSIC,alaska air group inc alk free report share rise report first quarter earning share surpass zack consensus estimate shareshare associate banc corp asb free report increase report first quarter adjust earning share surpass zack consensus estimate sharehenry schein inc hsic free report share rise news company spin animal health business order merge vet first choiceshare humana inc hum free report increase health insurer announce enter partnership privately equity consortium order buy curo health service privately hold hospice facility provider
327,HSIC,align technology inc algn free report be set report first quarter earning result apr market close last quarter company post positive earning surprise align technology have outperformed zack consensus estimate precede quarters average positive earning surprise be let take look thing be shape prior announcement invisalign system major growth driversimilar prior quarters align technology be expect gain continue adoption invisalign technology first quarter well accordingly company project invisalign case shipment band be report quarter year notably november align technology announce achievement milestone patient undergo treatment invisalign system interestingly consider fast expand market clear aligner therapy align technology have undertake several strategy drive adoption core invisalign product line include product technology development extend clinical effectiveness promote invisalign brand name boost international growth company have also be focuse increase invisalign utilization orthodontist particularly target teenager align technology have adopt marketing strategy accelerate consumer demand allow gp dentist treat increase number case invisalign system align technology inc price ep surprise align technology inc price ep surprise align technology inc quotestrength scanner service businessalign technology have also be witness strong revenue growth scanner service business past few quarters moreover company have be witness increase adoption itero scanner invisalign case submission instead pvs impression especially north america thereby drive invisalign utilization management expect bullish trend reflect company first quarter result well same time align technology have be focuse expand option itero scanner context last november company sign agreement glidewell dental distribute itero element intraoral scanning system latest glidewell io office solution north america align technology have also sign distribution agreement patterson dental make available itero element intraoral scanning system part patterson dental cad cam portfolio unite state canada solid global prospect align technology have introduce clear aligner solution class ii correction invisalign technology mandibular advancement certain market canada emea apac be indicative grow popularity dental product international market further recent past align technology report strong international invisalign technology volume continue strong performance emea apac region last report quarter emea volume be continue adoption invisalign technology core market spain france well rapid growth smaller market eastern europe central europe middle east africa asia pacific region company witness impressive volume growth lead china japan australia expect see similar trend yet be report quarter result well overall align technology project ep cent revenue first quarter zack consensus estimate total revenue first quarter indicate rise year quarter quantitative model suggestsper proven zack model company favorable zack rank strong buy buy hold have good chance beating estimate also have positive earning esp align technology have earning esp zack rank combination suggest company likely beat earning quarter uncover best stock buy sell re report earning esp filter zack consensus estimate earning cent reflect rise year year basis other stock considerhere be few other medical stock worth consider have right combination element beat estimate time laboratory corporation america holding lh free report have earning esp zack rank see complete list today zack rank stock here henry schein inc hsic free report have earning esp zack rank edward lifescience corporation ew free report have zack rank earning esp hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
328,HSIC,laboratory corporation america holding lh free report also know labcorp be slate report first quarter result apr market open last quarter company deliver positive earning surprise have average trail quarter beat let see thing be shape announcement factor playlabcorp be likely repeat success trend last quarter company be expect gain strong labcorp diagnostic segment period be report banking favorable price mix tuck acquisition organic volume particularly be look forward company partnership mount sinai former owner pathology associate medical laboratory paml providence catholic health earlier company anticipate partnership benefit full year ownership growth generate approximately incremental profitable revenue expect likely upside get reflect first quarter result laboratory corporation america holding price ep surprise laboratory corporation america holding price ep surprise laboratory corporation america holding quote covance drug development note dull show several quarters segment have start report revenue growth third quarter onward back chiltern acquisition strong organic growth favorable foreign currency translation buyout chiltern prove accretive labcorp portfolio add highly complementary capability company offering include scale expansion asia pacific belt broader reach fast grow emerge mid tier biopharma customer segment well expertise oncology drug development factor together continue benefit top line labcorp covance drug development yet be report quarter well significantly company be putt more emphasis create new growth opportunity woman health medical drug monitoring genetic oncology testing apart critical collaboration such walgreen andme covance drug development labcorp expect effort help fortify book bill net order drive revenue conversion process also multus year project launchpad business process improvement initiativeof labcorp look promising company last year saving already achieve platform further project additional net saving year period end thereby substantially expand drug development margin however surface ongoing reimbursement issue state company new pama protect access medicare act rate publish cms center medicare medicaid service do not reflect intent congress direct cms implement market base medicare rate lab testing statement read process cms follow determine rate be fatally flaw fail account significant segment lab market exclude percent lab report datum limit datum collection percent laboratory dominate independent lab be therefore quite apprehensive entire scenario current uproar latest clinical lab fee schedule draft cms finally get enforce san amendment favor testing laboratory continuation launchpad project growth covance benefit chiltern purchase paml mount sinai covance launchpad process be offset reduce pama rate labcorp previously provide guidance revenue growth be expect remain band include likely improvement bps positive foreign currency movement zack consensus estimate current year revenue be peg adjust ep outlook have be project range consensus mark metric fall company forecast quantitative model suggestsper proven zack model company favorable zack rank strong buy buy hold have good chance beating estimate also have positive earning esp labcorp have earning esp zack rank combination suggest company likely beat earning quarter conversely sell rate stock never be consider go earning announcement especially company be see negative estimate revision uncover best stock buy sell re report earning esp filter other stock considerhere be few other medical stock worth consider right combination element beat estimate time myriad genetic inc mygn free report have earning esp zack rank see complete list today zack rank stock here henry schein inc hsic free report have earning esp zack rank quest diagnostic incorporate dgx free report have earning esp be zack rank player breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
329,HSIC,zimmer biomet holding inc zbh free report be set report first quarter result apr market open last quarter company post earning line zack consensus estimate however zimmer biomet miss consensus mark precede quarters average be let take look thing be shape prior announcement key company be expect report strong topline number surgical sport medicine foot ankle extremity trauma arm be report period last quarter revenue be drive solid quarterly sale company surgical portfolio also upper extremity business company see solid demand comprehensive shoulder line regard note last november company have receive several fda clearance be particularly excited approval sidus stem free shoulder system expect development significantly contribute company top line first quarter zimmer biomet holding inc price ep surprise zimmer biomet holding inc price ep surprise zimmer biomet holding inc quote flip side company business have be recent past massively ail supply issue continue pricing pressure zack consensus estimate revenue reflect decline last quarter be also upbeat spine thoracic spine cmf segment be expect deliver quarter promising performance spine category zimmer biomet continue gain strong uptake mobi cervical disc also be look forward top line contribution company recent launch product avenue tlif cage vitality vital spinal fixation system unite state however be apprehensive ongoing revenue dissynergy related company spine sale force integration zimmer biomet be work resolve impact dissynergy chance term resolution be bleak zack consensus estimate spine revenue indicate decrease year quarter overall first quarter revenue be project sequentially other factor likely influence zimmer biomet first quarter result be look focuse execution zimmer biomet sale team expect global adoption rate flagship personalize knee system persona be impressive be also enthusiastic launch persona partial knee system last september knee system marked latest addition company portfolio personalize anatomically design knee implant system zack consensus estimate knee revenue register reduction last quarter hip business expect company once again demonstrate sturdy performance asia pacific region notably previous quarter company register double digit sale growth hip aforementioned geography company be anticipate produce improve quarterly sale taperloc arco system however other segment supply constraint continue limit zimmer biomet ability meet demand high growth brand zack consensus estimate knee revenue represent dip last quarter emerge market have always be significant revenue generate source zimmer biomet recent economic downturn latin america company manage drive growth operation other emerge market especially asia pacific emea europe middle east africa zone zack consensus estimate first quarter revenue emea denote improvement last quarter however zack consensus estimate revenue apac quarter be report translate fall last quarter believe macroeconomic uncertainty unfavorable currency fluctuation have be dent company sale past few quarters company have also be burden pricing wo result zimmer biomet struggle negative pricing pressure approximately absence favorable change line headwind be mirror company first quarter result here quantitative model predict proven zack model company favorable zack rank strong buy buy hold have good chance beating estimate also have positive earning esp zimmer biomet have zack rank lower predictive power esp earning esp caution sell rate stock go earning announcement especially company be see negative estimate revision therefore combination do not suggest company be likely beat earning quarter uncover best stock buy sell re report earning esp filter stock considerhere be few medical stock worth consider right combination element beat estimate time myriad genetic inc mygn free report have earning esp zack rank see complete list today zack rank stock here henry schein inc hsic free report have earning esp zack rank quest diagnostic incorporate dgx free report have earning esp be zack rank player investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
330,HSIC,thermo fisher scientific inc tmo free report be slate report first quarter result market open apr last quarter company deliver positive earning surprise moreover thermo fisher have surpass estimate trail quarters average beat let see thing be shape announcement key catalyststhermo fisher have be go strong analytical instrument business increase global demand particularly company acquisition fei have be largely contribute analytical instrument portfolio past year buyout have enabled thermo fisher access fei industry lead high performance electron microscopy platform used protein study well facilitate life science research be also vital highlight quarter be report thermo fisher anticipate realize total synergy approximately end year follow deal closure cost synergy roughly adjust operate income benefit revenue related synergy thermo fisher scientific inc price ep surprise thermo fisher scientific inc price ep surprise thermo fisher scientific inc quote follow completion deal company have launch host product expand thermo scientific helio dualbeam platform scope material science application also get reflect first quarter performance apart fei related development notable unveil company analytical instrument business be new line thermo scientific air quality monitor call iq series platform include mobile application remote monitoring control well wireless connectivity enhance service turn be likely contribute company top line yet be report quarter overall waltham base company be gear yet quarter strong analytical instrument segmental growth period be report thermo fisher expect see positive impact electron microscopy business well robust volume expansion productivity zack consensus estimate analytical instrument revenue be peg higher year figure here be other factor influence thermo fisher first quarter result company focus boost growth implementation strategy consolidate product offering be encourage initiative be likely help post impressive result first quarter company have spend research development same trend be continue expect innovation product introduction substantially drive company top line first quarter company aim expand capability fast grow asia pacific zone well emerge market also lead solid result recent standout contributor be china india south korea strategic investment support key customer application thermo fisher forecast maintain bullish momentum moreover growth be estimate apply market such environmental food safety apart life science addition company be bet key area focus enormous opportunity disposal include advance precision medicine mass spectrometry target gene sequence structural biology however be apprehensive thermo fisher face foreign exchange headwind revenue adjust ep also hostile macroeconomic condition continue weigh heavily stock stiff competition consistently pose challenge stock value here quantitative model predict proven zack model company favorable zack rank strong buy buy hold have good chance beating estimate also have positive earning esp thermo fisher have zack rank increase predictive power esp earning esp leave surprise prediction inconclusive be company need positive esp be confident earning surprise thus combination do not suggest stock be likely beat earning quarter caution sell rate stock go earning announcement especially company be see negative estimate revision uncover best stock buy sell re report earning esp filter stock considerhere be few medical stock worth consider right combination element outpace expectation time myriad genetic inc mygn free report have earning esp zack rank see complete list today zack rank stock here henry schein inc hsic free report have earning esp zack rank quest diagnostic incorporate dgx free report have earning esp be zack rank player investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
331,HSIC,illumina inc ilmn free report be slate report first quarter result market close apr last quarter company deliver positive earning surprise average earning beat be trail quarters let see thing be shape prior announcement key prior quarter illumina be expect gain strong product revenue last few quarters company product revenue have be gain rise demand sequence consumable instrument well microarray range consumable novaseq platform continue see growth close novaseq system currently customer hand launch last january novaseq shipment be project range management be hopeful launch flow cell xp nextera dna flex library preparation kit drive novaseq demand term give transition illumina high throughput portfolio related novaseq introduction instrument revenue have also be rise illumina inc price ep surprise illumina inc price ep surprise illumina inc quote accordingly zack consensus estimate product revenue reflect increase year quarter total service other revenue include genotyp sequence service instrument maintenance contract revenue oncology agreement have also be strong upside be be drive strength genotyp service due sequence instrument maintenance contract increase consumer demand nipt illumina win dutch national contract previous quarter other encourage development management factor more double sale business moreover company be make progress nipt adoption courtesy continue uptake veriseq nipt solution include ce ivd marked library prep analysis software miniseq miseq shipment accounting roughly new sequence customer demand grow nextseq adoption commercial customer used platform production setting illumina benchtop portfolio have be encourage bullish trend be expect be reflect be report quarter result thus zack consensus estimate service other revenue show rise year quarter here be other factor influence illumina first quarter result january illumina announce launch iseq sequence system next generation sequence system deliver excellent datum accuracy low capital cost make illumina technology available virtually lab company begin shipping product january investor be watch difference make top line result quarter be report geographically illumina have be witness grow revenue europe middle east africa emea lead sequence instrument consumable solid performance asia pacific propel shipment growth greater china also encourage recently management have noticed uptick demand customer be attempt set nipt operation china believe development open channel illumina thereby enhance business growth immaterial be report quarter ongoing tension unite state china regard imposition tariff import have raise concern major medtech player adverse move mar sale china term total oncology testing be last report quarter management solid result be primarily lead continue growth translational liquid biopsy segment furthermore illumina continue expect robust demand oncology testing overall first quarter total revenue be project prior year quarter model zack model company zack rank strong buy buy hold have good chance beating estimate also have positive earning esp uncover best stock buy sell re report earning esp filter illumina have zack rank earning esp combination suggest company be likely beat estimate zack consensus estimate earning reflect rise year year basis other stock worth lookhere be few other medical stock worth consider have right combination element post earning beat quarter myriad genetic inc mygn free report have earning esp zack rank see complete list today zack rank stock here henry schein inc hsic free report have earning esp zack rank quest diagnostic incorporate dgx free report have earning esp zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
332,HSIC,edward lifescience corporation ew free report be slate report first quarter result market close apr last quarter company earning share beat zack consensus estimate moreover edward lifescience have deliver positive earning surprise trail quarters average beat be let see thing be shape prior announcement key catalystsimilar prior quarter edward lifescience be expect gain strength transcatheter heart valve therapy segment thvt banking continue therapy adoption geography notable strength unite state company be expect maintain bullish trend first quarter well company be expect continue gain strong clinical performance sapien unite state well strong therapy implementation region zack consensus estimate transcatheter heart valf thv sale unite state show increase year quarter outside unite state underlie growth rate be solid double digit procedure growth europe be maintain last quarter company also continue see strong tavr therapy adoption japan drive sapien overall first quarter total revenue be project prior year quarter edward lifescience corporation price ep surprise edward lifescience corporation price ep surprise edward lifescience corporation quote here be other factor influence edward lifescience first quarter result edward lifescience be expect continue strong performance base strength other segment surgical heart valve therapy critical care surgical heart valve therapy product group deliver strong performance last quarter drive encourage performance new product strong uptake aortic valf geography moreover buoy continue strong adoption intuity elite valve system management expect intuity elite valve system sale remain track account global aortic sale fiscal management january company have rolled inspiris resilium aortic valf unite state edward lifescience also inform plan launch inspiris resilium japan be track progress well thezack consensus estimate surgical heart valve therapy product sale reflect rise year quarter be also upbeat critical care product group sale witness solid growth product category drive strong growth company core product mainly unite state china also edward lifescience aim strengthen hold critical care technology ongoing rollout hemosphere monitoring platform expansion enhance surgical recovery program accordingly zack consensus estimate critical care product group sale show increase year quarter first quarter company project sale adjust ep model zack model company zack rank strong buy buy hold have good chance beating estimate also have positive earning esp uncover best stock buy sell re report earning esp filter edward lifescience have zack rank earning esp combination suggest company be likely beat estimate zack consensus estimate earning reflect rise year year basis other stock worth lookhere be few other medical stock worth consider also have right combination element post earning beat quarter myriad genetic inc mygn free report have earning esp zack rank see complete list today zack rank stock here henry schein inc hsic free report have earning esp zack rank quest diagnostic incorporate dgx free report have earning esp zack rank medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
333,HSIC,abbott free report be slate report first quarter result market open apr last quarter company earning share exceed zack consensus estimate moreover abbott have deliver positive earning surprise trail quarters average beat be let see thing be shape announcement factor playover past few quarters abbott have be healthy growth trajectory medical device business company have be hog limelight development flagship sensor base continuous glucose monitoring cgm system freestyle libre system notably freestyle libre system be partially fully cover country include france germany japan historically company have be witness solid growth global diabetes care business primarily back contribution freestyle libre apart investor be confident abbott development other business form part medical device segment zack consensus estimate medical device revenue indicate rise year quarter similar prior quarter abbott be expect gain strong performance establish pharmaceutical division epd business have be record operational sale growth last few quarters management expect high single digit sale growth first quarter furthermore zack consensus estimate epd revenue show rise year quarter abbott laboratory price ep surprise abbott laboratory price ep surprise abbott laboratory quotewe be also upbeat diagnostic business have be go strong solid contribution sub segment core laboratory diagnostic molecular diagnostic point care moreover synergy alere buyout form revenue rapid diagnostic have be benefit company moreover management expect rapid diagnostic contribute first quarter zack consensus estimate diagnostic revenue show rise year quarter encouragingly note nutrition be abbott fastest grow business courtesy age population increase rate chronic disease rise middle class emerge market furthermore abbott pediatric nutrition business continue be strong unite state thus zack consensus estimate nutrition revenue indicate rise year quarter favorable currency translation also have positive impact total revenue last report quarter encouragingly note management expect foreign exchange boost result be report quarter drive top line overall first quarter total revenue be project prior year quarter model zack model company zack rank strong buy buy hold have good chance beating estimate also have positive earning esp uncover best stock buy sell re report earning esp filter abbott have zack rank earning esp combination suggest company be likely beat estimate zack consensus estimate earning cent reflect rise year year basis other stock worth lookhere be few other medical stock worth consider also have right combination element post earning beat quarter myriad genetic inc mygn free report have earning esp zack rank see complete list today zack rank stock here henry schein inc hsic free report have earning esp zack rank quest diagnostic incorporate dgx free report have earning esp zack rank medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
334,HSIC,quest diagnostic inc dgx free report be schedule report first quarter earning performance open bell apr last quarter company earning surpass zack consensus estimate penny deliver positive surprise also metric outperformed consensus mark trail quarters average beat let take look thing be shape prior announcement factor playon positive note quest diagnostic seem well align point growth agenda accelerate growth drive operational excellence new long term growth outlook revenue increase period be expect be growth project acquisition earning period be anticipate rise faster revenue mid high single digit range company estimate revenue growth period company increase number partnership other health care leader strategic acquisition be create promising opportunity top bottom line growth improve patient experience reduce overall cost care regard take note recent strategic quest diagnostic first acquisition cleveland heartlab help strengthen company position new york metropolitan marketplace second buyout mobile medical examination service medxm fortify quest diagnostic mobile provider capability population health management solution health plan transaction garner favorable result yet be report quarter quest diagnostic incorporate price ep surprise quest diagnostic incorporate price ep surprise quest diagnostic incorporate quote be also optimistic company successful execution strategy build esoteric testing business well boost profitable growth additionally quest diagnostic have recently witness significant improvement infectious disease testing prescription drug monitoring industry lead wellness business therefore expect growth driver replicate company success story upcoming quarterly result have thus remain active also performance be likely drive same primary metric precede quarter strongly believe recent development have significantly contribute company top line first quarter company expect revenue range annualize growth zack consensus estimate revenue be peg ahead company project range exclude impact special item amortization expense etb excess tax benefit associate stock base compensation adjust ep full year be project band zack consensus estimate fall guide range flip side phase continual drag several quarters company revenue requisition performance last quarters see slight rebound however still remain be see upside be here stay not company professional lab service engagement wj barnabas health healthone system hca holding inc hca also carry lower revenue requisition due nature work further take consideration persistent headwind unit price be moderately less basis point exclude impact protect access medicare act pama company expect unit price headwind remain basis point pama add extra headwind approximately basis point also get reflect first quarter result overall believe lack employment slow growth commercially insure life continuously affect company volume measure number requisition economy turn better model suggestsper proven zack model company favorable zack rank strong buy buy hold have good chance beating estimate also have positive earning esp quest diagnostic have zack rank increase predictive power esp earning esp raise confidence positive surprise together combination suggest company be likely beat earning quarter conversely caution sell rate stock go earning announcement especially company be see negative estimate revision uncover best stock buy sell re report earning esp filter other stock worth lookhere be few other medical stock worth consider right combination element surpass estimate time abaxis inc abax free report have earning esp zack rank see complete list today zack rank stock here abbott laboratory free report have earning esp zack rank henry schein hsic free report have earning esp be zack rank player look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
335,HSIC,gnc holding inc gnc free report be schedule report first quarter result apr open bell last quarter company post negative earning surprise also gnc holding trail quarter average earning miss be factor playgnc holding last report quarter revenue drop year year apart sluggishness canada segment decline revenue manufacturing wholesale segment lead downside absence growth catalyst expect similar trend first quarter well moreover gnc holding have number competitor market include large international pharmacy chain supermarket firm big base company global operation thus anticipate company slash product price face stiff competition turn hurt margin gnc holding inc price ep surprise gnc holding inc price ep surprise gnc holding inc quote however bright side gnc holding international business have be key growth driver company recent year revenue segment increase higher cross border commerce sale china last quarter march company announce plan expand presence india company operate collaboration master franchise partner guardian healthcare service pvt ltd country latest announcement guardian add gnc holding product store india regard new store be expect shelf gnc product compare approximately retail location present apart company have be target other channel retail commerce distribution expansion late company have be experience solid growth china regard last december gnc holding announce plan enter strategic partnership joint venture agreement harbin pharmaceutical group hold co ltd meanwhile company witness improvement trend mexico south korea hong kong immaterial be report quarter ongoing tension unite state china regard imposition tariff import have raise concern medtech player adverse move affect sale performance china term furthermore performance new gnc be improve gradually notably more consumer joined company loyalty program pro access company premium loyalty offer enrolled nearly member launch march apart management be work product pricing innovation meanwhile new consumer enrolment mygnc reward program launch gnc storefront amazon buoy optimism model suggestsour proven model do not conclusively show earning beat gnc holding quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see gnc holding have zack rank strong sell earning esp zack consensus estimate earning cent reflect plunge year year basis caution sell rate stock go earning announcement especially company be see negative estimate revision uncover best stock buy sell re report earning esp filter stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter myriad genetic inc mygn free report have earning esp zack rank see complete list today zack rank stock here henry schein inc hsic free report have earning esp zack rank quest diagnostic incorporate dgx free report have earning esp zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
336,HSIC,bid fortify dental business henry schein inc hsic free report recently form joint venture internet brand notably internet brand be provider web presence online marketing software dental office subject certain customary close condition transaction be expect be complete second quarter however financial term deal be keep wrapped henry schein plan integrate portfolio practice management system dental practice management software company henry schein practice solution internet brand web base software application enhance dental practice management marketing well improvise patient communication joint venture company name joint venture henry schein notably comparison internet brand henry schein hold majority ownership joint venture exclude impact time transfer taxe henry schein anticipate deal be immaterial rest earning share accretive thereafter furthermore annual synergy be expect be realize end third year joint venture initiation dental business major growth driverhenry schein dental business contribute total revenue last report quarter accordingly have be leave stone unturned strengthen hold business regard last year henry schein sign distribution agreement dentsply sirona inc xray free report distribute latter entire product line encouragingly note henry schein bank part strategic plan digital dentistry company be busy promote digital workflow general dentistry well dental specialty management solid performance be attribute continue focus offer diversify portfolio value add service favorable end market thus believe company latest tie be strategic market potentialper company dental industry rise oral healthcare expenditure be predict population agee year increase moreover henry schein be upbeat expect increase dental insurance coverage lower insurance reimbursement rate lead rise need new technology believe boost demand henry schein product service moreover report transparency market research global dental practice management software market be expect see cagr consider huge potential market believe latest development be strategic help henry schein cash bountiful opportunity market share price movementover past month henry schein have be underperform broader industry stock lose contrast industry gain believe latest development help boost investor confidence stock reverse downtrend zack rank key pickshenry schein currently carry zack rank hold few better rank stock broader medical sector be bio rad laboratory bio free report align technology inc algn free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here have long term expect earning growth rate align technology have long term expect earning growth rate stock carry zack rank buy zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
337,HSIC,recent year grow healthcare cognizance have lead continuous technological innovation dental equipment space time have emerge most favore sector medical device investor look consistent attractive return let delve deeper last year dental supply market have be fare better index market have gain eclipse broader market ally market research report global dental implant prosthetic market be expect catapult value cagr go estimate american dental association publish grand view research year implant be carry unite state indicate huge market potential today fast pace time implant be prefer conventional removable denture owing comfort convenience factor drive demand dental treatmenthigh demand child teenager market market report child teenager be expect dominate global orthodontic market come year high number patient malocclusion jaw disorder be likely drive demand also rise need fix brace child teenager act major demand propeller notably orthodontic treatment be more effective successful childhood teenage noteworthy development niche space be launch align technology clear aligner solution class ii correction invisalign technology mandibular advancement certain market canada emea apac cosmetic need grow awareness esthetic need have also be major growth catalyst dental prosthetic market market market global cosmetic dentistry be expect make cagr moreover increase disposable income give rise higher demand cosmetic dental surgery rise geriatric population age population have also be significant contributor higher incidence calcium deficiency older person lead tooth loss accord national institute dental craniofacial research more adult age year have lose tooth person medication chronic metabolic disorder also reach edentulous state other factor poor lifestyle choice unhygienic dental care lead higher demand dental procedure increase dental disease be factor also dental injury cause road accident lead higher demand dental implant prosthetic technological advancement shape dental implant marketthe global dental implant prosthetic market be gradually shift conventional technologically advanced laser dentistry be much demand dental patient painless extraction tooth orthodontic periodontal decay market market dental laser market be expect scale value cagr dental printing be process create dimensional solid dental model such implant surgical guide brace denture crown bridge etc notably printing be gain popularity allow dentist carry procedure more precision efficiency save patient excess trauma go report transparency market research global dental printing market be expect see cagr reach worth stock focuswe have select company believe be well poise provide impressive long term return give encourage growth prospect global dental implant prosthetic market align technology inc algn free report have long term earning growth rate current quarter estimate revision trend stock have be encourage estimate move upward compare downward movement past month resultantly zack consensus estimate earning share rise company year historical growth rate be favorable compare industry company share price movement past year have be encourage company yielded almost better industry align technology recently sign agreement glidewell dental distribute itero element intraoral scanning system latest glidewell io office solution north america henry schein inc hsic free report have long term earning growth rate company historical year earning growth rate compare favorably industry past month share henry schein have outperformed industry belong stock have lose compare industry fall estimate revision current year have be solid estimate north compare move south past month resultantly consensus estimate earning climb ride strength full range dentsply sirona inc xray free report line company have be gain solid uptake product key dental equipment manufacturer dec midmark shape furthermore management believe company be well position gain wave digitalization corporation dhr free report have long term earning growth rate estimate revision current year have be solid estimate move compare movement opposite direction past month resultantly consensus estimate earning rise company year historical growth rate be higher industry share company have rally past year outperform industry decline today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
338,HSIC,walgreen boot alliance inc wba free report be slate release second quarter fiscal result market open mar last quarter company have deliver positive earning surprise be noteworthy walgreen boot have outperformed zack consensus estimate precede quarters average positive earning surprise let take look thing be shape prior announcement key catalystsover recent past have observed walgreen boot retail pharmacy usa division witness comparable prescription growth benefit strength retail prescription market several plan development early benefit new pharmacy contract well increase volume owing previously announce pharmacy partnership have be drive growth space past few quarters moreover rise expenditure prescription drug grow demand specialty drug have be strengthen retail pharmacy market meanwhile first quarter fiscal company exceed script day adjust roll annual basis first time touch new milestone furthermore company effort boost digital capability have start pay regard more company retail refill script be initiate digital channel walgreen mobile app have be download excess time launch be also encourage increase sale retail pharmacy international segment furthermore company have be gain account company strategic tie up bring more patient pharmacy walgreen boot alliance inc price ep surprise walgreen boot alliance inc price ep surprise walgreen boot alliance inc quote meanwhile strong market growth certain emerge market drive company pharmaceutical wholesale division solid performance first quarter fiscal expect trend get reflect fiscal second quarter result well zack consensus estimate total revenue reflect rise year year basis also be upbeat company expand global footprint decision acquire stake sinopharm hold guoda drugstore co ltd guoda subsidiary china national accord medicine corporation ltd completion investment provide strong impetus walgreen boot worldwide retail pharmacy business notably shanghai base guoda be large national pharmacy chain china be retail pharmacy platform china national pharmaceutical group corporation cnpgc moreover company acceptance proposal sell part investment chinese wholesale partner guangzhou pharmaceutical corporation huge cash return buoy optimism be also upbeat walgreen boot plan expand exist group purchasing effort express script hold company ensure availability specialty brand drug biosimilar have potential lower production cost move be consider be prudent timely flip side walgreen boot gross margin figure continue contract last report quarter well lower pharmacy margin reflect reduction funding lead downside however company be work tirelessly increase efficiency provide high quality cost effective pharmacy service order reduce overall pharmacy cost here be quantitative model predict walgreen boot have right combination main ingredient positive earning esp zack rank hold higher need increase odd earning beat zack esp earning esp walgreen boot be uncover best stock buy sell re report earning esp filter zack rank walgreen boot carry zack rank buy zack consensus estimate earning reflect rise year year basis other stock worth lookhere be few other medical stock worth consider have right combination element post earning beat quarter edward lifescience corporation ew free report have earning esp zack rank see complete list today zack rank strong buy stock here align technology inc algn free report have earning esp zack rank henry schein hsic free report have earning esp zack rank medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
339,HSIC,gnc holding inc gnc free report be expect report fourth quarter result feb open bell last quarter company post negative earning surprise also gnc holding trail quarter average earning miss be let take look gnc holding announcement preliminary fourth quarter result announcement gnc holding see increase fourth quarter same store sale domestic company own store include gnc com sale also adjust diluted earning share ep be expect range cent compare cent prior year quarter year quarter ep decline be lead substantial fall revenue gnc holding inc price ep surprise gnc holding inc price ep surprise gnc holding inc quote meanwhile zack consensus estimate earning be peg cent reflect decline last quarter further zack consensus estimate revenue be peg reflect drop precede quarter other factor playdull prospect canada segmentgnc holding third quarter revenue drop year year lower sale canada manufacturing wholesale segment be cite main reason disappointing performance absence catalyst expect similar trend fourth quarter zack consensus estimate revenue segment stand reflect decline year quarter china commerce drive international segment revenue international segment increase whopping last quarter revenue international franchisee rise impressively solid performance china commerce platform be likely be key catalyst result zack consensus estimate revenue segment be peg reflect growth year earlier quarter however gnc holding have number competitor market include large international pharmacy chain supermarket firm big base company global operation expect company slash price face stiff competition turn hurt margin other developmentson bright side performance new gnc be improve gradually pro access company premium loyalty offer have enrolled nearly member launch march apart management be work product pricing innovation meanwhile new consumer enrolment mygnc reward program launch gnc storefront amazon buoy optimism earning whisper proven model do not conclusively show earning beat gnc holding quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp gnc holding be uncover best stock buy sell re report earning esp filter zack rank gnc holding carry zack rank increase predictive power esp however also need have positive esp be confident positive earning surprise stock considerhere be few medical stock worth consider have right combination element post earning beat quarter bio rad laboratory bio free report have earning esp zack rank see complete list today zack rank stock here myriad genetic mygn free report have earning esp zack rank henry schein hsic free report have earning esp zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
340,HSIC,idexx laboratory inc idxx free report be expect beat earning report fourth quarter result feb open bell last quarter company deliver positive earning surprise be worth note idexx have outperformed zack consensus estimate precede quarters average be let take look thing be shape prior announcement key catalystsimilar prior quarter idexx be expect gain strong global growth companion animal group cag diagnostic recur revenue upside be drive double digit organic revenue gain consumable reference lab strong acceptance rapid assay veterinary software service diagnostic imaging system well continue expansion idexx premium instrument install base management expect solid performance reflect fourth quarter result well be also upbeat idexx enhance commercial capability unite state maintain recur revenue growth cag diagnostic management expect fourth quarter result show rise productivity new sale representative establish new customer relationship switch commission base compensation instrument placement also expect company report exceptional customer retention rate reference lab instrument consumable unite state worldwide fourth quarter zack consensus estimate cag diagnostic revenue reflect increase year quarter overall zack consensus estimate fourth quarter total revenue be project prior year quarter notably idexx expect revenue range reflect organic revenue growth idexx laboratory inc price ep surprise idexx laboratory inc price ep surprise idexx laboratory inc quote here be other factor influence idexx fourth quarter result be upbeat growth water business have be growth trajectory late encourage test result unite state benefit global go direct initiative moreover last report quarter business witness organic growth management be also look forward benefit favorable regulatory development pertain wastewater unite state drink water europe accordingly zack consensus estimate water revenue reflect increase year quarter idexx continue expand globally have be significantly benefitting bountiful opportunity companion animal diagnostic market emerge nation further management consistent share buyback reflect strong free cash flow reserve believe outcome endeavor be reflect fourth quarter performance management also estimate ep band support continue operate margin expansion align long term goal outlook represent year year ep growth report basis zack consensus estimate earning cent show increase year flip side foreign currency fluctuation be major headwind concern be company high reliance third party distributor purchasing dynamic distributor have significant impact company sale instrument consumable rapid assay product also idexx have be see rise operate expense owing increase head count higher investment portfolio development expansion unite state internationally also competitive landscape domestic overseas market weigh idexx performance struggle gain market traction prove be drag fourth quarter result here be quantitative model predict idexx have right combination main ingredient positive earning esp zack rank hold higher need increase odd earning beat zack esp earning esp idexx be uncover best stock buy sell re report earning esp filter zack rank idexx carry zack rank buy other stock worth lookhere be few other medical stock worth consider have right combination element post earning beat quarter bio rad laboratory bio free report have earning esp zack rank stron buy see complete list today zack rank stock here myriad genetic mygn free report have earning esp zack rank henry schein hsic free report have earning esp zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
341,HSIC,boston scientific corporation bsx free report be schedule report fourth quarter result open bell feb last quarter company deliver earning line zack consensus estimate however average trail quarter beat be peg let see thing be shape prior announcement preliminary resultson jan boston scientific announce upbeat fourth quarter preliminary sale performance year year preliminary net sale quarter have be forecast report basis operational basis constant exchange rate cer approximately organic basis report preliminary revenue figure lie zack consensus estimate notably organic revenue growth exclude impact change foreign currency exchange rate well sale recent acquisition endochoice holding symetis sa company have announce preliminary net sale reflect growth report basis increase operational basis rise organic basis compare prior year number company preliminary tally again compare favorably zack consensus estimate key catalystsboston scientific corporation price ep surprise boston scientific corporation price ep surprise boston scientific corporation quote be optimistic company gradually improve performance interventional cardiology ic lead innovative portfolio robust commercial team globally more specifically company have late successfully gain business strong sale watchman left atrial appendage closure device portfolio complex pci product watchman platform be expect experience excellent quarter consistent global momentum boston scientific multiple market development effort continue push growth regard medicare reimbursement rate drg increase average effective oct watchman implant fall development be expect have significantly boost ic business fourth quarter company earlier state expect end more account implant watchman increase reorder rate previously open account however ahead company earning release fourth quarter believe ic business be grossly impact product recall issue europe notably february company recall prime product lotus range heart device europe due device malfunction company also delay submission marketing application lotus edge device recently company have announce further delay earlier report timeline commercial return lotus edge aortic valve system europe well unite state notably recall product last february boston scientific announce expect time reintroduction lotus edge delivery system europe first quarter company also expect file final pre market approval pma module food drug administration january however latest press release company be likely provide further update status lotus edge valve feb delay have be justified boston scientific cite continuous focus manufacturing regulatory milestone support long term success lotus platform company state be work hard implement necessary modification device pass internal quality standard however extra delay lead further setback company fast grow transcatheter aortic valve replacement business ic soon be report quarter zack consensus estimate fourth quarter ic revenue be peg higher year report number other factor playamong segment medsurg be estimate demonstrate steady performance lead endoscopy urology woman health be also project grow market level drive investment strategy key international geography zack consensus estimate fourth quarter endoscopy revenue be peg prior year quarter report count urology woman health consensus mark remain ahead year earlier quarter report tally flip side severe currency headwind boston scientific have be face late remain concern fact company record sale international market get highly expose currency fluctuation full year boston scientific predict unfavorable foreign exchange challenge tune basis point cent share earning here quantitative model predict boston scientific do not have right combination main ingredient positive earning esp favorable zack rank strong buy buy hold increase odd earning beat zack esp boston scientific have earning esp make surprise prediction difficult uncover best stock buy sell re report earning esp filter zack rank boston scientific carry zack rank sell lower predictive power esp stock worth lookhere be few medical stock worth consider right combination element beat earning quarter bio rad laboratory bio free report have earning esp zack rank see complete list today zack rank stock here myriad genetic mygn free report have earning esp zack rank henry schein hsic free report have earning esp be zack rank player hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
342,HSIC,edward lifescience corporation ew free report be schedule report fourth quarter earning feb market close edward lifescience have outperformed zack consensus estimate precede quarters average positive earning surprise let take look thing be shape prior announcement key prior quarter edward lifescience be expect gain strength transcatheter heart valve therapy segment thvt banking continue therapy adoption geography notable strength unite state company be expect maintain bullish trend fourth quarter well unite state transcatheter heart valve sale grow year year third quarter outside unite state underlie growth rate be strong contribution japan edward lifescience corporation price ep surprise edward lifescience corporation price ep surprise edward lifescience corporation quote last report quarter growth thvt be drive excellent clinical performance result sapien well continue strong therapy implementation region also zack consensus estimate thvt net sale reflect increase year quarter overall fourth quarter revenue be project here be other factor influence edward lifescience fourth quarter result investor be bullish harpoon medical acquisition be complete dec intention enhance surgical heart valve therapy portfolio however buyout be not expect contribute significantly fourth quarter revenue meanwhile intuity elite valve system be approve medicare new tech add payment effective oct recognize intuity latest technology provide substantial clinical improvement conventional valf company believe many hospital be help add payment next year simplify adoption rapid deployment valve shorten minimally invasive complex procedure edward lifescience expect sale meet high end range moreover note company project total sale adjust earning share cent cent fourth quarter however company expect change fourth quarter gross margin earning be expect be impact foreign currency fluctuation also tough competition cardiac device market reimbursement issue continue raise caution here be quantitative model predict edward lifescience have right combination main ingredient positive earning esp zack rank hold higher increase odd earning beat zack esp earning esp edward lifescience be uncover best stock buy sell re report earning esp filter zack rank edward lifescience carry zack rank increase predictive power esp meanwhile zack consensus estimate earning cent reflect improvement year year basis other stock worth lookhere be few other medical stock worth consider have right combination element post earning beat quarter bio rad laboratory bio free report have earning esp zack rank buy see complete list today zack rank strong buy stock here myriad genetic mygn free report have earning esp zack rank henry schein hsic free report have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
343,HSIC,zimmer biomet holding inc zbh free report be set report fourth quarter result jan market open last quarter company post negative earning surprise however zimmer biomet have outperformed zack consensus estimate precede quarters average positive earning surprise be let take look thing be shape prior announcement key prior quarter company be expect gain strength surgical sport medicine foot ankle extremity trauma arm last report quarter revenue be drive surgical business sport medicine offering such gel quattro link moreover solid uptake plate system foot ankle portfolio boost segment performance company witness strength intellicart system fluid waste management historically strong performance key brand acquisition increase focus sale force specialization have be partially offset adverse impact supply issue continue pricing pressure segment zack consensus estimate revenue reflect increase year quarter report number zimmer biomet holding inc price ep surprise zimmer biomet holding inc price ep surprise zimmer biomet holding inc quote be also upbeat spine thoracic spine cmf segment be expect deliver quarter promising performance spine category zimmer biomet continue gain strong uptake mobi cervical disc also be look forward top line contribution company launch product avenue tlif cage vitality vital spinal fixation system unite state october moreover ldr holding acquisition have insignificant contribution top line basis point third quarter initial phase integration be expect contribute basis point full year revenue cer also management be hopeful gain significant cross selling opportunity acquisition provide back strong spine sale force unite state continue uptake trauma plate system sternalock blu sternalock primary closure system well ribfix blu thoracic fixation system thoracic arm buoy optimism zack consensus estimate spine revenue indicate rise year quarter overall fourth quarter revenue be project prior year quarter here be other factor influence zimmer biomet fourth quarter result look focuse execution zimmer biomet sale team expect global adoption rate flagship personalize knee system persona be impressive be also upbeat launch persona partial knee system last september knee system marked latest addition company portfolio personalize anatomically design knee implant system also zimmer biomet release ray base patient specific instrument psi knee system first half buoy optimism be world first ce marked surgical plan system allow patient specific implant position solely utilize ray technology development be expect boost fourth quarter revenue zack consensus estimate knee revenue indicate uptick year quarter emerge market have always be significant revenue generate source zimmer biomet recent economic downturn latin america company manage drive growth operation other emerge market especially asia pacific emea europe middle east africa zack consensus estimate third quarter revenue emea indicate improvement year quarter moreover zack consensus estimate third quarter revenue apac indicate rise year quarter meanwhile macroeconomic uncertainty unfavorable currency fluctuation have be dent sale company past few quarters company have also be deal pricing pressure regard zimmer biomet face negative pricing pressure approximately last report quarter absence favorable change line headwind reflect company fourth quarter result second half management continue expect impact reduce sale expectation continue spending critical program rise manufacturing cost warsaw north campus facility earning whisper proven model do not conclusively show earning beat zimmer biomet quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp zimmer biomet have earning esp be most accurate estimate be peg zack consensus estimate stand zack rank zimmer biomet carry zack rank sell please note caution stock zack rank strong sell go earning announcement especially company be see negative estimate revision momentum zack consensus estimate fourth quarter adjust earning reflect decline year quarter stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter bio rad laboratory bio free report have earning esp zack rank see complete list today zack rank stock here myriad genetic mygn free report have earning esp zack rank henry schein hsic free report have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
344,HSIC,illumina inc ilmn free report be slate report fourth quarter fiscal result jan market close last quarter company deliver positive earning surprise let see thing be shape ahead announcement let take look illumina announcement preliminary fourth quarter result morgan healthcare conference hold san francisco announcement preliminary revenue fourth quarter be estimate year year figure be also higher zack consensus estimate preliminary figure revenue be drive adoption novaseq growth clinical consumer genomic figure be also zack consensus estimate illumina inc price ep surprise illumina inc price ep surprise illumina inc quote similar last quarter illumina be expect gain strong product well service other revenue last few quarters company product revenue increase primarily higher sequence consumable revenue total service other revenue demonstrate strong growth lead continue demand nextseq nipt customer partner company expect fourth quarter sequence consumable increase more year quarter back increase utilization high throughput system strong pull nextseq zack consensus estimate product revenue reflect increase year quarter also zack consensus estimate service other revenue indicate rise year quarter here be other factor influence illumina fourth quarter result november illumina introduce second fda regulate ce ivd marked next generation sequence ngs system nextseq dx illumina now have solid diagnostic ngs portfolio courtesy nextseq dx miseqdx product portfolio be capable meeting clinical requirement ngs base diagnostic ivd product be likely boost top line yet be report quarter last october illumina announce availability novaseq flow cell reagent kit novaseq system management expect witness strong novaseq uptake fourth quarter moreover same month illumina announce availability nextera dna flex whole genome sequence library prep product expect factor drive revenue well also encourage solid third quarter performance illumina raise adjust ep band earlier flip side tough competitive landscape challenge be also apprehensive issue pertain nih funding illumina have be face quite time now here be quantitative model predict illumina have right combination main ingredient positive earning esp zack rank hold better increase odd earning beat zack esp earning esp illumina be uncover best stock buy sell re report earning esp filter zack rank illumina carry zack rank zack consensus estimate earning cent reflect improvement year year basis other stock worth consideringhere be few medical other stock worth consider have right combination element post earning beat quarter bio rad laboratory inc bio free report have earning esp zack rank buy see complete list today zack rank stock here myriad genetic inc mygn free report have earning esp zack rank henry schein inc hsic free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
345,HSIC,thermo fisher scientific inc tmo free report be slate report fourth quarter result market open jan last quarter company deliver positive earning surprise moreover thermo fisher have surpass estimate trail quarters average beat let see thing be shape announcement key catalystthermo fisher have be go strong analytical instrument business increase global demand particularly company acquisition fei have already start generate synergy largely contribute analytical instrument portfolio last quarters buyout have enabled thermo fisher access fei industry lead high performance electron microscopy platform used protein study facilitate life science research be also vital highlight quarter be report thermo fisher anticipate realize total synergy approximately end year follow deal closure cost synergy roughly adjust operate income benefit revenue related synergy get reflect fourth quarter performance thermo fisher scientific inc price ep surprise thermo fisher scientific inc price ep surprise thermo fisher scientific inc quote apart fei related development notable launch company analytical instrument business be new line thermo scientific air quality monitor call iq series platform include mobile application remote monitoring control well wireless connectivity enhance service turn be likely contribute company top line yet be report quarter last not least worth mention be company recent completion take desktop scanning electron microscopy sem solution provider phenom world thermo fisher plan integrate business analytical instrument segment management addition phenom world desktop sem platform be project leverage position electron microscopy space expand entry level desktop sem offering customer work material science industrial manufacturing life science electronic industry overall waltham base company be gear yet quarter strong analytical instrument segmental growth period be report thermo fisher expect see positive impact electron microscopy business well robust volume expansion productivity zack consensus estimate analytical instrument revenue be peg higher sequentially last quarter report figure total revenue estimate segment also remain impressive level here be other factor influence thermo fisher fourth quarter result company focus boost growth implementation strategy consolidate product offering be encourage initiative be likely help post impressive result fourth quarter company have spend research development same trend be continue expect innovation product launch significantly contribute company top line fourth quarter company aim expand capability fast grow asia pacific zone well emerge market also lead solid result recent standout contributor be china india south korea strategic investment support key customer application thermo fisher forecast maintain bullish momentum rest growth be also estimate apply market such environmental food safety apart life science addition company be bet key area focus enormous opportunity disposal include advance precision medicine mass spectrometry target gene sequence structural biology however be apprehensive thermo fisher cite foreign exchange headwind revenue adjust ep also hostile macroeconomic condition continue weigh heavily stock stiff competition consistently impose challenge stock value here quantitative model predict thermo fisher do not have right combination main ingredient positive earning esp zack rank hold higher increase odd earning beat quarter zack esp thermo fisher have earning esp uncover best stock buy sell re report earning esp filter zack rank thermo fisher zack rank increase predictive power esp however need positive esp be confident earning surprise hence combination leave surprise prediction inconclusive zack consensus estimate fourth quarter earning share reflect rise year year basis stock considerhere be few medical stock worth consider right combination element beat estimate time bio rad laboratory inc bio free report have earning esp zack rank strong buy see complete list today zack rank stock here myriad genetic inc mygn free report have earning esp be zack rank player henry schein inc hsic free report have earning esp be rank player make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
346,HSIC,align technology inc algn free report be set report fourth quarter earning result jan market close last quarter company post positive earning surprise align technology have outperformed zack consensus estimate precede quarters average positive earning surprise be let take look thing be shape prior announcement factor lead manufacturer marketer system clear aligner therapy intra oral scanner cad cam computer aid design manufacturing digital service used dentistry orthodontic dental record storage have be witness strong revenue growth scanner service business past few quarters moreover company have be see increase adoption itero scanner invisalign case submission instead pvs impression especially north america thereby drive invisalign utilization management expect bullish trend reflect fourth quarter result well same time align technology have be focuse expand work flow option itero scanner context be upbeat company itero element intraoral scanning system available part patterson dental cad cam portfolio unite state canada moreover company launch software upgrade itero element intraoral scanner be capable compare patient scan time latest timelapse technology also boost confidence stock also company collaborate exocad gmbh last march integrate portfolio result high tech solution efficient scanning design manufacturing house dental prosthesis positive place align technology be expect witness solid top line contribution scanner service business fourth quarter result investor also be look forward company recent signing agreement glidewell dental distribute itero element intraoral scanning system latest glidewell io office solution north america management collaboration widen itero reach more dentist used glidewell service notably company aim launch first quarter align technology inc price ep surprise align technology inc price ep surprise align technology inc quotealign technology achieve milestone patient undergo treatment flagship clear aligner system invisalign november company have be adopt several strategy drive adoption core invisalign product line term product development company receive patent align technology smarttrack aligner material be exclusively used invisalign aligner treatment moreover bid gain traction invisalign platform align technology collaborate digital design last march meanwhile order expand invisalign brand offering align technology introduce patient friendly solution invisalign mandibular advancement teen certain market canada europe middle east africa emea asia pacific apac first half come geographic expansion company open first office canada major market term opportunity expansion growth management launch invisalign technology lite north america post introduction emea company witness strong adoption particularly gp dentist moreover align technology have be witness continue adoption invisalign technology core market emea apac region interestingly recently report third quarter company achieve milestone term invisalign therapy adoption china become second largest invisalign market unite state top number align technology register almost threefold year year increase asset customer base major contribution china also bid expand region company open invisalign treatment plan facility china last june zack consensus estimate total revenue fourth quarter indicate rise year quarter earning whisper proven model do not conclusively show align technology be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp align technology have earning esp be most accurate estimate be peg cent zack consensus estimate stand cent zack rank align technology carry zack rank increase predictive power esp however esp make surprise prediction difficult meanwhile caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision momentum nonetheless zack consensus estimate fourth quarter adjust earning cent reflect growth year quarter stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter bio rad laboratory bio free report have earning esp zack rank see complete list today zack rank stock here myriad genetic mygn free report have earning esp zack rank henry schein hsic free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
347,HSIC,abbott free report diagnostic business have be growth trajectory late solid contribution sub segment core laboratory diagnostic molecular diagnostic point care expect strength get reflect fourth quarter result be schedule release jan core laboratory diagnosticsin june abbott announce ce mark alinity hq have become fifth diagnostic system be launch europe ongoing rollout instrument area immunoassay clinical chemistry blood screening point care have strengthen company core laboratory diagnostic business considerably late company have be headline follow receipt ce mark commercial launch alinity series integrate system hematology testing notably alinity portfolio cover clinical chemistry immunoassay blood plasma screening point care hematology molecular diagnostic abbott aliniq interestingly company also continue initial launch certain new alinity system core laboratory include alinity clinical chemistry alinity immunoassay diagnostic alinity blood plasma screening globally last report third quarter continue slew development illinois base global medical device company sign manage equipment service contract north west london pathology nwlp host imperial college healthcare nhs trust august term collaboration abbott be authorize supplier analytical equipment consumable cover alinity ci alinity series diagnostic instrument aliniq nwlp alliance presently cover pathology market be expect carry test year thus investor be eagerly look forward outcome deal company financial zack consensus estimate core laboratory diagnostic revenue indicate rise year quarter report number abbott laboratory price ep surprise abbott laboratory price ep surprise abbott laboratory quote point careabbott successful closure alere acquisition prolong legal battle have instilled confidence investor buyout close october amend financial term favor abbott take attractive prospect point care testing diagnostic market consideration abbott be highly optimistic alere integration accord company alere buyout significantly expand diagnostic presence create broadest point care testing portfolio strong position cardio metabolic infectious disease toxicology testing moreover abbott expect alere contribute top line thus zack consensus estimate point care revenue indicate massive rise year quarter surge sequential quarter molecular abbott have effectively focuse core area thus company have be strongly perform infectious disease testing business molecular diagnostic have be partially offset decline due plan scale other testing area company zack consensus estimate molecular diagnostic revenue indicate rise year quarter positive place abbott anticipate mid single digit increase diagnostic sale fourth quarter here be quantitative model predict abbott do not have right combination main ingredient positive earning esp zack rank hold higher increase odd earning beat zack esp earning esp abbott be uncover best stock buy sell re report earning esp filter zack rank abbott carry zack rank increase predictive power esp however also need have positive esp be confident positive earning surprise zack consensus estimate earning cent reflect rise year year basis stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter bio rad laboratory inc bio free report have earning esp zack rank buy see complete list today zack rank strong buy stock here myriad genetic inc mygn free report have earning esp zack rank henry schein inc hsic free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
348,HSIC,abbott free report be slate report fourth quarter result market open jan last quarter company deliver positive earning surprise moreover abbott have deliver positive earning surprise trail quarters average beat let see thing be shape announcement key prior quarter abbott be expect gain strong performance establish pharmaceutical division epd business have be record operational sale growth last few quarters major part growth be stimulate series strategic action include abbott sale develop market business acquisition cfr pharmaceutical latin america veropharm russia accordingly zack consensus estimate epd revenue show rise year quarter apart russia latin america company also continue expect strong growth epd upcoming quarters particularly china back strong market position competitive advantage also expect third quarter sale india be drive purchasing pattern follow implementation new good service tax system dent second quarter sale country thus zack consensus estimate epd revenue key emerge market indicate rise year quarter be also upbeat medical device business have be healthy growth trajectory past few quarters abbott have be hog limelight development flagship sensor base continuous glucose monitoring cgm system freestyle libre system historically company have be witness solid growth global diabetes care business primarily back contribution freestyle libre follow fda approval september freestyle libre flash glucose monitoring system abbott achieve major milestone center medicare medicaid service cms grant freestyle libre approval medicare coverage abbott laboratory price ep surprise abbott laboratory price ep surprise abbott laboratory quote moreover last september company announce receipt national reimbursement freestyle libre mark milestone company positive abbott freestyle libre system stand partially fully cover country include france germany japan moreover zack consensus estimate diabetes care revenue indicate rise year quarter apart market be bullish abbott development other business form part medical device segment august company announce fda approval full maglev heartmate left ventricular assist device lvad be expect boost top line contribution cardiovascular neuromodulation sub segment segment have be highest contributor total medical device revenue historically zack consensus estimate cardiovascular neuromodulation revenue indicate rise sequential quarter overall fourth quarter total revenue be project prior year quarter here be quantitative model predict abbott do not have right combination main ingredient positive earning esp zack rank hold higher increase odd earning beat zack esp earning esp resm be uncover best stock buy sell re report earning esp filter zack rank abbott carry zack rank increase predictive power esp however also need have positive esp be confident positive earning surprise zack consensus estimate earning cent reflect rise year year basis stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter bio rad laboratory inc bio free report have earning esp zack rank strong buy see complete list today zack rank stock here myriad genetic inc mygn free report have earning esp zack rank henry schein inc hsic free report have earning esp zack rank zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
349,HSIC,resm rmd free report be slate report second quarter fiscal result market close jan last quarter company deliver positive earning surprise moreover resm have deliver positive earning surprise trail quarters average beat let see thing be shape announcement key prior quarter resm be expect gain strong performance domestic international front last few quarters company revenue domestic front be drive solid growth device mask well continue double digit software sale growth moreover sleep apnea patient volume continue witness steady growth expect trend continue second quarter well internationally company receipt french reimbursement approval telemonitoring buoy optimism company believe reimbursement grant continue drive uptake air solution ecosystem include airsense aircurve device platform well airview myair software platform be report quarter moreover company continue invest expand presence high growth market china south korea india brazil several country eastern europe zack consensus estimate domestic revenue include contribution reflect increase year quarter also zack consensus estimate international revenue indicate rise year quarter be also upbeat resm solid performance mask other accessory business company be seek new application significant unmet medical need space thus recent past company introduce airfit airfit airtouch full face mask different geography airtouch ultrasoft memory foam cushion be breakthrough treatment sleep apnea accordingly zack consensus estimate mask other accessory revenue indicate rise year quarter overall fiscal second quarter total revenue be project prior year quarter resm inc price ep surprise resm inc price ep surprise resm inc quote here be other factor influence resm second quarter result management be particularly upbeat top line contribution launch make last fiscal last report quarter latest product be world smallest continuous positive airway pressure cpap resm airmini have be commercially launch country north america europe asia pacific moreover company recently announce connect airmini airview world largest remote patient monitoring platform resm continue progress steadily back prong growth strategy regard company be look growth adjacent product geographic market include homecare ventilation chronic obstructive pulmonary disease copd amyotrophic lateral sclerosis al other respiratory disorder emerge market china india brazil resm continue see portable oxygen concentrator pocs important addition menu respiratory care product regard company have re launch activox poc last report fiscal first quarter better quality performance unite state canada latin america sale conference company also expect solid top line contribution launch moreover fiscal resm progressed latest offer outcome assessment information set oasis home health hospice market expect get reflect resm top line second quarter well current zack consensus estimate revenue reflect increase year quarter here be quantitative model predict resm do not have right combination main ingredient positive earning esp zack rank hold higher increase odd earning beat zack esp earning esp resm be uncover best stock buy sell re report earning esp filter zack rank resm carry zack rank increase predictive power esp however also need have positive esp be confident positive earning surprise zack consensus estimate earning cent reflect rise year year basis stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter bio rad laboratory inc bio free report have earning esp zack rank strong buy see complete list today zack rank stock here myriad genetic inc mygn free report have earning esp zack rank henry schein inc hsic free report have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
350,HSIC,henry schein inc hsic free report recently announce purchase stake veterinary product distributor certain undisclosed financial term company deal drive earning notably sao paulo brazil base be family own distributor veterinary health care product begin henry schein have enter brazilian animal health market investment tecnew privately hold distributor animal health product latest acquisition company expect boost business brazil diversify relationship global supplier recent development animal healthhenry schein have be consistently try expand global animal health business segment witness rise revenue last report third quarter october company complete buyout merritt veterinary supply merritt become part veterinary business henry schein company offer comprehensive line product include pharmaceutical diagnostic equipment veterinary clinic eastern unite state strong presence southeastern part nation henry schein animal health also open new national distribution service center columbus brookhollow neighborhood expand presence central ohio market potentialaccord report grand view research global animal health market be expect reach value consider huge potential market believe latest development be strategic share price movementover past month henry schein have be underperform broader industry stock have lose contrast industry gain believe latest development help boost investor confidence stock reverse downtrend zack rank key pickshenry schein carry zack rank hold few better rank stock broader medical sector be amedisys inc am free report bio rad laboratory inc bio free report intuitive surgical inc isrg free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate amedisys have long term expect earning growth rate stock carry zack rank buy intuitive surgical have long term expect earning growth rate stock carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
351,HSIC,patterson company inc pdco free report have have unimpressive run bourse last month trading industry further lackluster performance dental segment downbeat guidance be concern stock have zack rank strong sell estimate revision trend patterson company have be dismal current year analyst moved south compare movement opposite direction last month result zack consensus estimate full year earning fall not right dental segment loss distribution recent loss exclusive distribution right dentsply sirona xray free report have force company shift new enterprise resource plan erp system efficiently manage inventory however system be create short term challenge undoubtedly termination contract present new opportunity patterson company expand distribution platform wider range product offering however company also witness heavy initial impact loss deal deteriorate salespatterson company decision end exclusive distribution affect result fiscal fact dental segment sale have be sluggish last couple quarters management have provide dull guidance come quarters well last quarter dental sale total sale decline cc year year approximately downside be cause lower sale cerec digital technology product management expect headwind technology base equipment business persist fiscal add company wo competition rifecutthroat competition dental product distribution industry be major dampener well notably patterson company face serious competition least full service distributor include henry schein dental unit henry schein hsic free report numerous small local distributor share lack lustera rapidly change healthcare environment unite state unfavorable price movement competitive dental product distribution industry integration risk significant challenge patterson company price movement past month have be disappointing company represent negative return almost compare unfavorably industry rally almost fact current level be lower index return same time period key picka top rank stock broader medical sector be petm express inc pet free report petm have long term expect earning growth rate zack rank strong buy stock have rally roughly year see complete list today zack rank stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
352,HSIC,henry schein inc hsic free report recently complete buyout evetpractice provider cloud base practice management solution veterinary clinic financial term deal have be keep wrapped company expect deal prove accretive earning share post company evetpractice be part henry schein veterinary solution portfolio comprise avimark improme north america well vision rxwork robovet globally notably evetpractice be rapidly grow cloud solution provider unite state customer base believe latest takeover widen henry schein customer base portfolio development technology vasin september henry schein have announce receipt office national coordinator health information technology onc health edition health module certification group llc practice management electronic health record software micromd company offer wide range practice management software system cover dental animal health medical have customer base more practice inclusive micromd physician practice continue slew development company have earlier announce partnership medical system simplifeye combine entity aim create mobile experience integration simplifeye henry schein micromd furthermore collaboration aim allow physician provide more customize patient experience simplify practice workflow keep concern team member well connect away workplace performance technology vaswe believe latest development boost sale company global technology value add service vas business interestingly segment see increase revenue last report quarter include growth local currency rise related foreign currency exchange acquisition contribute quarter review market potentialaccord report global veterinary software market be expect reach value cagr consider substantial potential market believe latest development be strategic company increase trend cost control have potential drive demand technology solution go report global healthcare market be project reach value cagr period believe agee population unhealthy lifestyle rise awareness expenditure healthcare continue drive growth healthcare market market be dominate number well establish player nextgen division quality system inc qsii free report be prominent share price performance
353,HSIC,nov issue update research report henry schein inc hsic free report company carry zack rank sell henry schein exit third quarter mixed note earning miss revenue beating zack consensus estimate be disappoint company lower high end ep guidance meanwhile year year deterioration henry schein gross operate margin be lead higher cost sale expense tough competitive landscape pricing pressure also weigh stock share company have underperform broader industry past month stock have lose gain broader industry positive note expect trend improve balanced growth operate segment henry schein be also encourage company effort grow internationally apart north america europe have presence australia new well emerge market china brazil israel czech republic poland henry schein inc price henry schein inc price henry schein inc quotealso lead distributor health care product service globe continue ride high dental business majorly accretive strategic merger integration colossal merger field be poland base dental cremer also henry schein gain several trend end market customer demographic increase number life cover follow healthcare reform unite state be likely boost company additionally company gain traction animal health business back tailwind north america well overseas market burgeon demand animal health product unite state further drive company growth key stocksa few better rank medical stock be petm express inc pet free report align technology inc algn free report myriad genetic inc mygn free report sporting zack rank strong buy see complete list today zack rank stock here petm have long term expect earning growth rate stock have surge roughly year align technologyha long term expect earning growth rate stock have sky-rocket year myriad genetic have long term expect earning growth rate stock have soar year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
354,HSIC,investor henry schein inc hsic free report need pay close attention stock base move option market lately be nov put have highest imply volatility equity option today be imply volatility imply volatility show much movement market be expect future option high level imply volatility suggest investor underlie stock be expect big move direction other also mean be event come soon cause big rally huge sell however imply volatility be only piece puzzle putt together option trading strategy do analyst think clearly option trader be pricing big move henry schein share be fundamental picture company currently henry schein be zack rank sell medical dental supply industry rank top zack industry rank last day analyst have increase earning estimate current quarter have drop estimate net effect have take zack consensus estimate current quarter cent share cent period give way analyst feel henry schein right now huge imply volatility mean trade develop oftentimes option trader look option high level imply volatility sell premium be strategy many seasoned trader use capture decay expiration hope trader be underlie stock do not move much originally expect look trade option week very own dave bartosiak give top option trade check recent live analysis option trade nflx earning report completely free see here bartosiak trading netflix nflx earning option check embed video more detail
355,HSIC,henry schein inc hsic free report report adjust earning share ep cent third quarter year year however adjust ep miss zack consensus estimate cent year year upside earning be drive strong revenue growth revenue detailhenry schein report revenue third quarter year year also zack consensus estimate year year improvement come back growth local currency increase owing foreign currency exchange local currency internally generate sale increase acquisition growth be company record sale north american market year year sale totale international market year year segment analysis henry schein derive revenue operate segment dental medical animal health technology value add service third quarter company derive revenue global dental sale year year include growth local currency contribution foreign currency exchange local currency internally generate sale increase acquisition growth be internal growth local currency include growth north america rise internationally henry schein inc price consensus ep surprise henry schein inc price consensus ep surprise henry schein inc company global animal health segment witness rise revenue include growth local currency increase foreign currency exchange local currency internally generate sale increase acquisition growth be internal growth local currency include rise north america improvement internationally worldwide medical revenue rise year year growth local currency be increase owing favorable foreign exchange revenue global technology value add service grow include growth local currency rise related foreign currency exchange acquisition contribute quarter review margin trend gross profit increase report quarter however gross margin decline basis point bps year quarter due rise cost sale higher revenue growth rate rise selling general administrative expense adjust operate income improve year year however adjust operate margin contract bps year year report quarter financial positionhenry schein exit third quarter cash cash equivalent compare end second quarter year date net cash provide operate activity be compare year period quarter review company buy back approximately share almost close third quarter company have authorize repurchase common stock ep guidancehenry schein update adjust ep guidance exclude litigation settlement expense fourth quarter loss related company divestiture equity ownership technology company now expect adjust ep range reflect growth adjust ep figure previous adjust ep guidance range be zack consensus estimate adjust ep be outside guide range company also provide guidance ep henry schein expect report ep band reflect annualize growth rate compare midpoint company adjust ep guidance range takehenry schein exit third quarter mixed note company operate segment record strong year year growth henry schein strong share gain north american overseas market solid revenue raise optimism better expect revenue performance be disappoint year year deterioration henry schein gross operate margin due higher cost sale expense zack rank key pickshenry schein have zack rank hold few better rank stock broader medical sector be petm express inc pet free report luminex corp lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter luminex report adjust earning share cent third quarter year year revenue increase almost year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
356,HSIC,headquarter melville ny henry schein inc hsic free report be global lead provider healthcare product service company serve office base dental medical animal health practitioner dental laboratory government well institutional health care clinic other alternate care site presently henry schein serve more customer have operation country company enter prestigious standard poor index mar currently henry schein have zack rank hold change follow third quarter earning report have just release see complete list today zack rank strong buy stock here have highlighted key detail just release announcement earning zack consensus estimate be peg cent share henry schein adjust earning share cent miss estimate revenue henry schein post revenue ahead zack consensus estimate revenue key stat revenue third quarter derive henry schein dental segment grow year year animal health segment record sale compare prior year quarter revenue medical segment increase year year sale technology value add service segment grow henry schein inc price ep surprise henry schein inc price ep surprise henry schein inc quote major factor management global segment gain solid market share quarter deliver solid earning growth back strategy grow business organically acquisition company decrease higher end earlier provide range adjust ep guidance stock price follow earning release share price do not show significant movement pre market trading session check back later full henry schein earning report later wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
357,HSIC,dentsply sirona inc xray free report third quarter result schedule release nov be expect show lackluster performance dental consumable laboratory major revenue generate component majorly impact third quarter earning expect improvement revenue other segment help company post solid number last quarter dentsply earning revenue miss zack consensus estimate quarter post lackluster result dental healthcare consumable segment comprise preventive restorative instrument endodontic laboratory dental product well consumable medical device product sale increase just quarter zack consensus estimate dental consumable laboratory stand third quarter reflect decline almost last report quarter notably dentsply have be grapple issue pertain equipment inventory level certain distributor basis furthermore unfavorable consumer trend be likely mar sale segment dentsply sirona inc price consensus dentsply sirona inc price consensus dentsply sirona inc quote let see thing be shape company prior release view upbeat zack consensus estimate dentsply third quarter earning stand cent share signify year year growth revenue consensus estimate stand year year company have be witness rebound asia particularly japan strong growth russia however company lower outlook year fact dentsply result first half year have lag expectation domestic market hold promise be upbeat gradual recovery market emerge market provide significant opportunity company area be vastly untapped low dental product penetration fact zack consensus estimate revenue region stand year year apart unite state europe have be significant revenue contributor internal growth last quarter buoy bullish trend quantitative model show earning beat dentsply quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp earning esp dentsply be uncover best stock buy sell re report earning esp filter zack rank dentsply currently carry zack rank here be few medical stock worth consider have right combination element post earning beat quarter inc research holding inc have earning esp zack rank see complete list today zack rank stock here penumbra inc pen free report have earning esp zack rank henry schein inc hsic free report have earning esp zack rank zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
358,HSIC,be thick earning season more index total market capitalization have already release quarterly number meanwhile medtech space uncertainty related trump administration obamacare repeal replacement effort continue make headline latest uproar be related president newly release executive order design provide affordable quality healthcare nation let now have quick look medical device space have fared so far report cycle report suggest hurricane end third quarter be likely mar revenue earning several medtech company primarily florida texas puerto rico medtech major ecolab ecl free report expect impact hurricane full year sale cost be approximately cent share fact medtronic mdt free report acknowledge impact hurricane marium quarterly metric company expect almost impact revenue earning overall lack visibility befuddle favorable trend past few quarters broader medical sector zack sector latest earning preview third quarter expect earning growth rate sector be revenue growth comparison report earning growth rate second quarter be quite impressive revenue growth note be powerful long term tailwind medical space include merger acquisition emerge market expansion positive demographic trend new product innovation have be major drive force sector impressive performance past few quarters even severe socio economic political instability make right pick existence number industry player find right stock have potential beat earning be daunting task proprietary methodology make fairly simple narrow list choice look stock have combination favorable zack rank strong buy buy hold positive earning esp earning esp be proprietary methodology determine stock have best chance surprise next earning announcement show percentage difference most accurate estimate zack consensus estimate research show stock combination have chance positive earning surprise earning beat boost investor confidence stock be reflect rapid price appreciation uncover best stock buy sell report earning esp filter choicesbelow be medical device player have right combination element post earning beat quarter henry schein inc hsic free report headquarter melville ny henry schein be lead distributor health care product service globe company serve office base dental medical animal health practitioner dental laboratory government well institutional health care clinic other alternate care site henry schein be expect report third quarter earning nov have beaten zack consensus estimate trail quarters deliver average positive earning surprise zack rank stock have earning esp see complete list today zack rank stock here biosystem inc ttoo free report be emerge player field diagnostic company be focuse provide better healthcare reduce cost healthcare empower clinician effectively treat patient faster ever company be set report third quarter result nov company have miss zack consensus estimate precede quarters result average earning miss currently company have earning esp carry zack rank opko health inc opk free report be diversify healthcare company diagnostic business include bioreference laboratory lead clinical laboratory unite state core genetic testing business opko be expect report third quarter earning nov have beaten zack consensus estimate trail quarters deliver average positive earning surprise zack rank stock have earning esp icu medical inc icui free report company develop manufacture sell advanced medical device used vascular therapy critical care application product portfolio include iv smart pump set connector close transfer device hazardous drug cardiac monitoring system pain management safety software technology icu medical be set report third quarter result nov company have surpass zack consensus estimate precede quarters average earning beat currently company have earning esp carry zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
359,HSIC,perkinelmer inc pki free report be expect release third quarter result nov close bell last quarter company register adjust earning cent share line zack consensus estimate furthermore adjust revenue approximately lag zack consensus estimate perkinelmer decision restructure discovery analytical solution da diagnostic segment hold promise third quarter furthermore company divestiture medical imaging segment last quarter be expect impact earning season let take look thing be shape prior third quarter earning announcement perkinelmer inc price consensus perkinelmer inc price consensus perkinelmer inc quotefactor considerview upbeat zack consensus estimate perkinelmer third quarter earning stand cent share signify year year growth revenue consensus estimate stand year year third quarter perkinelmer project revenue range represent organic revenue growth approximately third quarter adjust earning share be expect range cent cent solid global foothold perkinelmer have be develop biochemical molecular testing menu meet need pharmaceutical company serve market china india last quarter company win newborn screening tender russia mexico add strong demand china laboratory business launch last year be expect yield solid result quarter be report perkinelmer also acquire goa india base tulip diagnostic private ltd undisclosed amount tulip be acquire early january be bullish buyout help perkinelmer tap opportunity emerge market diagnostic takeover be also likely strengthen perkinelmer foothold infectious disease testing space foreign exchange volatility increase exposure international market increase risk foreign exchange volatility foreign exchange pose headwind approximately top line last quarter fluctuation currency exchange rate adversely impact company international sale due sluggish european economy revenue earning be likely be affected adversely season quantitative model do not conclusively show earning beat perkinelmer quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp earning esp perkinelmer be uncover best stock buy sell re report earning esp filter zack rank perkinelmer carry zack rank favorable zack rank increase predictive power esp company negative esp make surprise prediction difficult here be few medical stock worth consider have right combination element post earning beat quarter inc research holding inc have earning esp zack rank see complete list today zack rank stock here penumbra inc pen free report have earning esp zack rank henry schein inc hsic free report have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
360,HSIC,myriad genetic inc mygn free report be schedule report first quarter fiscal result nov close bell last quarter company post positive earning surprise moreover myriad genetic beat zack consensus estimate trail quarters average be let take look thing be shape prior announcement key last quarter myriad genetic be expect gain strong molecular diagnostic performance lead solid contribution genesight endopredict test zack consensus estimate molecular diagnostic revenue reflect increase year quarter be also upbeat management expectation double digit volume growth fiscal genesight vectra da prolaris endopredict revenue make most molecular diagnostic portfolio myriad genetic inc price ep surprise myriad genetic inc price ep surprise myriad genetic inc quoteper company genesight test represent significant opportunity genesight be initial stage adoption be place highly penetrate preventive care market product have huge growth potential management expect consistent growth genesight test revenue quarters ahead zack consensus estimate genesight test reflect increase year quarter sequentially march company launch endopredict test unite state patient early stage breast cancer then have receive encourage response august myriad genetic receive positive coverage decision test palmetto gba medicare administrative contractor mac anthem inc largest private insurer unite state notably full implementation decision lend myriad genetic coverage approximately breast cancer patient company recently announce positive result clinical study evaluate endopredict highlight superiority first generation oncotype dx breast recurrence score predict breast cancer recurrence woman determine be intermediate clinical risk nottingham prognostic index zack consensus estimate genesight test reflect increase year quarter here be other factor influence myriad genetic first quarter result management seem upbeat prospect prolaris test company announce receipt positive final local coverage determination lcd expand medicare coverage prolaris test palmetto gba mac again company announce plan showcase datum demonstrate utility prolaristest efficiently predict year risk metastase man treat prostate cancer american urological association aua annual meeting positive flow news be expect boost top line be report quarter zack consensus estimate prolaris test revenue reflect increase year quarter management estimate adjust earning share cent total revenue first quarter fiscal zack consensus estimate adjust earning cent revenue be company guide range flip side unfavorable foreign currency translation continue threat considerable portion revenue come outside unite state company face risk exchange rate fluctuation additionally macroeconomic uncertainty higher expense owing extensive pipeline testsmay impact company margin here be quantitative model predict proven model show myriad genetic be likely beat earning have perfect combination key ingredient zack esp myriad genetic have earning esp favorable zack esp serve meaningful lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank myriad genetic currently carry zack rank buy note stock zack rank strong buy hold have significantly higher chance beating earning estimate conversely caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision combination myriad genetic zack rank esp make reasonably confident earning beat other stock worth lookhere be few other medical stock worth consider have right combination element post earning beat quarter cooper company inc coo free report have earning esp zack rank see complete list today zack rank stock here henry schein inc hsic free report have earning esp zack rank penumbra inc pen free report have earning esp zack rank zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
361,HSIC,baxter international inc bax free report be schedule report fourth quarter earning feb market open last quarter company post positive earning surprise baxter international have outperformed zack consensus estimate precede quarters average positive beat be let take look thing be shape prior announcement key last quarter baxter international be expect gain strength hospital product solid sale fluid system business well solid demand injectable pharmaceutical baxter international inc price ep surprise baxter international inc price ep surprise baxter international inc quote hospital product third quarter sale fluid system be significantly robust iv solution sale unite state expect fluid system maintain trend be evident zack consensus estimate fourth quarter reflect rise year quarter global sale integrate pharmacy solution ip sub segment hospital product increase formidable margin third quarter partly back increase sale premixed injectable drug fourth quarter zack consensus estimate ip be peg year report number surgical care include anesthesia biosurgery sale also record year year sale growth third quarter low double digit growth anesthesia critical care product drive grow demand inhaled anesthetic internationally well increase sale brevibloc fast act iv beta blocker fourth quarter zack consensus estimate segment sale stand year quarter also biosurgery sale increase low single digit globally last report quarter company expect growth business continue result continuous effort enhance commercial effectiveness overall zack consensus estimate hospital product net sale reflect increase year quarter notably sep baxter announce launch comprehensive asset tracking solution devicevue solution be used company proprietary pump system sigma spectrum infusion system aid clinician biomedical engineer quickly find unused pump view location status datum pcs ipad iphone be bullish development provide edge sigma spectrum compare other smart pump market here be other factor influence baxter fourth quarter result sale renal business grow significantly third quarter back solid performance line business take stellar third quarter performance consideration expect renal business perform well yet be report quarter well sep baxter announce commercial launch new indication company oxiris set now be used remove excessive level cytokine endotoxin other inflammatory mediator patient blood launch be likely drive top line yet be report quarter company earlier provide guidance sale fourth quarter be expect increase net sale quarter be expect rise constant currency company expect hurricane marium have negative impact fourth quarter revenue company also expect adjust earning range cent cent diluted share include cent negative earning impact hurricane marium be mitigate increase sale projection lower expect tax rate fourth quarter zack consensus estimate fourth quarter revenue be peg same earning be cent reflect increase however pricing pressure continue raise caution here be quantitative model predict baxter have right combination main ingredient positive earning esp zack rank hold higher increase odd earning beat zack esp earning esp baxter international be uncover best stock buy sell re report earning esp filter zack rank baxter international carry zack rank meanwhile zack consensus estimate earning cent reflect improvement year year basis other stock considerhere be few other medical stock worth consider have right combination element post earning beat quarter bio rad laboratory bio free report have earning esp zack rank strong buy see complete list today zack rank stock here myriad genetic mygn free report have earning esp zack rank henry schein hsic free report have earning esp zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
362,HSIC,hologic inc holx free report be slate report fourth quarter fiscal financial result nov close bell last quarter company deliver positive earning surprise notably hologic earning surpass zack consensus estimate past quarters average beat be let see thing be shape prior announcement key catalystsimilar last quarter hologic be expect see stellar performance molecular diagnostic business unite state company be expect gain increase market share utilization fully automate panther system market expansion conform testing guideline notably hologic recently receive fda approval market aptimaherpe simplex virus molecular assay panther system company believe approval draw customer apart broaden panther woman health menu internationally molecular diagnostic result be strong last report quarter courtesy benefit new leadership healthy panther placement multiple product introduction include viral load assay meanwhile be upbeat company receipt european ce mark new panther fusion system panther fusion assay flu respiratory testing june company also receive ce mark aptima combo assay chlamydium trachomatis neisseria gonorrhoeae same month development boost molecular diagnostic revenue be report quarter hologic inc price ep surprise hologic inc price ep surprise hologic inc quote zack consensus estimate molecular diagnostic revenue reflect increase year quarter sequentially here be other factor influence hologic fourth quarter result hologic be hopeful sustain solid earning trend back gain gyn surgical segment strong global sale myosure have be drive top line segment give huge market potential myosure expect company maintain bullish trend zack consensus estimate gyn surgical revenue reflect increase year quarter also zack consensus estimate myosure revenue reflect increase year quarter company be also position rake significant benefit fourth quarter integration cynosure medical aesthetic system technology company be acquire hologic march fda recently grant expand clearance cynosure invasive body contour product sculpsure treat submental area approval marked sculpsure sixth clear body treatment area fourth quarter fiscal hologic expect revenue represent annualize growth current zack consensus estimate fourth quarter revenue be project range reflect increase year quarter adjust ep be project cent show annualize decline however current zack consensus estimate fourth quarter adjust ep cent reflect decline year quarter flip side hologic blood screening divestiture be expect impede company growth momentum expect get reflect company financial performance be report quarter hologic also have face challenge related unfavorable foreign currency past few quarters escalate operate expense intense competition particularly tomosynthesis market continue concern here be quantitative model predict proven model do not conclusively show hologic be likely beat earning quarter be stock need have positive earning esp solid zack rank strong buy buy hold happen be not case here see zack esp hologic have earning esp uncover best stock buy sell re report earning esp filter zack rank hologic currently carry zack rank sell stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter qiagen qgen free report have earning esp zack rank see complete list today zack rank stock here henry schein inc hsic free report have earning esp zack rank penumbra inc pen free report have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
363,HSIC,corp abc free report fourth quarter fiscal result schedule release nov be expect show steady growth pharmaceutical distribution segment significant contributor revenue majorly drive fourth quarter earning let take look broader factor be expect influence quarterly release earning precede quarter surpass zack consensus estimate courtesy strong growth consult service mwi animal health world courier business revenue rise almost quarter zack consensus estimate pharmaceutical distribution segment stand quarter review reflect improvement almost year quarter corporation hold co price consensus ep surprise corporation hold co price consensus ep surprise corporation hold co quoteother factor zack consensus estimate earning stand share year year company benefit continue solid organic revenue growth mwi pharmedium acquisition consensus estimate net revenue be peg signify growth year year basis flipside generic inflation have be nominal rate deflation be rise gradually factor combine anticipate shift product mix lower margin higher price specialty brand drug lack generic inflation affect company bottom line temporary slowdown pharmedium segment be expect mar bottom line fourth quarter notably company aim boost investment enhance pharmedium quality assurance qa quality control qc system term product quality patient safety lend company competitive edge affect bottom line fourth quarter fiscal however quantitative model do not conclusively show earning beat quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp earning esp be uncover best stock buy sell re report earning esp filter zack rank currently carry zack rank favorable zack rank increase predictive power esp company negative esp make surprise prediction difficult here be few medical stock worth consider have right combination element post earning beat quarter inc research holding inc have earning esp zack rank see complete list today zack rank stock here medpace holding inc medp free report have earning esp zack rank henry schein inc hsic free report have earning esp zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
364,HSIC,cvs health corporation cvs free report be schedule report third quarter result nov open bell last quarter company deliver positive earning surprise trail quarter average positive earning surprise be let take look thing be shape prior announcement key catalystscvs health be optimistic sustain solid year year earning trend back gain be realize pharmacy service segment zack consensus estimate third quarter pharmacy service segment revenue reflect increase year quarter report number however be several timing factor have already affected cadence profit delivery last quarter such aspect be timing profitability medicare part business company same be expect continue rest cvs health corporation price ep surprise cvs health corporation price ep surprise cvs health corporation quoteper cvs health timing medicare part profit third quarter remain difficult forecast be period risk sharing corridor be usually least effective provide risk sharing protection hence change current estimate utilization significantly impact timing profit third fourth quarters timing medicare part profitability factor apart company expect benefit enterprise streamline initiative be much more back half year year date figure keep mind last earning call company have project third quarter adjust earning share reflect decline increase year year here be other factor also influence cvs health third quarter result company be worry retail long term care business revenue be expect be third quarter year period due restrict network change notably decision restrict cvs health participate tricare network many fully insure prime network have continue negatively impact pharmacy sale script comp additionally company adjust script comp be expect be range total same store sale be band yet be report quarter however expect pbm revenue grow drive continue strong growth volume specialty pharmacy overall zack consensus estimate third quarter retail pharmacy segment net revenue reflect decline year quarter report figure consolidated net revenue have project rise third quarter overall company estimate deliver healthy pbm growth successful pbm selling season specialty business be expect record strong growth silverscript business also hope retain good performance here be quantitative model predict proven model do not conclusively show cvs health be likely beat earning quarter be stock need have positive earning esp solid zack rank strong buy buy hold happen be not case here see zack esp cvs health have earning esp uncover best stock buy sell re report earning esp filter zack rank cvs health currently carry zack rank increase predictive power esp stock worth lookhere be few medical stock worth consider right combination element come earning beat quarter cooper company inc coo free report have earning esp zack rank see complete list today zack rank stock here henry schein inc hsic free report have earning esp zack rank penumbra inc pen free report have earning esp zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
365,HSIC,cerner corporation cern free report third quarter result schedule release oct be expect show steady growth system sale major revenue component majorly drive third quarter earning expect improvement revenue other segment help company generate solid result season be important note cerner last quarter earning meet zack consensus estimate similar prior quarter strong growth license software subscription be expect be main factor drive system revenue zack consensus estimate system sale stand third quarter reflect increase almost year quarter growth acute ambulatory ehr sale population health revenue cycle solution service hold promise cerner cerner corporation price consensus cerner corporation price consensus cerner corporation quote delve deeper fundamental stock let see thing be shape prior release other factor playview upbeat third quarter cerner forecast revenue adjust earning be expect band cent cent share notably zack consensus estimate revenue be currently peg signify growth year year basis furthermore zack consensus estimate earning stand cent share year year solid participation ehr placement market have lend cerner competitive edge global space cerner offer exposure worldwide healthcare automation growth support maintenance service last quarter management cerner announce company expect growth band segment rest year fact zack consensus estimate segment revenue stand year year basis sequentially strategic partnership cerner follow strategy acquire complementary business allow company expand solution device offering service grow market client base august cerner announce formation post acute innovation center healthsouth corporation nation largest provider post acute service furthermore cerner partner lifepoint health large investor own health company own operate more hospital last quarter booking update be important note booking last quarter be time high year year basis buoy solid trend management expect third quarter booking band midpoint reflect growth year year basis zack consensus estimate third quarter booking stand believe solid growth ambulatory communitywork offering drive booking third quarter however quantitative model do not conclusively show earning beat cerner quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp earning esp cerner be uncover best stock buy sell re report earning esp filter zack rank cerner currently carry zack rank favorable zack rank increase predictive power esp company negative esp make surprise prediction difficult stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter inc research holding inc have earning esp zack rank see complete list today zack rank stock here medpace holding inc medp free report have earning esp zack rank henry schein inc hsic free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
366,HSIC,becton dickinson company bdx free report be set report fourth quarter fiscal result nov becton dickinson have impressive track comfortably beating estimate trail quarters last report quarter deliver positive earning surprise take quarter average let take look thing be shape prior fourth quarter earning announcement likely positive surprise proven model indicate becton dickinson be likely beat earning estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen be case here zack esp earning esp represent difference most accurate estimate zack consensus estimate be uncover best stock buy sell re report earning esp filter zack rank becton dickinson have zack rank be favorable combination zack rank positive esp indicate likely positive surprise note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision becton dickinson company price consensus becton dickinson company price consensus becton dickinson company quotefactor playbecton dickinson innovative product pipeline be key catalyst view plethora regulatory approval unite state international market be help company rapidly expand product portfolio management becton dickinson expect strong demand pyxis es platform infusion pump be growth driver fiscal fourth quarter overall fiscal revenue be anticipate increase approximately zack consensus estimate bd medical segment be fourth quarter signify sequential growth meanwhile zack consensus estimate medical surgical system be peg sequentially additionally partnership collaboration be provide company competitive edge however unfavorable foreign exchange rate be anticipate remain headwind rest year furthermore uncertainty associate possibility repeal affordable care act president trump add company concern company estimate revision trend be also encourage current quarter analyst moved north compare downward revision last month last month current quarter estimate improve share overall fiscal adjust earning currency neutral basis be expect range reflect year year growth stock considerhere be few medical stock worth consider have right combination element post earning beat quarter inc research holding inc have earning esp carry zack rank see complete list today zack rank stock here medpace holding inc medp free report have earning esp carry zack rank henry schein inc hsic free report have earning esp carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
367,HSIC,ecolab inc ecl free report third quarter result schedule release oct be expect show steady growth global energy major revenue component majorly drive third quarter earning expect improvement revenue other segment help company generate solid result season be important note ecolab last quarter earning surpass zack consensus estimate similar prior quarter strong growth well stimulation business modest gain downstream business be expect be main factor drive global energy revenue zack consensus estimate global energy stand third quarter reflect increase almost year quarter apart energy segment growth global industrial global institutional segment hold promise ecolab ecolab inc price ep surprise ecolab inc price ep surprise ecolab inc quote delve deeper fundamental stock let see thing be shape prior release other factor playview upbeat third quarter ecolab project adjust diluted earning share compare year sale be grow sequentially back pricing new business improvement energy segment however margin be modest pressure owing raw material hedge comparison result management ecolab expect deliver solid excellent momentum enter full year come estimate revision trend zack consensus estimate revenue stand third quarter depict growth year year basis consensus estimate third quarter earning stand share year year ecolab earning growth challenge business environment raise investor confidence additionally company large base recur revenue industry lead technology excellent field service be significant propeller global industrial institutional segment zack consensus estimate global industrial unit stand third quarter signify sequential growth year year growth industrial segment prospect food beverage process business be likely show positive result third quarter meanwhile zack consensus estimate global institutional stand year year fundamental strong ecolab be lead provider water hygiene energy technology service protect person vital resource company program service help promote food safety maintain clean environment optimize water energy use improve operational efficiency customer food energy healthcare industrial hospitality market more country fact september ecolab be select member dow jone sustainability index djsi global indicator tracking financial performance lead sustainability drive company launch djsi be consider benchmark area index be draw dow jone collaboration investment management firm strategic asset management sam however quantitative model do not conclusively show earning beat ecolab quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp earning esp ecolab be uncover best stock buy sell re report earning esp filter zack rank ecolab currently carry zack rank sell notably caution stock zack rank strong sell go earning announcement especially company be see negative estimate revision here be few medical stock worth consider have right combination element post earning beat quarter inc research holding inc have earning esp zack rank see complete list today zack rank stock here medpace holding inc medp free report have earning esp zack rank henry schein inc hsic free report have earning esp zack rank zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
368,HSIC,cardinal health cah free report global player healthcare service product space be set report first quarter fiscal result nov close bell company report adjust earning share last report quarter beat zack consensus estimate increase year year basis stock deliver positive earning surprise trail quarters average beat let take look thing be shape prior fourth quarter earning announcement factor playstrong outlook management cardinal health be bullish significant cash generation first quarter furthermore company cordis business be expect generate accretive return quarter review note solid commercial momentum global basis cordis segment generate sluggish return last report quarter however first quarter cardinal health be expect leverage patient recovery business cordis profile meanwhile cardinal health affirm fiscal guidance adjust earning share continue operation outlook represent growth approximately prior fiscal pricing pressure generic portfolio cardinal health have be grapple pricing deflation generic segment long management reimbursement pressure be likely affect company customer base also impede generic launch term incremental expense specifically pharma segment dent profit first quarter cutthroat competition niche space cardinal health witness tough competition business segment example pharmaceutical supply chain business face competition several smaller medical surgical distributor intensify competition global market be likely mar cardinal health top line first quarter estimate revision trend company estimate revision trend lack luster current quarter analyst moved south compare upward revision last month last month current quarter estimate decline almost share add concern earning whispersour proven model do not conclusively show cardinal health be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold beat estimate be not case here see zack esp earning esp cardinal health be most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank cardinal health currently carry zack rank sell caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision cardinal health inc price ep surprise cardinal health inc price ep surprise cardinal health inc quotestock warrant look here be few company want consider proven model show have right combination element post earning beat quarter inc research holding inc have earning esp carry zack rank see complete list today zack rank stock here medpace holding inc medp free report have earning esp carry zack rank henry schein inc hsic free report have earning esp carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
369,HSIC,illumina inc ilmn free report be slate report third quarter fiscal result market close oct last quarter company deliver positive earning surprise average earning beat trail quarters let see thing be shape announcement key prior quarter illumina be expect gain strong performance product revenue well service other revenue segment last few quarters company product revenue increase primarily onrising sequence consumable revenue total service other revenue be demonstrate strong growth lead continue demand nextseq nipt customer partner expect factor drive yet be report quarter performance well zack consensus estimate product revenue reflect increase year quarter also zack consensus estimate service other revenue indicate rise year quarter overall third quarter total revenue be project prior year quarter illumina inc price ep surprise illumina inc price ep surprise illumina inc quote here be other factor influence illumina third quarter result illumina earlier announce fda approve next generation sequence ngs extend ra panel have meet current colorectal cancer guideline new kit fulfill most date guidance ra testing determine eligibility epidermal growth factor receptor egfr inhibitor metastatic colorectal cancer management expect shipment kit start third quarter hence expect drive top line second quarter illumina witness growth asia pacific region propel rise china emerge market china currently offer most favorable space illumina business growth recent time management have noticed considerable rise demand customer look set nipt operation china china currently be fourth largest develop nation term nominal gdp believe progress country open channel illumina thereby drive top line yet be report quarter also encourage solid second quarter performance illumina have raise full year revenue growth expectation earlier provide range flip side tough competitive landscape challenge company be also apprehensive issue pertain nih funding illumina have be face quite time now here be quantitative model predict illumina do not have right combination main ingredient positive earning esp zack rank hold better increase odd earning beat zack esp earning esp illumina be uncover best stock buy sell re report earning esp filter zack rank illumina carry zack rank increase predictive power esp however also need have positive esp be confident positive earning surprise nonetheless zack consensus estimate earning cent reflect improvement year year basis stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter abbott free report have earning esp zack rank buy see complete list today zack rank strong buy stock here align technology inc algn free report have earning esp zack rank henry schein inc hsic free report have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
370,HSIC,henry schein inc hsic free report be expect report third quarter result nov last quarter company deliver positive earning surprise encouragingly henry schein earning surpass zack consensus estimate past quarters average let see thing be shape prior announcement likely positive surprise proven model show henry schein be likely beat earning have perfect combination key ingredient zack esp henry schein have earning esp most accurate estimate be cent zack consensus estimate be lower cent favorable zack esp serve meaningful lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank henry schein currently carry zack rank hold note stock zack rank strong buy buy have significantly higher chance beating earning estimate conversely caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision combination henry schein zack rank esp make reasonably confident earning beat henry schein inc price ep surprise henry schein inc price ep surprise henry schein inc quotefactor playhenry schein second quarter result be quite impressive record growth segment dental animal health medical technology value add service geographically company gain traction north america overseas expect similar trend third quarter well company strategy expand digital dentistry globally be also encourage be also upbeat management expectation witness least low single digit growth north america dental consumable merchandise market second half zack consensus estimate third quarter total revenue reflect increase year quarter company be currently banking digital dentistry be part strategic plan henry schein be busy promote digital workflow general dentistry well dental specialty begin sep company start selling full range dentsply sirona dental equipment north america include lead cerec cad cam restoration system be expect boost top line extent notably second quarter henry schein animal health open new national distribution service center ndsc columbus brookhollow neighborhood have help company operate complete solution provider veterinary practice country expect boost top line yet be report quarter flip side henry schein disappointing gross operate margin past few quarters due higher cost sale expense be matter concern apart currency fluctuation tough competitive landscape add wo also entry group purchasing organization gpos unite state have intensified competition overall henry schein expect ep range reflect growth ep figure stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter cooper company inc coo free report have earning esp zack rank see complete list today zack rank stock here thermo fisher scientific inc tmo free report have earning esp zack rank align technology inc algn free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
371,HSIC,stryker corporation syk free report lead player medical technology space be set report third quarter result oct close bell august stryker announce voluntary recall oral care line be offer company sage product unit add voluntary recall company have place temporary hold certain cloth base product mar third quarter result expect improvement revenue major revenue segment help company generate solid result season be important note stryker deliver positive earning surprise past quarters average be meanwhile zack consensus estimate third quarter revenue stand year year basis furthermore zack consensus estimate earning stand share year year stryker corporation price consensus stryker corporation price consensus stryker corporation quote factor playguidance take hit recent product recall be likely impact company sale operate income fact third quarter stryker estimate adjust net earning diluted share low end previously issue band recall decision follow complaint minor irritation allergic reaction consumer however management expect reinitiate full supply capacity end year neurotechnology spine segment stryker have be grapple supply issue spine unit neurotechnology spine segment long major factor hurt segment challenge global economic condition fluctuation foreign currency exchange rate deserve mention precisely foreign exchange volatility affect adjust earning share approximately cent third quarter owing softness spine unit zack consensus estimate neurotechnology spine segment decrease sequentially lower demand health care product stryker have be face challenge global economic condition particularly unite state western europe late ongoing political conundrum pertain repeal obamacare have give rise uncertainty medical product space add lower reimbursement medical product service have be impose downward pressure price company product furthermore longer sale cycle slower adoption new technology mar revenue third quarter medsurg unit decline sale medsurg equipment segment be likely impede revenue growth third quarter notably zack consensus estimate revenue segment stand sequentially however solid prospect canada australia china be likely boost company medsurg instrument unit notably zack consensus estimate segment increase sequentially year year basis be important note last report quarter medsurg whole post organic growth year year basis however quantitative model do not conclusively show earning beat stryker quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp earning esp stryker be uncover best stock buy sell re report earning esp filter zack rank stryker currently carry zack rank sell please note caution stock zack rank sell rate go earning announcement stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter inc research holding inc have earning esp zack rank see complete list today zack rank stock here medpace holding inc medp free report have earning esp zack rank henry schein inc hsic free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
372,HSIC,mckesson corporation mck free report largest healthcare service provider be schedule release second quarter fiscal result oct last report quarter company earning miss zack consensus estimate also last quarters mckesson earning miss same average let see thing be shape prior announcement likely positive surprise proven model show mckesson be likely beat earning have perfect combination key ingredient zack esp mckesson have earning esp most accurate estimate be peg zack consensus estimate be favorable zack esp serve meaningful lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank mckesson currently carry zack rank hold note stock zack rank strong buy buy have significantly higher chance beating earning estimate conversely caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision combination mckesson zack rank esp make reasonably confident earning beat mckesson corporation price ep surprise mckesson corporation price ep surprise mckesson corporation quotewhat drive better expect earning mckesson be major player pharmaceutical medical supply distribution market management expect gain gradually stabilize generic brand market company distribution solution segment perform favorably recent time weak pricing trend customer consolidation also mckesson project earning share range fiscal distribution solution business revenue growth be expect increase mid single digit year year consider company performance last quarter promising guidance expect similar trend yet be report quarter well furthermore mckesson be likely benefit recent acquisition covermymed llc international segment management expect percentage revenue growth mid single digit constant currency basis management international business be likely be impact additional reimbursement cut incremental cut impact fiscal be significantly smaller fiscal however continue volatility unfavorable pricing trend reimbursement generic drug significant fluctuation nature frequency magnitude generic pharmaceutical launch have adverse impact mckesson also competitive landscape add wo other stock considerhere be other company consider model show also have right combination element post earning beat upcoming quarter inc research holding inc have earning esp carry zack rank see complete list today zack rank stock here medpace holding inc medp free report have earning esp carry zack rank henry schein inc hsic free report have earning esp carry zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
373,HSIC,laboratory corporation america holding lh free report also know labcorp be slate report third quarter result market open oct last quarter company deliver positive earning surprise have average earning beat trail quarters let see thing be shape announcement factor playlabcorp top line performance continue be affected softness covance drug development business be case last report quarter well weak performance be lead sluggish early development central lab business be affected slower revenue conversion backlog cancellation sponsor large clinical study also adverse foreign exchange rate affected number tune basis point bps segment meanwhile be upbeat company expectation improvement covance drug development arm start second half get reflect third quarter performance last year labcorp have face several reimbursement issue have dent revenue company be concern cms center medicare medicaid service proposal related protect access medicare act pama believe reimbursement pressure affect company performance soon be report quarter well laboratory corporation america holding price ep surprise laboratory corporation america holding price ep surprise laboratory corporation america holding quotenotably company be not positive latest center medicare medicaid service cms publication propose medicare reimbursement rate clinical laboratory test clinical lab fee schedule clf however most likely have impact third quarter result unfavorable foreign exchange continue be press concern company previously labcorp have anticipate approximate bps negative currency impact revenue company currently expect bps impact adverse foreign exchange net revenue covance drug development labcorp have be continuously grapple issue rise operate expense have affected margin last report quarter also chance turnaround scenario time soon be slim meanwhile positive note labcorp be focuse research development collaboration academic institution order gain traction grow lab testing market july labcorp launch adamts test distinguish disease characterize life threaten acute thrombotic microangiopathy tma also company expand vistaseq hereditary cancer portfolio addition new test panel focus risk specific hereditary cancer syndrome labcorp recently team walgreen boot alliance inc wba free report set specimen collection service station various walgreen store unite state company also expand reach close acquisition mount sinai health system clinical outreach laboratory labcorp highly differentiate portfolio be used exist customer mount sinai development be expect boost top line third quarter labcorp companion diagnostic portfolio grow robust last couple year maintain momentum earning whispersour proven model do not conclusively show labcorp be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp labcorp have earning esp be most accurate estimate be peg zack consensus estimate stand uncover best stock buy sell re report earning esp filter zack rank labcorp have zack rank increase predictive power esp however also need have positive esp be confident positive earning surprise stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter cooper company inc coo free report have earning esp zack rank see complete list today zack rank strong buy stock here henry schein inc hsic free report have earning esp zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
374,HSIC,gnc holding inc gnc free report specialty retailer health nutrition related product be schedule report third quarter result oct open bell last quarter company post positive earning surprise however gnc holding trail quarter earning average miss stand let see thing be shape prior announcement factor playgnc holding last report second quarter revenue drop year year apart lower sale canada international manufacturing wholesale segment decline revenue be attribute overall drop sale protein vitamin weight management food drink category absence catalyst drive growth expect similar trend third quarter well moreover gnc holding have number competitor market include large international pharmacy chain supermarket firm big base company global operation thus expect company slash product price face stiff competition turn hurt margin gnc holding inc price ep surprise gnc holding inc price ep surprise gnc holding inc quote also currency headwind continue be grow concern gnc holding management also expect failure comply ftc regulation change consumer preference hamper business however bright side performance new gnc be improve gradually also last report quarter pro access member double visit purchase double product spend significantly more second quarter banking factor expect company continue gain yet be report quarter well meanwhile new consumer enrolment mygnc reward program launch gnc storefront amazon buoy optimism earning whisper proven model do not conclusively show earning beat gnc holding quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp gnc holding be uncover best stock buy sell re report earning esp filter zack rank gnc holding carry zack rank increase predictive power esp however also need have positive esp be confident positive earning surprise stock considerhere be few medical stock worth consider have right combination element post earning beat quarter cooper company inc coo free report have earning esp zack rank see complete list today zack rank strong buy stock here henry schein inc hsic free report have earning esp zack rank thermo fisher scientific inc tmo free report have earning esp zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
375,HSIC,edward lifescience corporation ew free report be schedule report third quarter earning oct market close last quarter company have post positive earning surprise be worth note edward lifescience have outperformed zack consensus estimate precede quarters average positive earning surprise let take look thing be shape prior announcement key catalystsimilar prior quarter edward lifescience be expect gain strength transcatheter heart valve therapy segment thvt banking continue therapy adoption geography notable strength unite state company be expect maintain bullish trend third quarter well growth thvt be drive excellent clinical performance result sapien well continue strong therapy implementation region last report quarter moreover receipt expand fda approval sapien valve early june be expect further boost top line thvt segment be report quarter also zack consensus estimate thvt net sale reflect increase year quarter zack consensus estimate transcatheter heart valf thv sale unite state show increase year quarter overall third quarter revenue be project edward lifescience corporation price ep surprise edward lifescience corporation price ep surprise edward lifescience corporation quotehere be other factor influence edward lifescience third quarter result domestic market edward lifescience be expect continue strong performance base strength thvt other segment surgical heart valve therapy critical care company witness strength surgical heart valve therapy back strong uptake edward intuity elite valve system progress surgical heart valve therapy company receive fda approval inspiris resilium aortic valf july other hand growth critical care group be lead double digit growth enhance surgical recovery program especially unite state also zack consensus estimate net sale unite state reflect increase year quarter edward lifescience earlier raise full year sale expectation high end previously provide range moreover note company project total sale adjust earning share cent cent third quarter flip side tough competition cardiac device market reimbursement issue continue challenge company also believe unfavorable foreign currency affect company gross margin be report quarter also management expect third quarter be seasonally lowest quarter add concern here be quantitative model predict edward lifesciencesdoe not have right combination main ingredient positive earning esp zack rank hold higher increase odd earning beat zack esp earning esp foredward lifescience be uncover best stock buy sell re report earning esp filter zack rank edward lifescience carry zack rank increase predictive power esp however also need have positive esp be confident positive earning surprise nonetheless zack consensus estimate earning cent reflect improvement year year basis stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter abbott free report have earning esp zack rank buy see complete list today zack rank strong buy stock here align technology inc algn free report have earning esp zack rank henry schein inc hsic free report have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
376,HSIC,boston scientific corporation bsx free report be schedule report third quarter result open bell oct last quarter company deliver positive earning surprise trail quarter average beat be peg let see thing be shape prior announcement key catalystswe be optimistic company gradually improve performance interventional cardiology ic lead innovative portfolio robust commercial team globally company gain share number cardiovascular segment de drug eluting stent continue build momentum globally boston scientific corporation price ep surprise boston scientific corporation price ep surprise boston scientific corporation quote however ahead earning release believe quarter ic business be grossly impact company product recall issue europe notably last february company recall prime product lotus range heart device europe due device malfunction company also delay submission marketing application lotus edge device product line have little hope return european other market fourth quarter lead major setback company fast grow transcatheter aortic valve replacement tavr business ic soon be report quarter believe downbeat ic business earn boost company recent acquisition switzerland base symetis sa full recovery take time accordingly zack consensus estimate third quarter ic revenue be currently peg lower sequentially last quarter report number other factor playamong segment medsurg be expect demonstrate consistent performance lead endoscopy urology woman health be also estimate grow market level drive investment strategy key international geography zack consensus estimate third quarter endoscopy revenue be peg significantly higher year quarter report figure urology woman health current zack consensus estimate remain ahead year report tally flip side severe currency headwind boston scientific have be face late remain concern fact company record sale international market remain highly expose currency fluctuation boston scientific expect unfavorable foreign exchange challenge tune revenue bps cent share earning overall boston scientific third quarter adjust earning be expect band cent share revenue here quantitative model predict boston scientific do not have right combination main ingredient positive earning esp favorable zack rank strong buy buy hold increase odd earning beat see complete list today zack rank stock here zack esp boston scientific have earning esp uncover best stock buy sell re report earning esp filter zack rank boston scientific carry zack rank sell fail increase predictive power esp stock considerhere be few medical stock worth consider right combination element beat estimate quarter thermo fisher scientific tmo free report have earning esp zack rank align technology inc algn free report have earning esp zack rank henry schein inc hsic free report have earning esp also carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
377,HSIC,varian medical system inc var free report be schedule report fourth quarter fiscal earning oct market close last quarter company deliver earning share beat zack consensus estimate cent however adjust earning decline year period factor playwe be upbeat varian medical oncology business account company total revenue fourth quarter notably company have be address tier mid tier market edge truebeam vitalbeam product have also be winning international contract oncology space fourth quarter varian expect adjust earning share range revenue be expect increase year year basis company recently launch fda approve product halcyon strengthen foothold oncology business varian medical also sign agreement vijametech upmc establish radiation oncology center vietnam be also upbeat varian prospect internationally primarily bank proton therapy advanced treatment option cancer patient regard note varian medical recently receive shonin approval japan market probeam system proton therapy varian medical recently enter international agreement concern proton therapy platform bangkok base king chulalongkorn memorial hospital have select probeam compact single room proton therapy system cancer treatment thailand delray medical center florida believe western europe china africa present significant top line growth opportunity term company be open office africa middle east depict be aware opportunity region moreover varian medical strong product pipeline be key catalyst nevertheless increase local competition be primary headwind unfavorable foreign currency affect company revenue be report quarter also company be expose seasonal demand fluctuation higher operate expense pertain increase investment target growth acceleration geographical expansion portfolio expansion earning whispersour proven model do not conclusively show earning beat varian medical quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp varian medical currently have earning esp be most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank varian medical carry zack rank increase predictive power esp however company esp make surprise prediction difficult please note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision varian medical system inc price ep surprise varian medical system inc price ep surprise varian medical system inc quotestock considerhere be company consider model show have right combination element post earning beat upcoming quarter abbott free report have earning esp carry zack rank see complete list today zack rank stock here align technology inc algn free report have earning esp carry zack rank henry schein inc hsic free report have earning esp carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
378,HSIC,baxter international inc bax free report be schedule report third quarter earning oct open bell last report quarter company deliver positive earning surprise take quarter average let see thing be shape prior release factor playwe be encourage company guidance third quarter full year third quarter baxter anticipate sale growth constant currency adjust earning share be forecast range cent versus year figure cent also full year company project earning band share continue operation special item full year earning late baxter international have accelerate pace acquisition strategic collaboration enhance product portfolio thereby open significant long term opportunity also several recent fda approval be likely drive growth yet be report third quarter company estimate revision trend be also encourage current year baxter international witness upward estimate revision movement opposite direction last month however lower sale threat company integrate pharmacy solution franchise third quarter decline sale be expect impact top line low single digit also foray group purchasing organization gpos unite state intensify competition company earning whispersour quantitative model doesn point earning beat quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp baxter international be be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank baxter international carry zack rank increase predictive power esp however company esp make surprise prediction difficult caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision baxter international inc price ep surprise baxter international inc price ep surprise baxter international inc quotestock considerhere be company consider model show have right combination element post earning beat upcoming quarter abbott free report have earning esp carry zack rank see complete list today zack rank stock here align technology inc algn free report have earning esp carry zack rank henry schein inc hsic free report have earning esp carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
379,HSIC,walgreen boot alliance inc wba free report be slate release fourth quarter full year fiscal result market open oct last quarter company have post positive earning surprise be worth note walgreen have outperformed zack consensus estimate precede quarters average positive earning surprise let take look thing be shape prior announcement factor playwalgreen boot retail pharmacy usa division continue witness comparable prescription growth well strength retail prescription market last report quarter notably fiscal second quarter retail pharmacy usa division see highest comparable prescription growth more year several plan development early benefit new pharmacy contract volume increase previously announce strategic pharmacy partnership have be drive growth space past few quarters expect growth momentum continue fiscal fourth quarter well walgreen boot alliance inc price ep surprise walgreen boot alliance inc price ep surprise walgreen boot alliance inc quotebased promising performance precede quarter walgreen boot raise low end guidance fiscal cent currently expect full year adjust earning range also zack consensus estimate fiscal fourth quarter earning reflect improvement year year basis moreover zack consensus estimate fiscal fourth quarter revenue reflect improvement year year basis however sale performance retail pharmacy international division continue disappoint reduction government pharmacy funding have be affect performance absence term catalyst expect scenario persist upcoming quarter well also note slowdown generic introduction have be affect walgreen boot margin late increase reimbursement pressure well generic drug cost inflation have be dent margin third quarter walgreen boot gross margin contract account reimbursement pressure price inflation brand drug management continue witness lower profitability boot uk comparable pharmacy gross profit due lower margin product company be work boost efficiency provide high quality cost effective pharmacy service term outlook remain bleak meanwhile market growth be expect be strong certain emerge market backed timing price increase also order expand footprint asia company launch first boot franchise store south korea april development be expect boost top line fiscal fourth quarter september walgreen boot announce receipt federal trade commission ftc approval purchase store distribution center related inventory rite aid total value post new transaction initial close synergy be expect be entirely realize year initial completion walgreen boot modify merger contract extend growth strategy offer additional operational benefit help company expand optimize retail pharmacy network key market include northeast here be quantitative model predict walgreen bootsdoe not have right combination main ingredient positive earning esp zack rank hold higher need increase odd earning beat zack esp earning esp forwalgreen boot be uncover best stock buy sell re report earning esp filter zack rank walgreen boot carry zack rank sell meanwhile caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter cooper company inc coo free report have earning esp zack rank buy see complete list today zack rank strong buy stock here align technology inc algn free report have earning esp zack rank henry schein inc hsic free report have earning esp zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
